579_Stenting_prels
16/8/2001 10:29
Page i
CORONARY LESIONS A PRAGMATIC APPROACH
579_Stenting_prels
16/8/2001 10:29
Page ii
579_Stenting_prels
16/8/2001 10:29
Page iii
CORONARY LESIONS A PRAGMATIC APPROACH Edited by
Patrick W Serruys MD PHD FACC FESC Head, Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
Antonio Colombo MD Director Cardiac Catheterization Laboratory EMO Centro Cuore Columbus Milan Italy
Martin B Leon MD Director and CEO Cardiovascular Research Foundation Lenox Hill Heart and Vascular Institute New York NY USA
Michael JB Kutryk MD Department of Cardiology St Michael’s Hospital Toronto ON Canada
MARTIN DUNITZ
© 2002 Martin Dunitz Ltd, a member of the Taylor & Francis group First published in the United Kingdom in 2002 by Martin Dunitz Ltd, The Livery House, 7–9 Pratt Street, London NW1 0AE Tel: Fax: E-mail: Webiste:
+44 (0) 20 7482 2202 +44 (0) 20 7267 0159
[email protected] http://www.dunitz.co.uk
This edition published in the Taylor & Francis e-Library, 2003. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London, W1P 0LP. A CIP record for this book is available from the British Library. ISBN 0-203-21327-0 Master e-book ISBN
ISBN 0-203-27030-4 (Adobe eReader Format) ISBN 1-85317-936-1 (Print Edition) Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. Distributed in the USA by Fulfilment Center Taylor & Francis 7625 Empire Drive Florence, KY 41042, USA Toll Free Tel.: +1 800 634 7064 E-mail: cserve@routledge_ny.com Distributed in Canada by Taylor & Francis 74 Rolark Drive Scarborough, Ontario M1R 4G2, Canada Toll Free Tel.: +1 877 226 2237 E-mail:
[email protected] Distributed in the rest of the world by ITPS Limited Cheriton House North Way Andover, Hampshire SP10 5BE, UK Tel.: +44 (0)1264 332424 E-mail:
[email protected] Composition by Wearset Ltd, Boldon, Tyne and Wear
579_Stenting_prels
16/8/2001 10:29
Page v
Contents
Preface Contributors 1
2
vii ix
Intracoronary brachytherapy: a new treatment for the prevention of restenosis 1 Alexander J Wardeh, Ken Kozuma, Arie HM Knook, Manel Sabaté, I Patrick Kay, Patrick W Serruys Therapeutic angiogenesis for coronary artery disease 21 Michael JB Kutryk, Saleem A Kassam, Duncan J Stewart
3
Spot stenting 43 Antonio Colombo and Takahiro Nishida
4
Ostial and bifurcation disease 67 Alexander JR Black, Jean Fajadet, Jean Marco
5
Left main disease 83 Alexander JR Black, Jean Fajadet, Jean Marco
6
Small vessel stenting 95 Flavio Airoldi, Carlo Di Mario, Remo Albiero, Antonio Colombo
7
Direct stenting 107 Sanjay Prasad, Ameet Bakhai, Ulrich Sigwart
8
9
Treatment of chronic total coronary occlusions Christopher EH Buller, Jaap N Hamburger
121
In-stent restenosis Raluca Arimie, David P Faxon
131
10 Restenosis, a pragmatic approach David R Holmes
141
11 Percutaneous intervention in acute coronary syndromes Michael J Curran, Cindy L Grines
153
12 Pediatric coronary artery abnormalities and interventions 185 Peter R Koenig, Ziyad M Hijazi 13 Post-angioplasty dissection David Antoniucci
197
14 Alternative imaging J Ligthart, Pim J de Feyter
211
15 Calcified and fibrotic lesions 237 Stefan Verheye, Glenn Van Langenhove, Mahomed Y Salame 16 Ablative techniques 255 Glenn Van Langenhove, Stefan Verheye, David P Foley
v
579_Stenting_prels
16/8/2001 10:29
Page vi
CONTENTS
17 Direct myocardial revascularization: surgical and catheter-based approaches 269 Shmuel Fuchs, Ran Kornowski, Martin B Leon 18 Stent retrieval 283 Antonio Colombo, Goran Stankovic 19 Adjunctive therapies in percutaneous coronary interventions 291 Thaddeus R Tolleson, Eric J Topol, Robert A Harrington
vi
20 Local drug delivery using drug-eluting stents 319 Yanming Huang, Eric Verbeken, Etienne Schacht, Ivan De Scheerder 21 The significance of biochemical markers for myocardial damage in interventional procedures 337 Nicholas M Robinson, Martin T Rothman Index
359
579_Stenting_prels
16/8/2001 10:29
Page vii
Preface
Since the first coronary balloon angioplasty was performed in 1977, enormous progress has been made in the field of interventional cardiology. The concerted efforts of the interventional community have advanced our understanding of the pathophysiology of coronary artery disease and restenosis, and have led to the implementation of new invasive technologies, the introduction of adjunct therapies, improvements in the design of interventional devices, and enhanced operator expertise. With the maturation of interventional cardiology into a discipline, advances in the field have progressed at an accelerated rate. This has resulted in an immense amount of new information, and keeping abreast of new developments can be daunting even for the most well read specialist. Coronary Lesions: A Pragmatic Approach was conceived to provide a comprehensive overview of the field of interventional cardiology. Each chapter focuses on a single important interventional subject, and the book is arranged to provide a practical, user-friendly
reference source for the busy specialist. The chapters were designed to provide a concise review of each topic and are written with a distinct how-to flavor. We hope that this unique format will provide the reader with essential background information with necessary practical tips on all facets of interventional cardiology. The editors are indebted to the contributing authors. They are each leading authorities in interventional techniques, and have done an extraordinary job in synthesizing basic science and clinical information to provide balanced reviews on each topic. The editors would also like to thank Mr Alan Burgess, our commissioning editor, and Ms Charlotte Mossop, project editor, at Martin Dunitz Ltd for their patience, encouragement and expertise. Patrick W Serruys Antonio Colombo Martin B Leon Michael JB Kutryk
vii
579_Stenting_prels
16/8/2001 10:29
Page viii
579_Stenting_prels
16/8/2001 10:29
Page ix
Contributors
Flavio Airoldi, MD
Christopher EH Buller, MD
Cardiac Catheterization Laboratory EMO Centro Cuore Columbus 20145 Milan Italy
Vancouver Hospital and Health Sciences Center Department of Medicine Vancouver BC V5Z 1L8 Canada
Remo Albiero, MD
Antonio Colombo, MD
EMO Centro Cuore Columbus 20145 Milan Italy
Director, Cardiac Catheterization Laboratory EMO Centro Cuore Columbus 20145 Milan Italy
David Antoniucci, MD Division of Cardiology Ospedale di Careggi 85-50134 Florence Italy
Michael J Curran, MD, FACC
Raluca Arimie, MD
Jean Fajadet, MD
University of Southern California Los Angeles CA USA
Unité de Cardiologie Interventionelle Clinique Pasteur 31076 Toulouse France
National Naval Medical Center Bethesda MD 20889–5600 USA
Ameet Bakhai, MBBS, MRCP Clinical Trials and Evaluations Unit Imperial College School of Medicine Royal Brompton Hospital London SW3 6NP UK
David P Faxon, MD
Alexander JR Black, MD
Pim J de Feyter, MD
Department of Cardiology The Geelong Hospital Geelong 3220 Australia
University Hospital-Dijkzigt Thoraxcenter 3000 CA Rotterdam The Netherlands
Chief, Section of Cardiology University of Chicago Chicago IL 60637 USA
ix
579_Stenting_prels
16/8/2001 10:29
Page x
CONTRIBUTORS
David P Foley
Yanming Huang, MD
University Hospital-Dijkzigt Thoraxcenter 3000 CA Rotterdam The Netherlands
Katholieke Universiteit Leuven Campus Gasthuisberg BE-3000 Leuven Belgium
Shmuel Fuchs, MD
Saleem A Kassam, MD, MCE
Director, Interventional Myocardial Angiogenesis Cardiovascular Research Institute Washington Hospital Center Washington DC 20010 USA
Division of Cardiology Terence Donnelly Heart Center St Michael’s Hospital Toronto ON M5B 2W8 Canada
Cindy L Grines, MD, FACC
Department of Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
Division of Cardiology William Beaumont Hospital Royal Oak MI 48073-6769 USA
Jaap N Hamburger, MD, PhD, FESC Director of Research Interventional Cardiology Program St Paul’s Hospital Vancouver BC V6Z 1L7 Canada
Robert A Harrington, MD
I Patrick Kay, MBChB
Arie HM Knook, MD Department of Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
Peter R Koenig, MD
Duke Clinical Research Institute Durham NC 27707 USA
Assistant Professor of Clinical Pediatrics University of Chicago Children’s Hospital Chicago IL 60637 USA
Ziyad Hijazi, MD
Ran Kornowski, MD, FACC
Chief, Section of Pediatric Cardiology The University of Chicago Children’s Hospital Chicago IL 60637 USA
Director, Interventional Cardiology Rabin Medical Center Petach Tikva 49100 Israel
David R Holmes Jr, MD
Ken Kozuma, MD
Consultant in Cardiovascular Diseases and Internal Medicine Mayo Clinic Rochester MN 55905 USA
Department of Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
x
579_Stenting_prels
16/8/2001 10:29
Page xi
CONTRIBUTORS
Michael JB Kutryk, MD, PhD
Sanjay Prasad, BSc, MBChB, MRCP, MD
Division of Cardiology Terence Donnelly Heart Center St Michael’s Hospital Toronto ON M5B 2W8 Canada
Royal Brompton Hospital London SW3 6NP UK
Glenn van Langenhove, MD Middelheim Hospital 2020 Antwerp Belgium
Martin B Leon, MD
Nicholas M Robinson, MA, MD, MRCP Consultant Cardiologist London Chest Hospital London E2 9JX UK
Martin T Rothman, MB, ChB, FRCP, FACC, FESC
Director and CEO, Cardiovascular Research Foundation Lenox Hill Heart and Vascular Institute New York NY 10021 USA
Consultant Cardiologist London Chest Hospital London E2 9JX UK
J Ligthart
Department of Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
University Hospital-Dijkzigt Thoraxcenter 3000 CA Rotterdam The Netherlands
Jean Marco, MD Unité de Cardiologie Interventionelle Clinique Pasteur 31076 Toulouse France
Carlo Di Mario, MD Director of Research EMO Centro Cuore Columbus 20145 Milan Italy
Manel Sabaté, MD
Mahomed Y Salame, MRCP Andreas Grüntzig Cardiovascular Center Emory University Hospital Atlanta GA 30322 USA
Etienne Schacht, PhD Department of Organic Chemistry University of Ghent BE-9000 Ghent Belgium
Ivan De Scheerder, MD, PhD Takahiro Nishida, MD Research Fellow EMO Centro Cuore Columbus 20145 Milan Italy
Professor, Invasive Cardiology Katholieke Universiteit Leuven Campus Gasthuisberg BE-3000 Leuven Belgium
xi
579_Stenting_prels
16/8/2001 10:29
Page xii
CONTRIBUTORS
Patrick W Serruys, MD, PhD, FACC, FESC Head, Interventional Cardiology Catheterization Laboratory Thoraxcenter Academic Hospital Rotterdam-Dijkzigt 3015 GD Rotterdam The Netherlands
Ulrich Sigwart, FRCP, FESC, FACC Consultant Cardiologist Royal Brompton National Heart & Lung Hospital London SW3 6NP UK
Eric J Topol, MD Department of Cardiology The Cleveland Clinic Foundation Cleveland OH 44195-0001 USA
Eric Verbeken, MD, PhD Department of Histopathology Katholieke Universiteit Leuven Campus Gasthuisberg BE-3000 Leuven Belgium
Stefan Verheye, MD
Research Fellow EMO Centro Cuore Columbus 20145 Milan Italy
Cardiovascular Translational Research Institute, Middelheim, Antwerp, Belgium and Interventional Cardiology Middelheim Hospital 2020 Antwerp Belgium
Duncan J Stewart, MD
Alexander J Wardeh, MD
Division of Cardiology Terence Donnelly Heart Center St Michael’s Hospital Toronto ON M5B 2W8 Canada
Department of Interventional Cardiology Thoraxcenter Academic Hospital Rotterdam-Dijkzigt Rotterdam The Netherlands
Goran Stankovic
Thaddeus R Tolleson, MD Division of Cardiology Duke University Medical Center Durham NC 27715 USA
xii
579_Stenting_ch.01
14/8/2001 13:48
Page 1
1 Intracoronary brachytherapy: a new treatment for the prevention of restenosis Alexander J Wardeh, Ken Kozuma, Arie HM Knook, Manel Sabaté, I Patrick Kay, Patrick W Serruys
Introduction Percutaneous transluminal coronary angioplasty (PTCA) is an accepted treatment for coronary artery disease.1 However, angiographical restenosis is reported in 30–60% of patients after a successful PTCA.1–3 The main mechanisms of restenosis include acute elastic recoil of the vessel, late constriction of the arterial wall (negative remodeling), and neointimal hyperplasia.4–8 Neointimal hyperplasia develops by migration and proliferation of smooth muscle cells and myofibroblasts after balloon-induced trauma of the arterial wall and by deposition of an extracellular matrix by the smooth muscle cells.7,9–11 The restenosis rate has been reduced to 15–20% by stent implantation,3,12 by preventing elastic recoil and negative remodeling.13 However, the occurrence of restenosis after stent implantation remains unresolved, especially in small vessels and long lesions, where it may take place in more than 30% of the cases.14 It is primarily caused by neointimal hyperplasia, which occurs due to trauma of the arterial wall by the stent struts.6 The treatment of in-stent restenosis with conventional techniques (balloon angioplasty or debulking) is rather disappointing, with restenosis rates of 27–63%, which increase with the number of re-interventions.15–19 The term brachytherapy is used to describe intracavitary or interstitial radiation therapy.20 Recently, the term vascular brachytherapy has been introduced to describe endovascular radiation therapy. Vascular brachytherapy with a radio-
active source after PTCA or stent implantation is a promising treatment that might reduce restenosis by inhibition of neointimal hyperplasia21–23 and constrictive remodeling24,25 after percutaneous intervention.
Rationale Radiotherapy can successfully treat hypertrophic scars, keloids, heterotopic bone formation after total hip replacement, ophthalmic pterygia and solid malignancies. Usually, radiation doses of 7–10 Gy are used to treat these benign diseases, thereby efficiently inhibiting fibroblastic activity without influencing the normal healing process, and without causing significant morbidity during long-term follow-ups of up to 20 years.26–28 Vascular brachytherapy, using radiation doses of 12–20 Gy, appears to be efficacious in preventing restenosis by inhibiting neointimal formation22,29–31 and by increasing lumen diameters (positive remodeling).22,32–34
History In 1964, Friedman35 reported on the first in vivo use of intravascular radiotherapy. The first clinical trial, treating 30 patients with gamma (192Ir) endovascular radiotherapy for the treatment of in-stent restenosis of femoropopliteal arteries, was started in 1990 by Liermann.23 A reduced restenosis rate was observed without short- or long-term (5-year follow-up) complications. In
1
579_Stenting_ch.01
14/8/2001 13:48
Page 2
INTRACORONARY BRACHYTHERAPY
1995, Popowski36 reported on the first centering catheter, used in vascular brachytherapy with beta radiation to give a more homogeneous dose distribution to the vessel wall. In 1997, Condado37 treated 21 patients with de novo coronary lesions with angioplasty followed by intracoronary brachytherapy, using 192Ir. A restenosis rate of 27% was observed at 6-month follow-up. Also, due to the high prescribed dose, the first occurrence of a pseudoaneurysm after vascular brachytherapy was reported. Later in 1997, Teirstein38 reported on the first randomized double-blind placebo-controlled intracoronary brachytherapy trial, showing safety and efficacy of gamma (192Ir) radiation for the treatment of in-stent restenosis. Currently, multiple brachytherapy trials are either completed, ongoing or will be started shortly. An overview of brachytherapy trials is given in Table 1.1.
Physics Radioactivity is the process in which an unstable nucleus, which has either too many or too few neutrons, changes to a stable state (ground state). When it reaches the stable state, the basic element itself has changed, and this is known as radioactive disintegration or radioactive decay. The stable state is reached by -particle emission, -particle emission or electron capture (Figure 1.1). -Particles are heavyweight charged particles which can travel very short distances within tissues. -Particles are lightweight highenergy electrons, with either positive or negative charge. When -particles, which can travel only finite distances within tissues, are slowed down by nuclear interactions, they give rise to highpenetration X-rays, called Bremsstrahlung. -Rays are photons originating from the center of the nucleus, and take the form of electromagnetic radiation. Most often, an unstable nucleus will emit an - or -particle followed by -radiation. Only a few radioisotopes, e.g. phosphorus32 (a pure -emitter) emit particles without -radiation. -Rays may have either one or two
2
discrete energy values or a broad spectrum of many energy values. They penetrate deeply within tissues.39–41 When reaching a stable state by electron capture, the nucleus captures an electron from the innermost (closest to the nucleus) orbit, thereby making the outer shell with electrons unstable. To fill the gap left by the captured electrons, electrons from the outer orbit jump to the innermost orbit, which also leads to the emission of photons, called X-rays, which take the form of electromagnetic waves. -Rays and X-rays are both high-energy photons, without charge or mass. The only difference between -rays and X-rays is in their origin. Visible light waves and radiowaves are low-energy photons.39
Radiobiology When radiation is absorbed in a tissue, it can either cause direct damage to a critical target by ionization or it can indirectly damage a critical target by interacting with other molecules to produce free radicals, which will subsequently damage the critical target. Approximately 80% of the radiation damage is caused by these free radicals. Clearly, the most critical target that could be damaged by radiation is DNA. A consequence of this damage is that the cell will lose its ability to proliferate, which will ultimately lead to its death. Early and late toxic effects in normal tissue are mainly caused by cell death.39,42 There are several hypotheses explaining how radiation therapy could inhibit neointimal proliferation and thereby prevent restenosis: • Radiation might cause the inactivation of all target smooth muscle cells and myofibroblasts, while the surviving endothelial cells would repopulate and reline the artery. If this is true, smooth muscle cells should be more radiosensitive than endothelial cells. However, experimental evidence suggests no differences in the radiosensitivity of smooth muscle cells and endothelial cells.31,43
579_Stenting_ch.01
14/8/2001 13:48
Page 3
RADIOBIOLOGY
Study
No. of patients
Dose (Gy)
Lesion criteria
Lesion length (mm)
Source
Sponsor
ARREST ARTISTIC BERT BERT 1.5 Betacath BetaWRIST BETTER BRIDGE BRIE Compassionate use Rotterdam CURE Dose Finding GAMMA-1 GAMMA-2 GAMMA-3 Geneva GRANITE INDIRA
50 50 20 31 1456 50 150 100 13 22
8, 35a 12, 15, 18b 12, 14, 16c 12, 14, 16b 0, 14, 18b 20.6d 20d 0, 20c 14, 18b 16, 20b
De novo In-stent restenosis De novo De novo De novo, restenotic In-stent restenosis De novo, restenotic De novo De novo, restenotic In-stent restenosis
25 25 15 20 20 47 25 15 20 30
192
Ir Ir Sr/90Y Sr/90Y Sr/90Y 90 Y 32 P 32 P Sr/90Y Sr/90Y
Vascular therapies Vascular therapies Novoste Novoste Novoste Boston Scientific Radiance Guidant Novoste Novoste
30 181 252 125 280 15 100 800
20e 9, 12, 15, 18d 0, 8–30f 14b 14b 18d 14b 0, 11g
22 15 45 45 45 29 45 30
188
Re Y Ir 192 Ir 192 Ir 90 Y 192 Ir 192 Ir
Columbia University Schneider Cordis Cordis Cordis Schneider Cordis Cordis
INHIBIT IRIS LongWRIST MARS PERTH PREVENT
360 37 120 35 100 37
0, 20c 5–12h 0, 15b 20 Gyc 18d 0, 28, 35, 42c
44 28 80 20 20–80 22
32
P P Ir 188 Re 188 Re 32 P
Guidant Isostent Cordis Mallinckrodt Royal Perth Hospital Guidant
P32 Dose Response P32 Dose Response Cold Ends P32 Dose Response Hot Ends Radiation Stent Safety Trial RENO
162
45–92h
28
32
Isostent
50
h
22–92
De novo De novo In-stent restenosis In-stent restenosis In-stent restenosis De novo In-stent restenosis De novo, in-stent restenosis In-stent restenosis De novo, restenotic In-stent restenosis De novo In-stent restenosis De novo, restenotic in-stent restenosis De novo, restenotic, in-stent restenosis De novo, restenotic
15
32
Isostent
50
71–126h
De novo, restenotic
15
32
Isostent
30
52–106h
De novo, restenotic
13
32
SCRIPPS-1 SCRIPPS-2 SCRIPPS-3 SMARTS START START 40/20 SVG WRIST Venezuela WRIST
1000 55 100 500 180 476 206 120 21 130
b
14–20 16–22b 0, 8–30f 0, 8–30f 0, 14b 12b 0, 16, 20b 16, 20b 0, 15b 19–55i 0, 15b
De novo, restenotic, In-stent restenosis Restenotic In-stent restenosis In-stent restenosis De novo In-stent restenosis In-stent restenosis SVG De novo, restenotic In-stent restenosis
192
90
192
32
192
P P
P
P
ACS 90
Not limited
Sr/ Y
Novoste
30 65 81 25 20 20 45 30 47
192
Cordis Cordis Cordis Vascular therapies Novoste Novoste Cordis Non-commercial Cordis
Ir Ir Ir 192 Ir Sr/90Y Sr/90Y 192 Ir 192 Ir 192 Ir 192 192
a With intravascular ultrasound guidance. b At 2 mm from the source. c At 0.5 mm into the vessel wall. d At 1 mm from balloon surface. e At media. f To EEM. g At 3 mm from the source.h Cumulative dose over 100 days delivered to 1-mm depth outside the stent surface. i At 1.5 mm from the source.
Table 1.1 Intracoronary brachytherapy trials.
3
579_Stenting_ch.01
14/8/2001 13:48
Page 4
INTRACORONARY BRACHYTHERAPY
-particle
241
Am
237
Np
A
Electron (-particle)
3
H
3
He
B
Photon (-particle)
3
He
3
He
C
Figure 1.1 Production of radioactivity. (A) Example of -radiation: unstable nuclear core (left illustration) turns into a stable core by emitting an -particle (right illustration). (B) Example of -radiation: unstable nuclear core (left illustration) turns into a stable core by emitting a -particle (right illustration). (C) Example of -radiation: unstable nuclear core (left illustration) turns into a stable core by emitting a -particle (right illustration).
previous trials is that doses of more than 20 Gy are required to completely eliminate the smooth muscle cell population, which could result in late complications (e.g. the development of aneurysms).31,37,38 • Lower doses (20 Gy) are less likely to result in late complications. Consequently, restenosis may only be delayed for the period of time necessary for the population of smooth muscle cells to regenerate. If this were true, a delayed restenosis of 1–3 years would be expected.31 Additional evidence for this theory comes from a clinical trial23 where 12 Gy was prescribed to prevent restenosis in femoral arteries. No stenoses were seen after 3–27 months of follow-up;45 however, 16% restenosis was seen after prolonged followup.46
Brachytherapy devices and used isotopes Vascular brachytherapy can be performed by catheter-based systems, radiation balloons (both high dose rate) or radioactive stents (low dose rate). Among high-dose--emitting rate devices are (192Ir) or -emitting (32P, 90Sr, 90Y) seeds or wires and temporary filling of a dilatation balloon catheter with a high-activity -emitting solution (radionuclide liquid 188Re or 186Re, or 133 xenon gas.40 For an overview of the brachytherapy devices currently used in patients, see Table 1.2. For an overview of the used isotopes, see Table 1.3.
Dosimetry • Radiation could cause a large amount of potentially proliferating and migrating smooth muscle cells to either lose their ability to proliferate or to perish. In this way, the remaining proliferating cells are too few to cause restenosis, especially when taking into account the fact that cells have a finite proliferative capacity.44 What can be learned from
4
Vascular brachytherapy requires accurate knowledge of the dose delivered at 0.5–5 mm from the radioactive source. The treated coronary artery segment is usually 2–5 cm in length, with a diameter of 3–5 mm and a vessel wall thickness of 0.5–3 mm. The radiation dose given to the vessel wall should probably target the media as well as the adventitia.40,47,48
Wire Liquid-filled balloon Seeds Wire Wire Liquid-filled balloon Stent
X-ray device Stent Balloon Seeds Liquid-filled balloon
Ir Re
Sr/90Y P 32 P 188 Re 32
90
Y
X-ray 32
Novoste Nucletron/Guidant Guidant Radiant ACS Schneider/Boston Scientific Interventional Innovations Corporation Isostent Radiance Cordis Mallinckrodt
Table 1.2 Brachytherapy devices.
Beta-stent RDX Radiation Delivery System Gamma IRT Delivery System Liquid-filled balloon 32
P P 192 Ir 186 Re
P
32
188
192
Wire
Seed ribbon
Manual Manual Manual Manual
Automated
Afterloader
Manual
Hydraulic Afterloader Afterloader Manual
Manual Manual
Manual
Delivery
Yes Yes No Yes
No
Yes
Yes
Yes Yes Yes Yes
No Yes
No
Centering
14/8/2001 13:48
Angiorad System Solution-Applied Beta Emitting Radioisotope (SABER) System Beta-Cath System Nucletron Coronary System Galileo System Isolated Liquid Beta Source Balloon Radiation Delivery System Multi-link RX Radiation Coronary Stent System Schneider–Sauerwein Intravascular Radiation System Soft X-ray System
Ir
192
Best Medical International/Cordis Vascular Therapies Columbia University
The 192Ir Radioactive seed ribbon
Source information
Manufacturer
Radiation device
579_Stenting_ch.01 Page 5
5
579_Stenting_ch.01
14/8/2001 13:48
Page 6
INTRACORONARY BRACHYTHERAPY
Isotope
Emission
Maximum energy
Half-life
192
Ir Sr/90Y 90 Y 32 P 188 Re 186 Re 188 W/Re 133 Xe 131 I
,
74 days 28.6 years 64 h 14.3 days 17 h 90.6 h 69.4 days 5.25 days 8.04 days
99m
612 keV 2.28 MeV 2.28 MeV 1.71 MeV 2.12 MeV 1.08 MeV 2.12 MeV 0.35 MeV 0.81 MeV () 723 keV () 140 keV
90
Tc
6.02 days
Table 1.3 Isotopes used for intracoronary brachytherapy.
Ideally, the dose distribution should be given to the area injured by balloon angioplasty, while keeping the dose to the surrounding tissues as low as possible. Irradiation times should be less than 10 min to minimize the risk of acute thrombosis and other coronary complications during treatment. This would require either highactivity -sources (100 mCi activity), introducing safety issues for both patient and personnel, or -sources of 10–100 mCi. The radiation source should have dimensions, stiffness and flexibility compatible for use in complex coronary lesions. From a cost-effectiveness point of view, the used radioisotope, when using a catheter-based system, should have a sufficiently long half-life so that it may be used during several treatments over a long period of time.39,40 Not only the total radiation dose, but also the dose rate, is important, since damage caused by radiation can be repaired between fractionated doses or during low-dose-rate exposure. Therefore, the dose rate effect should be accounted for when comparing results of treatments using high dose rates with those of treatments using low dose rates. Cell death is markedly demonstrated in vitro at dose rates between 1 and 100 cGy/min.49,50 Curiously, an in vitro experi-
6
ment with human cells has shown that a dose rate of 0.6 cGy/min causes more cell death than 0.2 or 2.6 cGy/min. The explanation given for this inverse dose rate effect is that continuous irradiation at a dose rate of approximately 0.6 cGy/min effectively blocks cells in the mitosis (G2) phase of the cell cycle, which is known to be more radiosensitive, thereby causing more cell death.39
Centering versus noncentering A more homogeneous dose distribution is obtained by centering the radiation source with a balloon catheter (Figure 1.2). However, even with a centered source, eccentric intraluminal positioning (caused by, for example, an angulated lesion or a heavily calcified plaque) will result in areas of both relative underdose and overdose. Another example: if an artery has a curvature radius of 1 cm, the dose along the concave curvature of the artery will be 10–15% higher compared to the convex curvature, since the source will be closer to the concave curvature.39,51 This could become clinically important,
579_Stenting_ch.01
14/8/2001 13:48
Page 7
-RADIATION VERSUS -RADIATION
A
B
Figure 1.2 Dose distribution differences in centered versus non-centered sources. A centered source (A) delivers a more homogenous dose to the vessel wall compared to a non-centered source (B).
since low doses may stimulate neointimal proliferation,32,52 and high doses can give rise to the development of aneurysms.37
-Radiation versus -radiation From a radiobiological point of view, it is unimportant whether -radiation, -radiation or X-radiation is used. An equal dose, given to the same location at an equal dose rate, will lead to an equal biological effect.53 -Radiation has the following advantages. It deeply penetrates into the tissue, making it ideal for the treatment of large vessels (Figure 1.3). -Radiation is not shielded by stents, making it ideal for the treatment of in-stent restenosis. The most important advantage of -therapy is that it is the first treatment showing a reduction of restenosis in several large randomized, doubleblind, placebo-controlled trials (Table 1.4). The disadvantages of -therapy are as follows.
-Rays penetrate through normally used lead shields. A 1-inch lead shield is required to block the -rays. When high-energy -radiation is used, all ‘unnecessary’ personnel must leave the catheterization laboratory in order to limit their exposure to radiation. Overall, the patient and personnel receive higher radiation doses from a -radiation procedure in comparison to a -radiation procedure. This problem of radiation exposure limits the maximal specific activity used for -therapy. Lower specific activities, however, result in longer dwell times (8–20 min) to achieve the same therapeutic doses, making total procedure times longer, which in turn increases the risk of cardiac events.40,54 The advantages of -radiation are as follows. Thick plastic is able to shield -energy. Since -radiation only penetrates a few millimeters into the surrounding area, exposure to -energy is limited. Therefore, higher specific activities can be used, making dwell times shorter (3–10 min) and total procedure times shorter. Additional radiation exposure to the patient and personnel
7
579_Stenting_ch.01
14/8/2001 13:48
Page 8
INTRACORONARY BRACHYTHERAPY
16 Gy
8Gy
A
recently reported55 (JJ Popma ACC2000 presentation, stent versus directional coronary atherectomy randomized (START) trial), its efficacy for de novo or restenotic lesions remains to be proven by a randomized, double-blind, placebocontrolled trial. Owing to the steeper depth–dose fall-off curve, -energy will probably not be able to treat vessels with diameters 4 mm and/or will require centering devices to ensure homogenicity of the dose (Figures 1.2 and 1.3). -Energy has also been shown to be partially shielded by stents and calcified plaques, which may require an increase in the prescribed dose of up to 20%. Finally, dose distribution calculations of -emitters are more complicated than those of -emitters.40,54,56 While working with -radiation is obviously easier, -radiation has been used for several years without causing significant problems.40,54
Radioactive stents
B
8Gy
16Gy
Figure 1.3 Example of the differences of isodose contours of - and -radiation. With -radiation (B) the minimum effective dose of 8 Gy (dark grey arrow), inhibiting neointimal proliferation, extends further into the surrounding tissue, compared to -radiation (A). Therefore, -radiation is preferable to -radiation in large coronary vessels.
is negligible. Healthcare personnel can therefore remain in the catheterization laboratory. -Therapy also has disadvantages. While results from clinical trials (Table 1.5) are encouraging, and its efficacy for in-stent restenosis has been
8
One of the advantages of a -particle-emitting radioactive stent is that the radioactive source is centered and in close contact with the vessel wall. Another advantage is the short procedure time, since the implantation time of a radioactive stent is equal to that of a non-radioactive stent. The dose distribution, however, will not be uniform, given the gridded structure of the stent and the concomitant inhomogeneous distribution of the radioactive source.39 This might not be a problem if the concept of an electron-beam fence is true.57 According to this concept, the radiation emitted by the stent generates a fence at the endoluminal surface, which prevents smooth muscle cells and myofibroblasts from migrating into the stent.58 The results of the clinical data so far are rather disappointing, with restenosis rates of up to 52% (Table 1.6).59–61 While strict in-stent restenosis is observed to decrease with increasing levels of radiation doses, edge restenosis is the main cause of target lesion revascularization at high dose levels (Figure 1.4).60,61 This edge restenosis is probably caused by a combination
579_Stenting_ch.01
14/8/2001 13:48
Page 9
RADIOACTIVE STENTS
Study
No. of patients
SCRIPPS
Gy
8–30a
53
Lesion length (mm)
Source
Restenosis rate
MACE
30
192
17 54 22 60 46 78 33 55 34
15 48 35 68 NA NA 28 44 30
WRIST
130
15b
47
Long WRIST
120
15b
36–80
GAMMA-1
252
GAMMA-2
125
8–30a
Ir Placebo 192 Ir Placebo 192 Ir Placebo 192 Ir Placebo 192 Ir
45 45
14b
MACE, major cardiac events; NA, not available. a To EEM. b Dose at 2 mm from the source.
Table 1.4 Results of placebo-controlled -radiation trials at 6-month follow-up.
Study
Geneva BERT BERT 1.5 Beta WRIST
No. of patients 15 20 35 50
Gy
Lesion length (mm)
Source length (mm)
Source
Restenosis rate
MACE
18a 12, 14, 16b 12, 14, 16b 20.6c
20 15 20 47
29 30 30 29
90
14, 18b 20 9, 12, 15, 18c 15
30 29
16, 20, 24d
22
27
40 15 11 34 71 34 9 26 22 50 29 45 53
33 15 9 34 76 34 16 13 26 32 18 25.9 47
BRIE Dose Finding Study PREVENT
149 181
START
396
18, 20b
20
30
18
16, 20b
30
30
Compassionate use Rotterdam
96
Y Sr/90Y Sr/90Y 90 Y Placebo Sr/90Y 90 Y 9 Gy 90 Y 18 Gy 32 P Placebo Sr/90Y Placebo Sr/90Y
MACE, major cardiac events. a Dose at the inner arterial surface. b Dose at 2 mm from the source. c Dose at 1 mm from balloon. d Dose at 1 mm into vessel wall. 50 placebo patients from WRIST.
Table 1.5 Results of -radiation trials at 6-month follow-up.
9
579_Stenting_ch.01
14/8/2001 13:48
Page 10
INTRACORONARY BRACHYTHERAPY
Study
No. of patients
IRIS 1A IRIS 1B IRIS Heidelberg IRIS Rotterdam P32 Dose Response Rotterdam P32 Dose Response Milan
32 25 11 26 40 23 29 30 40
Stent activity (µCi)
Lesion length (mm)
Restenosis rate
TLR
0.5–1.0 0.75–1.5 1.5–3.0 0.75–1.5 6.0–12
15 15 15 28 28
31 50 54 17 44
21 32 NA 12 25
0.75–3.0 3.0–6.0 6.0–12 12–21
28
52 41 50 30
52 41 50 30
NA, not available; TLR, target lesion revascularization.
Table 1.6 Results of 32P radioactive stents at 6-month follow-up.
of balloon trauma and low-dose radiation at the stent edge, so geographical miss occurs in all cases. Since geographical miss has been shown to be one of the determinants of edge restenosis,62 future therapies will concentrate on the prevention of geographical miss by minimizing trauma and/or increasing radiation dose at the edges. Several new therapies are currently under investigation. Square-shouldered balloons, used for stent deployment, in which the entire balloon remains within the stent, will minimize barotrauma at the proximal and distal edges. Cold end stents, in which the center of the stent is made radioactive, while the proximal and distal 5 mm of the stent edges are non-radioactive, may decrease edge restenosis, if this restenosis is caused by negative remodeling. Another option is the implantation of hot end stents, in which the stent edges are made more radioactive compared to the center of the stent, thereby decreasing the chance of geographical miss.
Limitations of brachytherapy Unfortunately, vascular brachytherapy has its limitations, which include the following:
10
• Low radiation doses (4–8 Gy) may stimulate neointimal proliferation.52,63 This could be due to the fact that growth factors are synthesized de novo and secreted by surviving cells.64 These growth factors promote the proliferation of smooth muscle cells.65 • Delayed depletion of some cells (adventitial cells, fibroblasts) could lead to subsequent repopulation, whereby smooth muscle cells from the media could be progressively replaced by fibroblasts and extracellular matrix, leading to fibrosis, as has been previously described in animal experiments.22,29 • Persisting dissections after -radiation have been observed at 6-month angiographical follow-up66,67 (Figure 1.5). • Geographical miss, where the injured area is not completely covered by the irradiated area, is a major cause of edge restenosis (Figure 1.6). The incidence of geographical miss ranges from 18% to 34%. In cases of geographical miss, a restenosis rate of 39% was seen, versus 9% when there was no geographical miss.68 Geographical miss increases the chance of restenosis rate up to four fold. Edge restenosis has been observed at the edges of
579_Stenting_ch.01
14/8/2001 13:49
Page 11
LIMITATIONS OF BRACHYTHERAPY
A
Figure 1.4 Example of edge restenosis. At 6-month angiographic follow-up, a radioactive stent (proximal and distal ends marked by the dotted lines) shows an excellent result. However, at the proximal edge, a severe edge restenosis (arrow) is observed.
B the treated area. It appears to occur when the area injured by the balloon is larger than the irradiated area69 (Figure 1.7). • Mid-term (2–3-year) follow-up indicates signs of delayed rather than inhibited restenosis70–72 (Figures 1.8 and 1.9) • Black holes are observed in 22–39% of cases at 6-month intravascular ultrasound (IVUS) follow-up of the cases at the Thoraxcenter. They are called black holes because they are
Figure 1.5 Example of a persisting dissection. (A) Post-procedure, a dissection (arrow) is observed by intravascular ultrasound. (B) At 2-year follow-up, the dissection (arrow) remains unhealed.
11
579_Stenting_ch.01
14/8/2001 13:49
Page 12
INTRACORONARY BRACHYTHERAPY
Proximal gold marker
Distal gold marker 30-mm RST
A Fully irradiated segment B
C D E
Injured area
Injured area Injured area Injured area
Geographical miss segments
Figure 1.6 Explanation of geographical miss. (A) A radiation source train (RST) of 30-mm length. Because of the dose fall-off at both ends, the fully irradiated segment is smaller than the total length of the source train. (B) No geographical miss: the injured area is fully covered by the RST. (C) Proximal geographical miss: the injured area is proximal and not covered by the RST. (D) Distal geographical miss: the injured area is distal and not covered by the RST. (E) Proximal and distal geographical miss: the injured area is both proximal and distal, and not covered by the RST.
echolucent on IVUS. Pathology reveals smooth muscle cells in the extracellular matrix containing abundant proteoglycans and an absence of elastin and mature collagen. Sixty per cent of the black hole cases have angiographic restenosis. Whether these limitations will reduce the use of brachytherapy remains unknown.
12
Figure 1.7 Example of proximal and distal geographical miss, resulting in a candy wrapper edge restenosis (arrows) at 6-month follow-up.
Safety issues of brachytherapy Work with radiation therapy must be performed with extreme care, because of the following safety issues: • The risk of perforation will probably be small, especially when keeping the dose delivered to the adventitia low.30 • Aneurysm formation (Figure 1.10) seems to be dose related and has been observed in patients receiving high radiation doses of up to 92 Gy.37 However, in other trials,30,46,73–75 using lower doses of up to 30 Gy, no excessive aneurysm formation has been observed. • A dose-dependent delay in endothelialization of the stent has been shown, which might increase the chance of subacute thrombo-
579_Stenting_ch.01
14/8/2001 13:49
Page 13
SAFETY ISSUES OF BRACHYTHERAPY
Change in MLD 3 2.68 2.49
2.5
2.12 1.97
mm
2
1
1.68
1.77
1.5 1.14 0.98
0.5 0 Pre
Post
6-month
Condado
3-year
SCRIPPS
A
A Long-term follow-up WRIST Trial 70
63.1
63.1
63.1
60 50 40 % 30 20
23.1
26.2
13.8
10 0 6-month
2-year
1-year 192
Ir
Placebo
B Figure 1.8 Indications of delayed, rather than inhibited, restenosis after intracoronary brachytherapy. (A) Both the Condado and the SCRIPPS trial show a continuing loss of MLD, after 6-month followup. (B) During 2-year follow-up, the restenosis rate remains stable at 65.1% in the placebo group, while it increases from 13.8% to 26.2% in the irradiated group.
B Figure 1.9 Example of delayed restenosis. (A) Good angiographic result, 6 months after intracoronary brachytherapy. (B) In the same patient, 16 months after treatment, a severe candy wrapper edge restenosis is observed.
13
579_Stenting_ch.01
14/8/2001 13:49
Page 14
INTRACORONARY BRACHYTHERAPY
• High doses of radiation (35 Gy) applied to larger tissue areas, used for the treatment of neoplasms, result in accelerated coronary artery disease.79–81 Intermediate doses (30–40 Gy) have shown a low risk of cardiac disease during long-term follow-up (mean 11 years).82 • Radiation-induced carcinogenesis is of great concern; however, since irradiation delivers an extremely low dose beyond the immediate lesion, and the exposed tissues (e.g. arteries, veins, cardiac muscle, and pericardium) have a low spontaneous carcinogenicity rate, this risk appears to be extremely low.30,75 The safety of radiation therapy for benign diseases has been confirmed for periods of more than 20 years.26 Also, the safety of peripheral vascular brachytherapy during a 6-year followup has been reported.46 Recently, the 2-year follow-up of patients treated with intracoronary brachytherapy has shown no signs of late clinical effects.30
Figure 1.10 Example of a coronary aneurysm (arrow), 6 months after intracoronary brachytherapy.
sis.29,76 Also, in patients treated by catheterbased brachytherapy, with and without stent implantation, late thrombotic occlusions, with an incidence of up to 11%, have been observed.77 Therefore, all patients treated with coronary brachytherapy should receive either ticlopidine or clopidogrel for at least 6 months and aspirin indefinitely. • Vessel enlargement (positive remodeling) due to brachytherapy can induce late stent malapposition, which may result in late stent thrombosis,78 which is another reason for prolonged, or even lifelong, antiplatelet therapy.
14
Indications Intracoronary brachytherapy should be given to patients at high risk of developing restenosis. Therefore, brachytherapy should be given to patients with: • in-stent restenosis • long lesions • multivessel disease • saphenous vein graft lesions • small coronary artery lesions • diabetic disease • renal insufficiency.
Contraindications Intracoronary brachytherapy should not be given if the patient has a high risk of receiving a toohigh cumulative dose at the vessel wall. This is
579_Stenting_ch.01
14/8/2001 13:49
Page 15
CONCLUSION
possible in patients with: • previous radiotherapy of the chest • previous intracoronary brachytherapy, in case of previous -irradiation, or previous brachytherapy of the treated vessel segment, in case of previous -irradiation.
Conclusion Intracoronary brachytherapy is a promising new therapy for the treatment of in-stent restenosis. Whether it may also prevent restenosis after balloon angioplasty for de novo or restenotic lesions will be known by the end of the year 2000, when the 6-month angiographical followup data of current ongoing trials will be available. Long-term clinical and angiographical follow-up is also necessary, to ensure long-term safety and efficacy.
15
579_Stenting_ch.01
14/8/2001 13:49
Page 16
INTRACORONARY BRACHYTHERAPY
References
1. Holmes DR Jr, Vliestra RE, Smith HC et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53(12):77C–81C. 2. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77(2):361–371. 3. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331(8):489–495. 4. Mintz GS, Pichard AD, Kent KM et al. Intravascular ultrasound comparison of restenotic and de novo coronary artery narrowings. Am J Cardiol 1994; 74(12): 1278–1280. 5. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995; 25(2):516–520. 6. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94(1):35–43. 7. Nobuyoshi M, Kimura T, Ohishi H et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991; 17(2):433–439. 8. Serruys PW, Emanuelsson H, van der Giessen W et al. Heparin-coated Palmaz–Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996; 93(3):412–422. 9. MacLeod DC, Strauss BH, de Jong M et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human
16
10.
11. 12.
13.
14.
15.
16.
17.
18.
coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994; 23(1): 59–65. Guarda E, Katwa LC, Campbell SE et al. Extracellular matrix collagen synthesis and degradation following coronary balloon angioplasty. J Mol Cell Cardiol 1996; 28(4): 699–706. Hamon M, Bauters C, McFadden EP et al. Restenosis after coronary angioplasty. Eur Heart J 1995; 16(suppl I):33–48. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331(8):496–501. Haude M, Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz–Schatz stents. J Am Coll Cardiol 1993; 21(1):26–34. Dussaillant GR, Mintz GS, Pichard AD et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26(3):720–724. Lau KW, Ding ZP, Johan A et al. Angiographic restenosis rate in patients with chronic total occlusions and subtotal stenoses after initially successful intracoronary stent placement. Am J Cardiol 1999; 83(6):963–965, A9–A10. Sharma SK, Duvvuri S, Dangas G et al. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. J Am Coll Cardiol 1998; 32(5):1358–1365. Eltchaninoff H, Koning R, Tron C et al. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol 1998; 32(4):980–984. Dauerman HL, Baim DS, Cutlip DE et al. Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. Am J Cardiol 1998; 82(3):277–284.
579_Stenting_ch.01
14/8/2001 13:49
Page 17
REFERENCES
19. Bauters C, Banos JL, Van Belle E et al. Sixmonth angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis. Circulation 1998; 97(4):318–321. 20. Hall EJ. Radiobiology for the radiologist, 4th edn. Philadelphia: JB Lippincott Company, 1994. 21. Waksman R, Robinson KA, Crocker IR et al. Intracoronary low-dose beta-irradiation inhibits neointima formation after coronary artery balloon injury in the swine restenosis model. Circulation 1995; 92(10):3025–3031. 22. Wiedermann JG, Marboe C, Amols H et al. Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: persistent benefit at 6-month follow-up. J Am Coll Cardiol 1995; 25(6):1451–1456. 23. Liermann D, Bottcher HD, Kollath J et al. Prophylactic endovascular radiotherapy to prevent intimal hyperplasia after stent implantation in femoropopliteal arteries. Cardiovasc Intervent Radiol 1994; 17(1):12–16. 24. Waksman R, Rodriguez JC, Robinson KA et al. Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 1997; 96(6): 1944–1952. 25. Sabate M, Serruys PW, van der Giessen WJ et al. Geometric vascular remodeling after balloon angioplasty and beta-radiation therapy: a three-dimensional intravascular ultrasound study. Circulation 1999; 100(11):1182–1188. 26. Kovalic JJ, Perez CA. Radiation therapy following keloidectomy: a 20-year experience. Int J Radiat Oncol Biol Phys 1989; 17(1):77–80. 27. Walter WL. Another look at pterygium surgery with postoperative beta radiation. Opthal Plast Reconstr Surg 1994; 10(4):247–252. 28. Blount LH, Thomas BJ, Tran L et al. Postoperative irradiation for the prevention of heterotopic bone: analysis of different dose schedules and shielding considerations. Int J Radiat Oncol Biol Phys 1990; 19(3):577–581. 29. Hehrlein C, Gollan C, Donges K et al. Lowdose radioactive endovascular stents prevent smooth muscle cell proliferation and neointi-
30.
31. 32.
33.
34.
35.
36.
37.
38.
39. 40.
mal hyperplasia in rabbits. Circulation 1995; 92(6):1570–1575. Teirstein PS, Massullo V, Jani S et al. Twoyear follow-up after catheter-based radiotherapy to inhibit coronary restenosis. Circulation 1999; 99(2):243–247. Brenner DJ, Miller RC, Hall EJ. The radiobiology of intravascular irradiation. Int J Radiat Oncol Biol Phys 1996; 36(4):805–810. Weinberger J, Amols H, Ennis RD et al. Intracoronary irradiation: dose response for the prevention of restenosis in swine. Int J Radiat Oncol Biol Phys 1996; 36(4):767–775. Mazur W, Ali MN, Khan MM et al. High dose rate intracoronary radiation for inhibition of neointimal formation in the stented and balloon-injured porcine models of restenosis: angiographic, morphometric, and histopathologic analyses. Int J Radiat Oncol Biol Phys 1996; 36(4):777–788. Sabaté M, Serruys PW, van der Giessen WJ et al. Geometric vascular remodeling after balloon angioplasty and beta-radiation therapy: a threedimensional intravascular ultrasound study. Circulation 1999; 100: 1182–1188. Friedman M, Felton L, Byers S. The antiatherogenic effect of iridium192 upon the cholesterol-fed rabbit. J Clin Invest 1964; 43:185–192. Popowski Y, Verin V, Papirov I et al. Intraarterial 90Y brachytherapy: preliminary dosimetric study using a specially modified angioplasty balloon. Int J Radiat Oncol Biol Phys 1995; 33(3):713–717. Condado JA, Waksman R, Gurdiel O et al. Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation 1997; 96(3):727–732. Teirstein PS, Massullo V, Jani S et al. Catheterbased radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336(24):1697–1703. Waksman R. Vascular brachytherapy, 2nd edn. New York: Futura Publishing Company, 1999. Waksman R. Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations. Herz 1998; 23(6):401–406.
17
579_Stenting_ch.01
14/8/2001 13:49
Page 18
INTRACORONARY BRACHYTHERAPY
41. Simpkin DJ, Cullom SJ, Mackie TR. The spatial and energy dependence of bremsstrahlung production about beta point sources in H2O. Med Phys 1992; 19(1): 105–114. 42. Munro TR. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res 1970; 42(3):451–470. 43. Hall EJ, Marchese M, Rubin J, Zaider M. Low dose rate irradiation. Front Radiat Ther Oncol 1988; 22:19–29. 44. Hayflick L. Aging, longevity, and immortality in vitro. Exp Gerontol 1992; 27(4):363–368. 45. Bottcher HD, Schopohl B, Liermann D et al. Endovascular irradiation—a new method to avoid recurrent stenosis after stent implantation in peripheral arteries: technique and preliminary results. Int J Radiat Oncol Biol Phys 1994; 29(1):183–186. 46. Schopohl B, Liermann D, Pohlit LJ et al. 192Ir endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. Int J Radiat Oncol Biol Phys 1996; 36(4):835–840. 47. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 86(6 suppl):III43–III46. 48. Wilcox JN, Waksman R, King SB, Scott NA. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys 1996; 36(4):789–796. 49. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiat Res 1979; 79(3):537–551. 50. Hehrlein C, Stintz M, Kinscherf R et al. Pure beta-particle-emitting stents inhibit neointima formation in rabbits. Circulation 1996; 93(4):641–645. 51. Waksman R, Robinson KA, Crocker IR et al. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995; 91(5):1533–1539. 52. Schwartz RS, Koval TM, Edwards WD et al.
18
53.
54. 55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Effect of external beam irradiation on neointimal hyperplasia after experimental coronary artery injury. J Am Coll Cardiol 1992; 19(5):1106–1113. Silber S, von Rottkay P, Gielow A et al. Intracoronary brachytherapy with strontium/ yttrium-90. Initial experiences in Germany. Herz 1998; 23(6):380–393. Teirstein PS. Gamma versus beta radiation for the treatment of restenosis. Herz 1998; 23(6): 335–336. Waksman R, Bhargava B, White L et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000; 101(16):1895–1898. Amols HI, Trichter F, Weinberger J. Intracoronary radiation for prevention of restenosis: dose perturbations caused by stents. Circulation 1998; 98(19):2024–2029. Fischell TA, Carter AJ, Laird JR. The betaparticle-emitting radioisotope stent (isostent): animal studies and planned clinical trials. Am J Cardiol 1996; 78(3A):45–50. Laird JR, Carter AJ, Kufs WM et al. Inhibition of neointimal proliferation with low-dose irradiation from a beta-particle-emitting stent. Circulation 1996; 93(3):529–536. Wardeh AJ, Kay IP, Sabate M et al. Betaparticle-emitting radioactive stent implantation. A safety and feasibility study. Circulation 1999; 100(16):1684–1689. Albiero R, Nishida T, Adamian M et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 2000; 101(21):2454–2457. Albiero R, Adamian M, Kobayashi N et al. Short- and intermediate-term results of (32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose–Response Study. Circulation 2000; 101(1):18–26. Sabate M, Kay IP, Gijzel AL et al. Compassionate use of intracoronary beta-irradiation for treatment of recurrent in-stent restenosis. J Invasive Cardiol 1999; 11:582–588. Dorr W, Emmendorfer H, Haide E, Kummermehr J. Proliferation equivalent of ‘accelerated repopulation’ in mouse oral mucosa. Int J Radiat Biol 1994; 66(2): 157–167. Witte L, Fuks Z, Haimovitz-Friedman A et al.
579_Stenting_ch.01
14/8/2001 13:49
Page 19
REFERENCES
65.
66.
67.
68.
69.
70.
71.
72.
73.
Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 1989; 49:5066–5072. Bertrand OF, Mongrain R, Lehnert S et al. Intravascular radiation therapy in atherosclerotic disease: promises and premises. Eur Heart J 1997; 18(9):1385–1395. Kay IP, Sabate M, Van Langenhove G et al. Outcome from balloon induced coronary artery dissection after intracoronary beta radiation. Heart 2000; 83(3):332–337. Meerkin D, Joyal MJV, Bonan R. Long-term morphological effects of post angioplasty betaradiation: an IVUS study. JACC 2000; 35(2):1A. Sabate M, Costa MA, Kozuma K et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation 2000; 101(21): 2467–2471. Albiero R, Di Mario C, van der Giessen WJ et al. Procedural results and 30-day clinical outcome after implantation of beta-particle emitting radioactive stents in human coronary arteries. Eur Heart J 1998; 19:457. Teirstein PS, Massullo V, Jani S et al. Threeyear clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000; 101(4):360–365. Waksman R, White LR, Mehran R et al. Two years follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. JACC 2000; 35(2):10A. Condado JA, Lansky AJ, Saucedo JF et al. Three year clinical and angiographic follow-up after intracoronary 192-iridium radiation therapy. Circulation 1998; 98(17):3422. King SB 3rd, Williams DO, Chougule P et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results
74.
75.
76.
77.
78.
79.
80.
81.
82.
of the beta energy restenosis trial (BERT). Circulation 1998; 97(20):2025–2030. Meerkin D, Bonan R, Crocker IR et al. Efficacy of beta radiation in prevention of postangioplasty restenosis. An interim report from the beta energy restenosis trial. Herz 1998; 23(6):356–61. Verin V, Urban P, Popowski Y et al. Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation 1997; 95(5): 1138–1144. Carter AJ, Laird JR. Experimental results with endovascular irradiation via a radioactive stent. Int J Radiat Oncol Biol Phys 1996; 36(4):797–803. Costa MA, Sabate M, van der Giessen WJ et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100(8): 789–792. Kozuma K, Costa MA, Sabate M et al. Late stent malapposition occurring after intracoronary beta-irradiation detected by intravascular ultrasound. J Invasive Cardiol 1999; 11(10):651–655. Savage DE, Constine LS, Schwartz RG, Rubin P. Radiation effects on left ventricular function and myocardial perfusion in long term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1990; 19(3):721–727. King V, Constine LS, Clark D et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1996; 36(4):881–889. Kleikamp G, Schnepper U, Korfer R. Coronary artery and aortic valve disease as a long-term sequel of mediastinal and thoracic irradiation. Thorac Cardiovasc Surg 1997; 45(1):27–31. Glanzmann C, Kaufmann P, Jenni R et al. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1998; 46(1):51–62.
19
579_Stenting_ch.01
14/8/2001 13:49
Page 20
579_Stenting_ch.02
14/8/2001 13:50
Page 21
2 Therapeutic angiogenesis for coronary artery disease Michael JB Kutryk, Saleem A Kassam, Duncan J Stewart
Introduction Ischemic heart disease is the major cause of death in adults in most developed and many developing countries, and is now the commonest cause of death worldwide. Effective treatments of coronary artery disease involve the percutaneous revascularization techniques of balloon angioplasty and stenting or coronary artery bypass grafting (CABG). The long-term success of both of these approaches is limited by the development over time of native vessel restenosis and graft occlusions. In addition, despite continued advances in the prevention and treatment of coronary artery disease, there are still many patients who are not candidates for conventional treatments. Therapeutic angiogenesis is a strategy designed to restore blood supply to the myocardium by the administration of growth factors to augment native angiogenesis.
Angiogenesis The term angiogenesis, first used by Hertig in 1935 to describe the growth of blood vessels in the placenta, was reintroduced by Folkman in 1972 to describe neovascularization accompanying solid tumor growth.1 Angiogenesis is the process by which new capillaries sprout and differentiate from pre-existing microvascular networks. This process results in newly developed microvessels, most of which resemble capillaries (diameter of 5–8 µm). Although the exact
mechanisms are not fully understood, angiogenesis is thought to involve a series of events including: (1) activation of endothelial cells within a pre-existing vessel and vasodilatation of the parent vessel; (2) degradation of the basement membrane and extracellular matrix; (3) migration of activated endothelial cell from the parent vessel directed by chemotactic factors liberated from fibroblasts, monocytes, platelets, mast cells and neutrophils, towards the site where angiogenesis is required; (4) proliferation of endothelial cells in the newly forming vessels; (5) differentiation of these endothelial cells back to a quiescent phenotype with lumen formation; (6) recruitment of pericytes along the newly formed vascular structures; (7) formation of a new basement membrane by the newly organized endothelial cells and pericytes; and (8) remodeling of the neovascular network, with maturation and stabilization of the blood vessels (Figure 2.1). Angiogenesis is rapidly initiated in response to hypoxia or ischemia, and endothelial cell activation is the first process to take place in physiological or pathophysiological angiogenesis. The expression of several endothelial genes initiates a cascade of reactions, which then involve neutrophils and smooth muscle cells. Hypoxia induces increased levels of a family of hypoxiainducible transcription factors (HIFs), including HIF-1 (or the aryl hydrocarbon receptor nuclear translocator, ARNT), HIF-1, and HIF-2. They mediate the response to hypoxia by binding to specific DNA sequences, the
21
579_Stenting_ch.02
14/8/2001 13:51
Page 22
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
Activation
Differentiation
1. BM dissolution (MMP act.) – TNF, IL-8, etc. – VEGF, bFGF – ET-1
4. Tube formation – VEGF, bFGF, etc. – NO – angiopoietin 1
2. Migration of ECs – cytokines – angiogenic GFs – ET-1, NO
5. Pericyte recruitment – angiopoietin1 – NO
3. Proliferation of ECs – VEGF, bFGF, etc. – ET-1
6. BM deposition – angiopoietin 1 – NO Vessel stabilization – angiopoietin 1
Figure 2.1 Sequential events in angiogenesis. (1) Basement membrane disintegration opens the way for (2) endothelial cell migration. (3) Cords of cells proliferate and (4) define a new vascular channel. (5) Cessation of cell migration and proliferation coincides with the recruitment of perivascular support cells (6) with the formation of a new basement membrane and vessel maturation and stabilization.
hypoxia-response promoter elements, which regulate the transcription of an array of genes critical to the cellular response to hypoxia, including several genes that regulate angiogenesis.2 Leukocytes and platelets are potent producers of angiogenic growth factors, and several adhesion, chemoattractant and activator molecules govern their emigration from the bloodstream. Integral membrane proteins, including integrins, play an important role in the process of angiogenesis. Integrins are heterodimeric cell surface receptors composed of two non-covalently associated transmembrane glycoproteins ( and ) that mediate attachment of cells to their foundation but are also involved in intracellular signal
22
transduction.3–5 Endothelial cells express a number of different integrins, and of these v3 has been shown to be particularly important during angiogenesis. v3 is a receptor for many proteins with an exposed Arg–Gly–Asp (RGD) tripeptide component, including vitronectin, fibronectin, fibrinogen, laminin, collagen, thrombospondin, osteopontin and von Willebrand factor. Although the v3 receptor is not widely expressed, it is prominent on cytokine-activated endothelial cells or smooth muscle cells, suggesting its relevance in angiogenesis.6 A number of angiogenic cytokines have been shown to increase the expression of the v and 3 subunits on endothelial cells,7,10 and it has been
579_Stenting_ch.02
14/8/2001 13:51
Page 23
ANGIOGENESIS
demonstrated that v3 antagonists (antibodies and cyclic RGD peptides) inhibit angiogenesis.11–14 Newer data suggest that endothelial cell survival and proliferation in response to vascular endothelial growth factor (VEGF) may require the association of one of its receptors with v3 (Figure 2.2). Basement membrane degradation, extracellular matrix invasion and capillary lumen formation are also essential components of the angiogenic process, all of which are dependent on a cohort of proteases and protease inhibitors. Although a number of enzymatic systems have been implicated in extracellular proteolysis, many of the enzymes belong to one of two famil-
ies, the serine proteases, in particular the plasminogen activator (PA)/plasmin system, and the matrix metalloproteases (MMPs). Plasminogen activators u-PA and t-PA convert the ubiquitous plasma protein plasminogen to plasmin. Plasmin activates certain MMPs, has a broad trypsin-like activity and degrades proteins such as fibronectin, laminin and the protein core of proteoglycans.15–17 Subsequent steps in angiogenesis, including endothelial cell migration, proliferation, new vessel formation and maturation, result in a functional vascular conduit.4,18–20 Nitric oxide (NO) appears to play a crucial role in mediating various processes, including terminating the
VEGF PIGF VEGF-B
VEGF VEGF-C VEGF-D VEGF-E
VEGF-C VEGF-D
VEGFR-1
VEGFR-2
VEGFR-3
Complement to C1r/s homology domain
ssss
Homology to coagulation factors V and VII
3 NRP-1
VEC
Ig-like domain
Tyrosine kinase domain MAM domain Angiogenesis
Lymphangiogenesis
Figure 2.2 The currently known growth factors and receptors of the VEGF family. The three signaling tyrosine kinase receptors of the VEGF family (VEGFR-1, VEGFR-2 and VEGFR-3), the soluble VEGFR-1 receptor, the accessory isoform-specific receptor neurolipin-1 (NRP-1), the integrin receptor v3 and VE-cadherin are displayed with their major structural features. Ligand binding induces receptor signal transduction, leading to various responses. VEGFR-1 and VEGFR-2 mediate angiogenesis, whereas VEGFR-3 is also involved in lymphangiogenesis. NRP-1 (and neurolipin-2) binds to specific C-terminal sequences present only on VEGFs that bind to VEGFR-1 and/or VEGFR-2. v3 integrin and VE-cadherin have been found complexed with activated VEGFR-2. VE-cadherin also associates with an activated VEGFR-3 complex. VEC, VE-cadherin; NRP-1, neurolipin-1; MAM, meprin, A5, mu. See Chan et al123 for explanations of the various structural motifs of the neurolipins. Modified from Veikkola et al.124
23
579_Stenting_ch.02
14/8/2001 13:51
Page 24
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
proliferative actions of growth factors, and promoting the formation of vascular tubes.20–22 In the setting of coronary ischemia, NO is required for VEGF to function23 which may, in turn, be mediated by endothelin release.24 Secretion of platelet-derived growth factor (PDGF) helps attract other elements to the neovascular platform. Cell-to-cell contact, and the presence of transforming growth factor-beta (TGF-) are thought to spur the differentiation and maturation of pericytes and smooth muscle cells.20 The glycoprotein angiopoietin-1 (Ang-1) and its tyrosine receptor kinase Tie-2 help the immature endothelial cell network to establish biochemical interactions and vessel integrity.20
Vasculogenesis The process of angiogenesis is distinct from that of vasculogenesis. The term vasculogenesis is strictly reserved for the formation of new blood vessels during embryogenesis. Initially, mesenchymal cells differentiate in situ into early hemangioblasts that form cellular aggregates (blood islands), in which the inner cell population differentiates into hematopoetic precursors, and the outer cell population gives rise to the primitive endothelial cells that generate a functioning vascular network.25–27 The primitive vascular plexus subsequently develops into a complex, interconnecting network of mature blood vessels.
Arteriogenesis The importance of the collateral coronary circulation has long been known,18,28–33 and the mechanisms governing the growth and proliferation of pre-existing collateral vessels differ from those regulating angiogenesis and vasculogenesis. The growth and proliferation of collaterals is called arteriogenesis. The clinical significance of collateral arteries is based on their ability to proliferate into large conductance arteries, which can efficiently restore bloodflow to ischemic
24
territories. Adequate development of these collaterals may take days to weeks, in order to compensate for critical stenoses of the nutrient branches of the coronary tree. Genetic factors are responsible for the variable number of preexisting intracoronary connections and their capacity to grow, and lead to marked inter- and intraspecies variability.34,35 An important stimulator of arteriogenesis is increased shear stress that leads to changes within the newly recruited artery. The most important change is the activation of the endothelium. The result is an increased expression of a number of genes, partially via a protein that binds to the shear stress responsive element (SSRE) that is present in the promoter of many of these genes, including nitric oxide synthase (NOS), PDGF and monocyte chemoattractant protein (MCP-1). Adhesion molecules are also upregulated, allowing for the adhesion and invasion of monocytes and platelets, which are also potent producers of growth factors. The process of arteriogenesis does not require hypoxia as a physical stimulus. Neovascularization depends on two distinct processes; cell proliferation and vessel differentiation. These processes must occur in proper timing and proportion in order for functioning vessels to arise. It is likely that cell proliferation and differentiation occur in concert, and growth modulators may preferentially promote one process over the other in response to specific signaling mechanisms. Indeed, most angiogenically active factors are present in normal resting conditions, and up- and downregulation of these substances is determined by physiological and pathophysiological moderators.21,36,37 Growthpromoting factors are generated and active to varying degrees in response to the local environment and, depending on the local milieu, may be capable of promoting neovascularization. While VEGF and fibroblast growth factor (FGF) may regulate basement membrane disintegration, the presence of Ang-1 may be required for leukocyte and precursor cell adhesion, recruitment and proliferation, cell differentiation, maturation and the establishment of a mature vessel. The inter-
579_Stenting_ch.02
14/8/2001 13:51
Page 25
OVERVIEW OF VASCULAR GROWTH FACTORS
dependence of angiogenic factors is exemplified by FGF and NO. In the presence of NO, the action of FGF may switch from one that causes endothelial proliferation to one responsible for differentiation.22 Finally, such a paradigm would suggest that therapeutic angiogenesis would require the provision of several factors at appropriate points in the process to allow for the desired product.38
Overview of vascular growth factors The existence of biological mediators of vascular growth was hypothesized more than three decades ago, with the discovery of a tumor factor that was found to be mitogenic for endothelial cells.39 This factor was subsequently identified as a member of the FGF family.40 It soon became evident that tumor biology could be applied in a practical way to common disease processes like peripheral vascular and coronary artery diseases. Many angiogenic proteins have now been identified (Table 2.1). The most extensively studied and best characterized angiogenic growth factors are members of the VEGF and FGF families. More recently, attention has focused on the angiopoietin family, which includes angiopoietins 1–4.
Fibroblast growth factor The fibroblast growth factor family consists of 19 structurally similar compounds, of which FGF-1 (acidic, aFGF) and FGF-2 (basic, bFGF) are best described.20,36,41 The members of the FGF family possess a high degree of homology and share important features, including: (1) an ability to bind heparin with high affinity; (2) an ability to bind high-affinity receptors possessing tyrosine kinase activity, which subsequently initiates intracellular signaling pathways responsible for inducing cell division (modulated by attachment to the low-affinity receptor); and (3) an ability to bind to a low-affinity, high-capacity
receptor that represents a site that modulates the activity and function of the high-affinity receptor with cell surface heparin sulfate proteoglycans.42–44 The aFGF and bFGF proteins are single-chain, heparin-binding polypeptides of 154 and 146 amino acids respectively.40,45 Unlike other members of the FGF family, which have signal sequences and are secreted through standard secretory pathways, aFGF and bFGF do not have signal sequences and are not secreted by classical mechanisms. The FGFs have been shown to modulate many intra- and extracellular activities that are necessary for angiogenesis, including: (1) the upregulation of proteases that are essential in the modulation of the extracellular matrix; (2) the activation of kinases that regulate intracellular signaling pathways that are important to cell replication; and (3) the signaling of molecules involved in cell–cell interactions and interactions related to capillary tubule formation. Their particular affinity for the smooth muscle cell has led to the hypothesis that FGF compounds are more active in larger-vessel formation.4,20,46
Vascular endothelial growth factor The VEGF family of mitogens and their tyrosine kinase receptors play a central role in both physiological and pathological angiogenesis. The VEGF family currently includes six known members, VEGF (VEGF-A, VEGF-1), placental growth factor (PlGF), VEGF-B, VEGF-C (VEGF-2), VEGF-D, and orf virus VEGF (VEGF-E). The family members are all secreted dimeric glycoproteins, and they all contain characteristic regularly spaced eight-cysteine residues, the cystine knot motif. The first identified and the best-studied member of the group is VEGF (VEGF-A), a soluble mitogen mapped to chromosome 6p21.3, which plays a role in all major angiogenic events.47–51 VEGF was described independently by a number of different groups using a variety of different assays. For a number of years the protein was variably referred to as vascular permeability factor (VPF)
25
579_Stenting_ch.02
14/8/2001 13:51
Page 26
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
Angiogen
Endothelial cell specific
Acidic fibroblast growth factor (aFGF) Basic fibroblast growth factor (bFGF) Fibroblast growth factor 3 (FGF-3) Fibroblast growth factor 4 (FGF-4) Fibroblast growth factor 5 (FGF-5) Fibroblast growth factor 6 (FGF-6) Fibroblast growth factor 7 (FGF-7) Fibroblast growth factor 8 (FGF-8) Fibroblast growth factor 9 (FGF-9) Angiogenin 1 Angiogenin 2 Hepatocyte growth factor/scatter factor (HGF/SF) Platelet-derived growth factor (PDE-CGF) Transforming growth factor- (TGF-) Transforming growth factor- (TGF-) Tumor necrosis factor- (TNF-) Vascular endothelial growth factor 121 (VEGF 121) Vascular endothelial growth factor 145 (VEGF 145) Vascular endothelial growth factor 165 (VEGF 165) Vascular endothelial growth factor 189 (VEGF 189) Vascular endothelial growth factor 206 (VEGF 206) Vascular endothelial growth factor B (VEGF-B) Vascular endothelial growth factor C (VEGF-C) Vascular endothelial growth factor D (VEGF-D) Vascular endothelial growth factor E (VEGF-E) Vascular endothelial growth factor F (VEGF-F) Placental growth factor Angiopoietin-1 Angiopoietin-2 Thrombospondin (TSP) Proliferin Ephrin-A1 (B61) E-selectin Chicken chemotactic and angiogenic factor (cCAF) Leptin Heparin affinity regulatory peptide (HARP) Heparin Granulocyte colony-stimulating factor Insulin-like growth factor Interleukin-8 Thyroxine
No No No No No No No No No Yes Yes No Yes No No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No Yes Yes Yes No Yes No No No No No No
Modified from Hamaway et al.122
Table 2.1 List of angiogenic proteins.
26
579_Stenting_ch.02
14/8/2001 13:51
Page 27
OVERVIEW OF VASCULAR GROWTH FACTORS
or vasculotropin, but has come to be predominantly known as VEGF. Alternative splicing from a single gene gives rise to five different isoforms of VEGF composed of 121, 145, 165, 189 and 206 amino acids. The 165 and 121 isoforms are the predominant forms. The 165 variant is the most potent stimulator of endothelial cell division, 50–100-fold more potent than the 121 isoform, while the latter lacks heparin-binding ability and, as a consequence, is not anchored to the extracellular matrix when secreted, which allows for a paracrine effect. The greater mitogenic potency of VEGF165 may be conferred by its neurolipin-1-binding region, which is encoded by exon 7 of the VEGF gene (Figure 2.2).52 Targeted inactivation of a single VEGF allele in the mouse results in haplo-insufficiency with embryonic lethality due to abnormal blood vessel development at around 9 days of gestation, attesting to its importance in embryonic development.53,54 The VEGF homologs are ligands for a set of tyrosine kinase receptors, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (FLT-4) (Figure 2.2). In adult tissues, VEGFR-1 and VEGFR-2 localize to vascular endothelial cells, whereas VEGFR-3 is expressed mainly in the lymphatic endothelium. The ligand specificities of the VEGF receptors differ: VEGFR-1 binds VEGF, VEGF-B and P1GF, VEGFR-2 binds VEGF, VEGF-C, VEGF-D and the orf virus VEGF, while VEGFR-3 binds VEGF-C and VEGF-D. Ligand binding induces receptor dimerization and subsequent auto- and transphosphorylation. Hypoxia is one of the main stimuli driving angiogenesis, and the expression of VEGF is highly regulated by oxygen tension, providing a physiological feedback mechanism to accommodate insufficient tissue oxygenation by promoting blood vessel formation. The transcription of the VEGF gene under hypoxic conditions is mediated by a family of hypoxia-inducible factors (HIF-1, HIF-1 and HIF-2), which bind to hypoxia-responsive elements in the VEGF promoter. In addition, hypoxia also
induces the upregulated expression of a ribonucleic acid-binding protein (HuR). HuR stabilizes the VEGF mRNA through interaction with sequences in the 3 untranslated region.55–57 Many other stimuli, which do not promote angiogenesis, can also modulate angiogenesis indirectly by regulating VEGF expression in specific cell types. These include cytokines, growth factors, endotoxins, adenosine derivatives and transcriptional factors such as c-fos and c-jun. VEGF is expressed by macrophages and leukocytes and, although VEGFR-1 and VEGFR-2 are both activated by the same ligand, their downstream signaling pathways lead to different cellular responses. VEGFR-2 activation is required for the determination of the fate of endothelial and hemopoietic cells, their migration and proliferation.58,59 VEGFR-1 activation is more important for proper regulation of endothelial cell migration and adhesion and blood vessel organization.60,61 In general, adult VEGF expression is low.62 One exception is the female reproductive organ, and the ovarian follicle, where it may be involved in embryo implantation, endometrial vascularization and the development of the corpus luteum.63 Expression is increased in pathological states dependent on increased vascularity, such as myocardial ischemia, arthritis and tumor growth.41 Among patients with coronary artery disease (CAD), VEGF concentrations have been found to be elevated in atherosclerotic lesions, particularly in those with increased collaterals.28,64 There are two features of VEGF that distinguish it from the FGF compounds. First, receptors for VEGF are found predominantly on vascular endothelial cells, resulting in a specific target organ effect. Second, the terminal amino acid sequence allows for secretion from cells. This feature allows for the delivery of the DNA sequence encoding VEGF, with its subsequent transcription and translation, which leads to greater and more sustained tissue concentrations when compared to protein delivery alone.65 The effects of FGF and VEGF on neovascularization may be synergistic.38
27
579_Stenting_ch.02
14/8/2001 13:51
Page 28
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
Recent animal data have identified a potential negative effect of recombinant human VEGF (rhVEGF) protein. When administered via a single intraperitoneal injection to apolipoprotein-E-deficient cholesterol-fed mice, rhVEGF enhanced atherosclerotic plaque progression.66 Similar results were reported with the administration of rhVEGF to cholesterol-fed rabbits. Whether this applies to angiogenic agents other than VEGF is currently not known; however, these findings have clinical implications and will impact on the design of future clinical trials.
The angiopoietins The angiopoietins represent a new family of angiogenic growth factors that bind a receptor tyrosine kinase that is primarily restricted to endothelial cells, Tie-2.67 The angiopoietins include a receptor activator, angiopoietin-1 (Ang-1), and a putative endogenous receptor antagonist, angiopoietin-2 (Ang-2). Ang-1 is a 70-kDa protein that induces tyrosine phosphorylation of Tie-2 in endothelial cells. Ang-1 binding induces endothelial cell chemotaxis but is not mitogenic for endothelial cells. In this regard, knockout mice lacking either Tie-2 or its activating ligand Ang-1 exhibit embryonic lethality; however, the early stages of VEGF-dependent vascular development still occur normally in these mice, resulting in the formation of a primitive vascular plexus. Morphological evaluation of these Tie-2 / and Ang-1 / mice demonstrates deficiencies in vessel branching, with fewer and simpler vessels, poorly organized subendothelial matrix, loosening of endothelial cell contacts with the basement membrane, and generalized lack of perivascular cells.68–71 Transgenic overexpression of Ang-2 during embryogenesis also leads to a lethal phenotype similar to that seen in embryos lacking either Ang-1 or Tie2, consistent with a role for Ang-2 as a natural antagonist for Tie-2.72 These transgenic phenotypes imply a function for Tie-2 in the expansion of the primitive endothelial tubules to a network of mature vessels composed of endothelial and
28
adventitial cells. The angiopoietins appear to act in a complementary and coordinated fashion with VEGF, increasing the complexity and maturity of the vasculature.73 The angiopoietins also appear to play an important role in postnatal neovascularization. In the adult, Ang-1 and Tie-2 appear to be widely expressed in the quiescent adult vasculature, while Ang-2 is highly expressed only at sites of vascular remodeling.72 In vitro studies have shown that hypoxia upregulates Ang-2 expression and downregulates Ang-1.74–76 In a corneal micro-pocket model of angiogenesis, Asahara et al77 showed that exogenous coadministration of Ang-1 and VEGF produced larger and more numerous blood vessels than VEGF alone. Ang-2 acts as a natural antagonist of Ang-1, blocking its stabilizing function. It may loosen capillary structure, render endothelial cells more responsive to angiogenic stimuli, and allow the activation of endothelial cells to a more plastic state where they are responsive to the sprouting signal provided by VEGF78 (Figure 2.3). Recent evidence has suggested that Ang-2 might also have biphasic actions under circumstances of low oxygen tension, initially blocking Ang-1 activity by acting as a Tie-2 antagonist, allowing endothelial cell activation in response to VEGF and other cytokines, and later contributing directly to the stabilization and maturation of newly formed blood vessels, as a partial or full Tie-2 agonist.79 Other members of the angiopoietin family have been described (Ang-3 and Ang-4), but their properties have not been fully described.
Therapeutic angiogenesis Preclinical studies Numerous animal experiments have demonstrated the link between growth factors and new vessel formation. Initial studies with FGF demonstrated accelerated wound healing in diabetic mice, leading to the first indicated use of topical growth factors for debrided diabetic
579_Stenting_ch.02
14/8/2001 13:51
Page 29
THERAPEUTIC ANGIOGENESIS
VEGF VEGF-R2 (Flk1)
VEGF-R1 (Flt1)
Basement membrane
Ang-1
Ang-2
Tie-2
Tie-2
VEGF VEGF-R1/2
Peri-endothelial cells
Endothelial cells
Birth, migration and proliferation of endothelial cells
Tube formation and cell-cell interaction
Recruitment of and interaction with pericytes. Maintains vessel integrity and quiescence.
Matrix contacts and support cell interactions loosen. Allows access to angiogenic inducers.
Vessel maturation
Figure 2.3 Coordinated and complementary angiogenic activities of VEGF and the angiopoietins. VEGF, angiopoietin-1, and angiopoietin 2 bind to receptor thymidine kinases (RTKs) that have similar cytoplasmic signaling domains. Binding of the ligands to their receptors elicits downstream signals with distinctive cellular responses. Only VEGF binding to the VEGF-R2 receptor sends a classical proliferative signal. VEGF binding to VEGF-R1 elicits endothelial cell–cell interactions and capillary tube formation. Ang-1 binding to the Tie2 RTK recruits and likely maintains association of peri-endothelial support cells (pericytes, smooth muscle cells, myocardiocytes), thus stabilizing a newly formed blood vessel. One property of Ang-2 is that it binds and blocks kinase activation in endothelial cells. The Ang2 negative signal causes vessel structures to become loosened, reducing endothelial cell–cell contacts with matrix and disassociating peri-endothelial support cells. This loosening likely renders the endothelial cells more accessible and responsive towards the angiogenic inducers like VEGF. Modified from reference 125.
ulcers.80–82 Animal studies of therapeutic angiogenesis have centered around two models: the rabbit hind limb model of peripheral ischemia, and the porcine model of myocardial ischemia.83–87 Both VEGF and FGF, administered by either an intra-arterial or an intramuscular route, can promote collateral blood vessel development after ligation of the rabbit femoral artery. In these studies, treated animals had more angiographically and histologically visible collat-
eral vessels, greater hind limb bloodflow, higher distal perfusion pressure, and enhanced muscle performance. Models of ischemic porcine myocardium, induced by placement of an ameroid constriction of a coronary artery, have also demonstrated augmentation of myocardial vascularization after both protein and gene treatment administered via intracoronary or perivascular injection.88–92 These preclinical studies supported the proof of principle that vascular
29
579_Stenting_ch.02
14/8/2001 13:51
Page 30
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
growth factors can promote angiogenesis to improve bloodflow to ischemic muscle.
Human studies Until recently, human angiogenic experiments have been predominantly limited to small series in which VEGF or FGF, protein or gene, have been administered.46,93–108 Delivery strategies have included intracoronary, epicardial or direct myocardial injection of either VEGF or bFGF protein, or genetic material. The latter can be delivered as naked plasma DNA or in a viral vector. Preliminary human trials in peripheral vascular disease have demonstrated improvements in ankle–brachial index, enhancements of angiographically visible collaterals, improvements in rest pain and analgesic medication use, ulcer healing and diminished critical limb ischemia.93,94 Schumacher and colleagues were the first to report on therapeutic angiogenesis in human myocardium. Among 40 patients undergoing CABG with a left internal mammary artery (LIMA) graft and a left anterior descending artery (LAD) stenosis distal to the anastomosis, they randomly assigned patients to direct intramyocardial injection of aFGF or denatured protein control near the distal non-grafted segment.95 At 3 months, they described significantly increased angiographic collaterals among FGF-injected patients compared to placebo. This effect persisted for 3 years, and was associated with improved echocardiographic ejection fraction and functional class.96 Sellke et al reported on a series of eight patients with ischemic heart disease who received bFGF as an adjunct to CABG.97 These patients had at least one major arterial distribution that was not amenable to revascularization but were otherwise candidates for CABG. The growth factor was delivered by sustained-release microcapsules that were implanted around the ischemic territory during surgery. At 12 week follow-up, three patients showed clear enhancement of perfusion to the unrevascularized
30
myocardium, three patients had minimal overall change, and one patient had a new fixed defect on stress nuclear perfusion imaging. Similarly, Laham and colleagues studied the effects of bFGF. They randomly assigned patients undergoing CABG to receive 10 or 100 µg of bFGF, or placebo via perivascular microcapsular delivery, into an artery serving an ischemic territory that was not grafted.46,98 Although only 24 patients were studied, promising trends were observed with respect to angina, perfusion scores and MRI-imaged ischemic areas between placebo and treated groups at 3 months, particularly in the higher-dose group. Intracoronary injection of bFGF protein was performed in patients with stable coronary artery disease by Unger and his colleagues.99 Doses greater than 30 µg/kg were associated with hypotension and bradycardia. Compared to placebo, patients receiving bFGF had similar exercise treadmill times at 1 month. Udelson’s group delivered escalating doses of intravenous or intracoronary bFGF to 59 patients with CAD that was unsuitable for revascularization.100 They reported improved scintigraphic perfusion scores reflecting decreased inducible ischemia. An overview of the clinical trials of FGF is shown in Table 2.2. Six small studies have evaluated VEGF delivery to ischemic myocardium (Table 2.3). Protein therapy performed with varying doses of intracoronary rhVEGF was studied by Henry et al in a series of 15 patients who were suboptimal candidates for conventional revascularization techniques.101 Nuclear perfusion imaging was performed at 30 and 60 days, and seven patients underwent angiographic assessment. The investigators reported an overall improvement in perfusion in seven patients and minimal changes in the patients who had received the lowest doses. Collateralization was improved in five of the seven patients who had undergone angiography. Hendel’s group also evaluated the intracoronary administration of VEGF protein. In their study, 14 patients received various doses of rhVEGF protein. The investigators reported a significant
Yes bFGF protein Heparin/alginate microcapsules 10/100 µg Epicardial fat implantation Clinical/MPI Positive
Yes aFGF protein None 70 mg Intramyocardial DSA Positive
Dose Delivery
Endpoint Result
GXT Safe
3–100 µg/kg Intracoronary
No bFGF protein None
25 RDB Yes
Unger et al99
MPI Positive
0.33–48 µg/kg IC/IV
No bFGF protein None
59 Observational No
Udelson et al100
Yes bFGF protein Heparin/alginate microcapsules 10/100 µg Epicardial fat implantation MPI Safe
8 Observational No
Sellke et al97
GXT/MPI/QOL Negative
200 µg Intracoronary
No bFGF protein None
337 RDB Yes
FIRST
Table 2.2 Clinical trials of FGF delivery
14/8/2001 13:51
GXT, graded exercise stress test; RDB, randomized, double blind; MPI, myocardial perfusion imaging; IC, intracoronary; IV, intravascular; DSA, digital subtraction angiography; QOL, quality of life.
24 RDB No
40 RDB Yes
N Design Placebo controlled Thoracotomy Agent Vector
Laham et al98
Schumacher et al95
Parameter
579_Stenting_ch.02 Page 31
31
579_Stenting_ch.02
14/8/2001 13:51
Page 32
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
improvement in resting (but not stress) perfusion as assessed by nuclear scintigraphy.102 Gene therapy, using either naked plasmid DNA or adenovirus as a vector for VEGF, has been tested in several early clinical trials. Losordo et al performed a phase I study of five patients with refractory angina who received intramyocardial injections of naked plasmid DNA encoding for VEGF165 as sole therapy via mini-thoracotomy (no CABG).103 All patients were found to have improved perfusion scores as assessed by nuclear imaging at 30 and 60 days and had radiographic evidence of improved collateral flow into ischemic areas on angiography. In addition, the patients reported improvements in anginal class and a reduction in nitroglycerin use. Similar results were reported by Vale et al.104 Their study employed three doses of naked plasmid DNA encoding the 165 isoform of vascular endothelial growth factor (phVEGF165), which was injected into the myocardium as sole therapy in patients with symptomatic myocardial ischemia. Thirty patients who were not candidates for conventional revascularization were treated with a total dose of either 125 µg (n 10), 250 µg (n 10) or 500 µg (n 10) of phVEGF165. Twenty-six (87%) of the 30 patients reported clinical improvement. Exercise tolerance (Bruce protocol) increased significantly up to 360 days post gene delivery. Stress SPECT-Sestamibi myocardial imaging was performed in 29 patients followed for 60 days. Mean perfusion-defect scores for both stress and rest images were significantly decreased (improved) at day 60. Left ventricular ejection fraction (LVEF) was either unchanged (n 16) or improved (n 14, mean increase in LVEF 5%) following gene therapy. Hendel et al and Fortuin et al have reported results of a dose-ranging trial examining gene transfer of VEGF-C (VEGF-2).105,106 VEGF-C shows 30% homology to VEGF165 and is a specific ligand for the endothelial receptor tyrosine kinases VEGFR-2 and VEGFR-3 (Figure 2.2).52 Three doses of VEGF-C were delivered via intramyocardial injection after mini-
32
thoracotomy in 30 patients. Stress SPECT-Sestamibi myocardial imaging was performed at baseline, and at 4 and 12 weeks after VEGF injection. In the 27 patients who were available for follow-up perfusion imaging, improvement was seen in 15 and 12 of the rest and stress scans respectively, with evidence for a dose-dependent effect. Canadian Cardiovascular Society (CCS) class decreased from 3.6 0.5 at baseline to 1.3 1.0 (p < 0.005) at 12 week follow-up, and average exercise times increased from 5:55 3:20 min to 7:56 3:24 min (p < 0.005). At 12 weeks after treatment, endocardial electromechanical mapping demonstrated a significant improvement in myocardial contractile function without an improvement in myocardial viability, suggesting rescue of hibernating myocardium.107 Rosengart and colleagues injected adenovirus vector containing VEGF121 directly into the myocardium of 21 patients as an adjunct to CABG (15 patients) or as sole therapy via minithoracotomy (6 patients).108 Coronary angiography and nuclear perfusion scans after 30 days suggested improvement in both groups. In addition, patients reported symptomatic improvement after therapy. Collectively, these phase 1 and 2 studies describe an experience of 291 patients without blinded outcome assessment. Although data from these studies cannot be used to draw conclusions concerning efficacy, they firmly established the feasibility and safety of different methods of gene transfer, and have set the stage for larger randomized trials. Also being tested is percutaneous catheter-mediated injection of vector. Trials are currently underway to assess the efficacy of this approach. Only two relatively large, randomized, double-blind, placebo-controlled studies have been performed in humans. The FIRST Study (FGF-2 Initiating Revascularization Support Trial) recruited 337 patients with angina considered to be suboptimal for traditional revascularization. In a double-blind, placebo-controlled manner, participants were randomized to three
30 Observational No
N
Design
Placebo
0.2/0.8/2.0 mg Intramyocardial IC Clinical/GXT/
Dose
Delivery
Endpoint
Positive
Plasmid
Positive
MPI
0.167 µg/kg
Positive
GXT/MPI
Clinical/
Intramyocardial
500 µg
0.005/0.017/0.05/ 125/250/
None
DNA
VEGF165
Yes
No
Observational
30
Vale et al104
Positive
angiography
Clinical/MPI/
Intramyocardial
125 µg
Plasmid
DNA
VEGF165
Yes
No
Observational
20
Symes et al108A
Positive
MPI
IC
0.167 µg/kg
0.005/0.017/0.05/
None
protein
rhVEGF
No
No
Observational
14
Hendel et al102
Positive
GXT
angiography/
Clinical/MPI/
Intramyocardial
1000 µg
Adenovirus
DNA
VEGF121
Yes
No
Observational
21
Rosengart et al108
Safety
angiography
Clinical/MPI/
Intramyocardial
125 µg
Plasmid
DNA
VEGF165
Yes
No
Observational
5
Losordo et al103
Negative
angiography
Clinical/GXT/
IC/IV
Table 2.3 Clinical trials of VEGF delivery.
min
17/50 ng/kg/
None
protein
rhVEGF
No
Yes
RDB
178
VIVA
GXT, graded exercise stress test; RDB, randomized, double blind; MPI, myocardial perfusion imaging; NOGA, NOGA electromechanical mapping; IC, intracoronary; IV, intravascular.
Result
Plasmid
Vector
MPI/NOGA
VEGF-C
Agent protein
No rhVEGF
Thoracotomy No
No
Observational
15
Henry et al101
14/8/2001 13:51
controlled
Hendel et al102
Parameter
579_Stenting_ch.02 Page 33
33
579_Stenting_ch.02
14/8/2001 13:51
Page 34
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
doses of intracoronary bFGF protein (0.3, 3 and 30 µg/kg). At 90 days, there was no difference between groups in the primary endpoint of exercise treadmill times, or in the secondary endpoints of nuclear perfusion parameters (p 0.64), and quality of life indices (Seattle Angina Questionnaire (SAQ) or short-form 36 (SF-36)). On post hoc analysis, there was a suggestion that the greatest reduction in anginal score was at the 3 µg/kg dose, among older patients (>65 years) and those with the most severe angina (p 0.06). The VIVA Trial (VEGF in Ischemia for Vascular Angiogenesis) involved a patient cohort similar to that of the FIRST Trial with nuclear evidence of a reversible perfusion defect; the patients were assigned randomly to two doses of growth factor (17 or 50 ng/kg) or placebo. VEGF protein was administered during coronary angiography via intracoronary injection, followed by three intravenous doses on days 3, 6 and 9. Although no improvement in treadmill scores was seen at 60 days, mean CCS anginal class was significantly lower for the high-dose group compared to placebo at 120 days (1.6 0.1 versus 2.1 0.1, p 0.04). No safety concerns were raised in either of these landmark trials. Although both trials were unable to demonstrate efficacy, several factors may account for the lack of effect. In the two randomized human trials, growth factor delivery was accomplished via an intracoronary or intravenous route. It is unclear if this method provides adequate tissue levels to stimulate and maintain angiogenesis. This is particularly true for bFGF, given the poor specificity for target endothelium. In fact, doseranging studies for both FGF and VEGF suggest a graded effect at higher doses.99,102 In addition, injection into myocardium or pericardial fat may be necessary for clinically relevant dose delivery and transfection rates, as suggested by several studies.98,109,110 In planning controlled trials to assess the effectiveness of gene therapies, investigators must consider a number of significant factors.
34
These include: (1) selection of the appropriate means of delivery of therapeutic material; (2) determination of appropriate endpoints to be studied; (3) quantification and resultant objectification of the results; (4) assurance of adequate controls; (5) selection of patients to be included; (6) determination of the mechanisms of any observed clinical effects; and (7) assessment of complications—potential, actual, local, systemic, immediate and long term. Delivery of growth factors has been accomplished using two means—through the use of single or multiple doses of recombinant protein, or by a gene transfer approach—and each strategy has its limitations. Factors that favor the use of proteins include the ability to regulate their dose and thus to define a therapeutic window between efficacy and toxicity. This would allow withdrawal of treatment if and when necessary. Factors arguing against the use of protein for therapeutic angiogenesis are: (1) the considerable cost involved in producing significant quantities of pyrogen-free materials; (2) the appearance of secondary effects (prolonged administration of bFGF is associated with a decrease in arterial pressure, moderate thrombocytopenia, and moderate anemia); and (3) the requirement for repeated or prolonged administration of protein. Local perivascular delivery via myocardial injection, pericardial fat implantation of coated microspheres or pericardial instillation has been attempted in order to address the latter limitation.111–113 In contrast, gene therapy results in the prolonged secretion of growth product by host cells, offering sustained protein levels with a single administration. However, the potential for extralesional uptake of the gene or vector and distant, unwanted effects in non-target tissues, related either to the vector or the gene product that it encodes, is of concern. There are many means to deliver genes coding for angiogenic products. The simplest is through the delivery of naked plasmid DNA. Injection of naked DNA into myocardium has been shown to result in growth factor expression for a considerable period of time, without incorporation into
579_Stenting_ch.02
14/8/2001 13:51
Page 35
THERAPEUTIC ANGIOGENESIS
host DNA.110,114 Many facilitated means of delivery have also been studied. Liposomal encapsulation has been tested; however, current techniques are associated with a low transfection efficiency. Retrovirus encapsulation and delivery allows for effective and long-term gene expression through DNA incorporation into the genome; however, the potential for activation of retroviral genes in the host DNA is of concern. Encapsulation of gene in adenoviral vectors is an effective means of delivery; however, it is associated with an immune response that can lead to destruction of the vector or a significant systemic inflammatory response.115 The choice of efficacy endpoints for clinical trials remains an area of controversy. The ideal endpoint for angiogenesis trials should have the following characteristics: (1) it should address the primary hypothesis and represent a direct marker of efficacy; (2) it should be clinically meaningful; (3) it should be easily measured and not be prohibitively costly to perform or analyze; (4) it should provide insight into mechanisms; and (5) it should lend itself to statistical analysis. The endpoints for trials of angiogenesis can be considered either clinical (angina status, functional capacity, or quality of life) or physiological (improved myocardial perfusion, improvement in vessel collateralization, improvement in global or regional wall motion). One of the clinical assessments which has been considered as an endpoint for angiogenesis trials is exercise stress testing. The advantages of employing exercise testing as a clinical endpoint for angiogenesis trials is that it is often used in phase 1 and 2 studies, and the results are quantitative and semi-objective (rate pressure product, time to ST depression) and fairly reproducible. The disadvantages of using exercise testing as an endpoint are that comorbidities (peripheral vascular disease, chronic obstructive lung disease, arthritis) may limit exercise performance, day-today variability exists, and the reasons for test termination may still be subjective. Changes in CCS score or response to the SAQ have also been used as clinical endpoints in
angiogenesis trials. The advantages of these types of assessments are that they are highly relevant to patients and easy to interpret (especially CCS), are sensitive to change, are fairly reproducible (especially SAQ), and are familiar to most clinicians (CCS used in clinical practice). The disadvantages of these assessments are that they are more subjective than exercise stress testing (double-blinding necessary), the CCS score requires observer input (the SAQ does not), changes in SAQ are not easily interpreted (lack of familiarity by clinicians), and the placebo effects are substantial (~40% in the DIRECT DMR study). The advantages of using the MOS SF-36 or Utility Index (HUI) are that they are both broadly applicable, they are sensitive to change, and normal values have been established for various disease states. Disadvantages of these types of analyses as endpoints are that they are considered to be softer endpoints, they are more subjective, and the changes are not easily interpreted (lack of familiarity by clinicians). One of the problems common to all clinical endpoints is that they are prone to placebo effects. One solution to this problem is to look for objective endpoints that can explain the subjective outcomes such as reduction in CCS class. In this regard, ‘angiogenesis-specific’ quality of life or symptom assessment tools may be necessary. An additional problem with clinical endpoints is that small changes may be undetected, but still clinically meaningful (basement effect). Although clinical endpoints are employed in trials of myocardial angiogenesis, physiological assessments are preferred as primary endpoints. Several physiological endpoints have been considered, including SPECT myocardial perfusion imaging, MRI, and PET. The advantages of nuclear scintigraphy are that it is sensitive to changes after revascularization, it is reproducible, and wall motion can be assessed. There are concerns, however, over the adequacy of the spatial resolution obtainable with nuclear imaging. MRI has enormous potential, and is
35
579_Stenting_ch.02
14/8/2001 13:51
Page 36
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
able to provide excellent spatial resolution and information on structure, function and flow. Although MRI is gaining greater acceptance with time, prohibitive cost and restrictive availability limits its use. PET scanning is more sensitive than SPECT in measuring coronary flow reserve. It remains the only way to measure absolute bloodflow. The limitations of PET imaging are the poor spatial resolution, the lack of widespread availability and its cost. There may be several reasons for the disparate results of the reported clinical trials of angiogenesis and the results from animal models. In addition to the issues of dose, mechanism of delivery, and endpoint, the choice of patient cohort to study may have confounded the clinical trials, making positive results unattainable. Unlike animal populations, the patient population of interest has demonstrated an inability to form or recruit adequate collateral vessels prior to inclusion in the trials. In addition, the response to simple growth factor delivery may differ in the presence of diffuse atherosclerosis and endothelial dysfunction, compared with the response in experimental ischemic models.116 Also, various cardiac medications and health states, including aspirin, captopril, lovastatin, furosemide, hypercholesterolemia, smoking, diabetes and age, inhibit negatively impact on the angiogenic response.32,112,117–121 Also impacting on the generalization of the results of the clinical trials is the recognition that patients enrolled in clinical trials of angiogenesis are highly selected on the basis of anatomy, symptoms, left ventricular function, concurrent disease and motivation.
36
Future research Current animal studies are focusing on the mechanisms of angiogenesis, examining in particular the roles of different compounds and the local and host factors that govern their effectiveness. The action of angiogenic factors in the mileu of CAD is also an area of active research. The results of animal studies and early results of clinical trials suggest that delivery of a cocktail of angiogenic factors might be more effective than delivery of a single agent, and may more closely mimic the physiological angiogenic response. Finally, stem cell transplantation may allow for the development of all components required for new myocardium and functioning vascular network, and may provide a feasible therapy in the future.
Summary Exciting and promising options are being explored for the treatment of CAD. Over the past decade, the discovery and study of vascular growth factors has shed much light on the complex mechanistic processes of vascular development cogent to a wide variety of disease processes. This research has pooled resources from many disciplines, including molecular sciences, oncology and vascular biology. While this field is still in its infancy, advances in the understanding of the endothelial organ, and the insights gained from clinical studies, will provide a wealth of therapeutic options for modern diseases.
579_Stenting_ch.02
14/8/2001 13:51
Page 37
REFERENCES
References
1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409–416. 2. Wang GL, Semonza GI. Purification and characterization of hypoxia inducible factor 1. J Biol Chem 1995; 270:1230–1237. 3. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157–1164. 4. Tomanek RJ, Schatteman GC. Angiogenesis: new insights and therapeutic potential. Anat Rec 2000; 261:126–135. 5. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999; 32(5):501–510. 6. Varner AJ, Brooks PC, Cheresh DA. The integrin v3: angiogenesis and apoptosis. Cell Adhes Commun 1996; 3:367–374. 7. Basson CT, Kocher O, Basson MD et al. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-1 correlates with reciprocal effects on cell migration. J Cell Physiol 1992; 153: 118–128. 8. Swerlick RA, Brown EJ, Xu Y et al. Expression and modulation of the vitronectin receptor on human dermal microvascular endothelial cells. J Invest Dermatol 1992; 99:715–722. 9. Sepp NT, Li L-J, Lee KH et al. Basic fibroblast growth factor increases expression of the v3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 1994; 103:295–299. 10. Senger DR, Ledbetter SR, Claffey KP et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the v3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149:293–305. 11. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin v3 for
angiogenesis. Science 1994; 264:569–571. 12. Brooks PC, Strömblad S, Klemke R et al. Antiintegrin v3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96:1815–1822. 13. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin v3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995; 108:2655–2661. 14. Hammes H-P, Brownlee M, Jonczyk A et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996; 2:529–533. 15. Dvorak HF. Tumours: wounds that do not heal. Similarities between tumour stroma generation and would healing. N Engl J Med 1986; 315:1650–1659. 16. Haas TL, Madri JA. Extracellular matrixdriven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 1999; 9: 70–77. 17. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49:117–137. 18. Buschmann I, Schaper W. The pathophysiology of the collateral circulation. J Pathol 2000; 190:338–342. 19. Henry TD. Therapeutic angiogenesis. BMJ 1999; 318:1536–1539. 20. Griffioen A, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharm Rev 2000; 52:237–268. 21. Jang J, Ho HV, Kwan H et al. Angiogenesis is impaired by hypercholesterolemia: role of assymmetric dimethylarginine. Circulation 2000; 102:1414–1419. 22. Babaei S, Teichert-Kuliszewska K, Monge JC et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998; 82:1007–1015. 23. Matsunaga T, Warltier DC, Weihrauch DW
37
579_Stenting_ch.02
14/8/2001 13:51
Page 38
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
24.
25.
26.
27. 28.
29. 30.
31.
32.
33.
34.
38
et al. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102:3098–3103. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999; 26:269–271. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997; 173: 206–210. Risau W, Sariola H, Zerwes HG et al. Vasculogenesis and angiogenesis in embryonicstem-cell-derived embryoid bodies. Development 1988; 102:471–478. Nicosia RF, Villaschi S. Autoregulation of angiogenesis by cells of the vessel wall. Int Rev Cytol 1999; 185:1–43. Fleisch M, Billinger M, Eberli FR et al. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1999; 100: 1945–1950. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992; 85:1197–1204. Charney R, Cohen M. The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Circulation 1993; 126:937–945. Ito W, Arras M, Scholz D. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol 1997; 273:H2155–H2165. Jones MK, Wang H, Peskar BM. Inhibition of angiogenesis by nonsteroidal antiinflammatory drugs; insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med 1999; 5:1418–1423. Cohen M, Rentrop KP. Limitations of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation 1986; 74:469. Marcus ML, Chilian WM, Kanatsuka H et al. Understanding the coronary circulation through studies at the microvascular level.
Circulation 1990; 82:1–7. 35. Schaper W. Control of coronary angiogenesis. Eur Heart J 1995; 16(suppl C):66–68. 36. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32:115–120. 37. Nakagawa K, Chen YX, Ishibashi H et al. Angiogenesis and its regulation: roles of vascular endothelial cell growth factor. Semin Thromb Hemost 2000; 26:61–66. 38. Asahara T, Bauthers C, Zheng LP. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92: 365–371. 39. Folkman J, Merier E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133:275–288. 40. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58:575–606. 41. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34:185–194. 42. Yayon A, Klagsbrun M, Esko J et al. Cell surface heparin-like molecules required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841–848. 43. Moscatelli D. Metabolism of receptor-bound and matrix-bound basic fibroblast growth by bovine capillary endothelial cells. J Cell Biol 1988; 107:753–759. 44. Brown KJ, Hendry IA, Parish CR. Acidic and basic fibroblast growth factor bind with differing affinity to the same heparin sulfate proteoglycan on BALB/c3T3 cells: implications for potentiation of growth factor action by heparin. J Cell Biochem 1995; 58:6–14. 45. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int 1995; 19:431–444. 46. Sellke FW, Laham RJ, Edelman ER et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65: 1540–1544. 47. Neufeld G, Cohen T, Gengrinovitch S,
579_Stenting_ch.02
14/8/2001 13:51
Page 39
REFERENCES
48.
49.
50. 51. 52. 53.
54.
55. 56.
57.
58.
59.
Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9–22. Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947–11954. Keyt BA, Berleau LT, Nguyen HV et al. The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271:7788–7795. Zachary I. Vascular endothelial growth factor. Int J Biochem Cell Biol 1998; 30: 1169–1174. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77:527–543. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211–220. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435–439. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439–442. Dor Y, Keshet E. Ischemia driven angiogenesis. Trends Cardiovasc Med 1997; 7: 289–294. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271:2746–2753. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417–6423. Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269:26988–26995. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phos-
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
phatidylinositol 3 -kinase/Akt signal transduction pathway. Requirement for Flk1/KDR activation. J Biol Chem 1998; 273:30336–30343. Fong Gh, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66–70. Fong GH, Klingensmith J, Wood CR et al. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev Dyn 1996; 207:1–10. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376(6535):62–66. Shweiki D, Itin A, Neufeld G et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993; 91:2235–2243. Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98:2108–2116. Isner JM, Pieczek A, Schainfield R. Clinical evidence of angiogenesis following arterial gene transfer of phVEGF165. Lancet 1996; 348:370–374. Celletti FL, Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Med 2001; 7:425–429. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the Tie2 receptor by secretion-trap expression cloning. Cell 1996; 87:1161–1169. Dumont DJ, Gradwohl G, Fong GH et al. Dominant–negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8:1897–1909. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376:70–74.
39
579_Stenting_ch.02
14/8/2001 13:51
Page 40
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
70. Suri C, Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171–1180. 71. Puri MC, Rossand J, Alitalo K et al. The receptor tyrosine kinase TIE is required for the integrity and survival of vascular endothelial cells. EMBO J 1995; 376:70–74. 72. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55–60. 73. Thurston G, Suri C, Smith K et al. Leakageresistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286:2511–2514. 74. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83:852–859. 75. Enholm B, Paavonen K, Ristimaki A et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997; 14:2475–2483. 76. Oh H, Takagi H, Suzuma K et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274:15732–15739. 77. Asahara T, Chen D, Takahashi T et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2 modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83:233–240. 78. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48–50. 79. Teichert-Kuliszewska K, Maisonpierre PC, Jones N et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001; 49:659–670. 80. Broadley KN, Aquino AM, Hicks B et al. Growth factors bFGF and TGB beta accelerate the rate of wound repair in normal and in diabetic rats. Int J Tissue React 1988; 10: 345–353. 81. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound
40
82.
83.
84.
85.
86.
87.
88.
89.
90.
healing in the genetically diabetic mouse. Am J Pathol 1990; 136:1235–1246. Thompson DW, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel therapies. J Pathol 2000; 190:330–337. Baffour R, Berman J, Garb JL et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose–response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16(2):181–191. Isner JM, Kaufman J, Rosenfield K et al. Combined physiologic and anatomic assessment of percutaneous revascularization using a Doppler guidewire and ultrasound catheter. Am J Cardiol 1993; 14:70D–86D. Pu LQ, Sniderman AD, Brassard R et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993; 88:208–215. Takeshita S, Pu LQ, Stein LA et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90:II228–II234. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93:662–670. Harada K, Friedman M, Lopez JJ et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270:H1791–H1802. Lazarous DF, Shou M, Stiber JA et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999; 44:294–302. Lopez JJ, Edelman ER, Stamler A et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997; 282:385–390.
579_Stenting_ch.02
14/8/2001 13:51
Page 41
REFERENCES
91. Lopez JJ, Edelman ER, Stamler A et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol 1998; 274:H930–H936. 92. Shou M, Thirumurti V, Rajanayagam S et al. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J Am Coll Cardiol 1997; 29:1102–1106. 93. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114–1123. 94. Lazarous DF, Unger EF, Epstein SE et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 2000; 36: 1239–1244. 95. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. First clinical results of a new treatment for coronary heart disease. Circulation 1998; 97:645–650. 96. Pecher P, Schumacher BA. Angiogenesis in ischemic human myocardium: clinical result after 3 years. Ann Thorac Surg 2000; 69: 1414–1419. 97. Sellke FW, Laham RJ, Edleman ER et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65: 1540–1544. 98. Laham RJ, Selke FW, Edelman ER et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100:1865–1871. 99. Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000; 85:1414–1419. 100. Udelson JE, Dilsizian V, Laham RJ et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities
101.
102.
103.
104.
105.
106.
107.
108.
in patients with severe symptomatic chronic coronary artery disease. Circulation 2000; 102:1605–1610. Henry TD, Rocha-Singh K, Isner JM et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J Am Coll Cardiol 1998; 31(suppl A):65A (abstract). Hendel RC, Henry TD, Rocha-Singh K et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dosedependent effect. Circulation 2000; 101: 118–121. Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800–2804. Vale PR, Symes JF, Esakof DD et al. Direct myocardial gene transfer of VEGF165 in patients with end-stage coronary artery disease: 12-month results of a phase I/II clinical trial. J Am Coll Cardiol 2001; 37(suppl A):285A (abstract). Hendel RC, Vale PR, Losordo DW et al. The effects of VEGF-2 gene therapy on rest and stress myocardial perfusion: results of serial SPECT imaging. Circulation 2000; 102(suppl):II-769 (abstract). Fortuin FD Jr, Vale P, Losordo DW et al. Direct myocardial gene transfer of vascular endothelial growth factor-2 (VEGF-2) naked DNA via thoracotomy relieves angina pectoris and increases exercise time: one-year follow-up of a completed dose-escalating phase 1 study. J Am Coll Cardiol 2001; 37(suppl A):285A–286A. Vale PR, Milliken CE, Fortuin D et al. Correlation of NOGA left ventricular electromechanical mapping and radionuclide perfusion imaging demonstrating augmented perfusion of ischemic myocardium in patients undergoing direct myocardial VEGF-2 gene transfer. J Am Coll Cardiol 2001; 37(suppl A):370A. Rosengart TK, Lee LY, Patel SR et al. Sixmonth assessment of a phase I trial of angiogenic gene therapy for the treatment of
41
579_Stenting_ch.02
14/8/2001 13:51
Page 42
THERAPEUTIC ANGIOGENESIS FOR CORONARY ARTERY DISEASE
coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230:466–470. 108A. Symes JF, Losardo DW, Vale PR et al. Genen therapy with vascular endothelial growth factor for inoperable coronary artery disease. Am Thorac Surg 1999; 68:830–836. 109. Rosengart TK, Lee LY, Patel SR et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468–474. 110. Li K, Welikson RE, Vikstrom KL, Leinwand LA. Direct gene transfer into the mouse heart. J Mol Cell Cardiol 1997; 29:1499–1504. 111. Rosengart TK, Patel SR, Crystal RG. Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk 1999; 6:29–40. 112. Simons M, Bonow RO, Chronos NA et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000; 102:E73–E86. 113. Laham RJ, Garcia L, Baim DS et al. Therapeutic angiogenesis using basic fibroblast growth factor and vascular endothelial growth factor using various delivery strategies. Curr Interv Cardiol Rep 1999; 1: 228–233. 114. Anderson ED, Mourich DV, Leong JA. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. Mol Mar Biol Biotechnol 1996; 5: 105–113. 115. McElvaney NG. Is gene therapy in cystic fibrosis a realistic expectation? Curr Opin Pulmonary Med 1996; 2:466–471. 116. Schultz A, Lavie L, Hochberg I et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the
42
117.
118.
119.
120.
121.
122.
123.
124.
125.
development of the coronary artery collateral circulation. Circulation 1999; 100:547–552. Volpert OV, Ward WF, Lingen MW. Captopril inhibits angiogenesis and slows the growth of experimental tumours in rats. J Clin Invest 1996; 98:671–679. Felesko W, Balkowiec EZ, Sieberth E. Lovastatin and tumour necrosis factor-alpha exhibit potentiated antitumour effects against Ha-ras-transformed murine tumour via inhibition of tumour-induced angiogenesis. Int J Cancer 1999; 81:560–567. Panet R, Markus M, Atlan H. Bumetanide and furosemide inhibited vascular endothelial cell proliferation. J Cell Physiol 1994; 158: 121–127. Van Belle E, Bauters C, Bertrand ME. From the angiogenic response to ischemia to the validation of the concept of ‘therapeutic angiogenesis’. Arch Mal Coeur Vaiss 1998; 91:1159–1170. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adenoVEGF. Am J Pathol 1999; 154:355–363. Hamaway AH, Lee LY, Crystal RG, Rosengart TK. Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. Curr Opin Cardiol 1999; 14: 515–522. Chen H, Chedotal A, He Z et al. Neurolipin2 a novel member of the neurolipin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 1997; 19:547–559. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60:203–212. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48–50.
579_Stenting_ch.03
14/8/2001 13:52
Page 43
3 Spot stenting Antonio Colombo and Takahiro Nishida
Introduction and background The treatment of long lesions has historically yielded poor immediate and long-term results when approached with traditional balloon angioplasty.1,2 The length of a coronary lesion is a predictor of procedural failure3–5 and balloon dilatation has been associated with a higher risk of vessel dissection, occlusion, and late restenosis.6–10 The application of new devices such as long balloons11 and rotational atherectomy12,13 increased procedural success but did not improve restenosis rate. Old studies using directional atherectomy (DCA) in long lesions (20 mm) reported high procedural failure (74% success rate) and an increase in complication rate (10.8%).14 In one study, in de novo lesions 10 mm in length, major complication rates were 12.5%, with a success rate of 84%.15 An early report by Robertson et al showed a restenosis rate of 62.5% in lesions 20 mm treated with DCA.16 Randomized device trials performed in long lesions, comparing excimer laser (ELCA) to percutaneous transluminal coronary angioplasty (PTCA) (AMRO trial: Amsterdam Rotterdam trial) and ELCA versus PTCA and versus rotablator in the ERBAC trial (Excimer Laser Rotablator Balloon Angioplasty Comparison), failed to show that any particular device has any advantage, with better follow-up results.17,18 The AMRO trial showed that there were more acute closures (8% versus 0.8%) and a trend towards more restenosis in the ELCA group (52% versus
41%). In the ERBAC trial, both rotablator and ECLA resulted in a better immediate lumen enlargement, but there was no benefit in 6-month restenosis rates. The introduction of coronary stents improved the immediate success in the treatment of long lesions.19 There are now numerous reports on the use of coronary stenting in long lesion. These studies indicate improved immediate outcome, as compared to balloon angioplasty, in terms of low incidence of occlusion.20–22 Despite this advancement, the restenosis rate increases with the length of the lesion23 and with the length of the stent used.24
Intravascular ultrasound guidance and the basis for spot stenting The concept at the basis of spot stenting is to try to obtain the best possible result with balloon angioplasty and to utilize a stent to improve the result where the balloon produced an insufficient lumen or caused an occlusive dissection. A number of studies employing the concept of intravascular ultrasound (IVUS)-guided PTCA in the treatment of coronary lesions produced promising results.25–27 Stone et al reported the early angiographic and clinical results of IVUS-guided PTCA in the Clinical Outcomes with Ultrasound Trial (CLOUT). On the basis of the vessel size and extent of plaque burden in the
43
579_Stenting_ch.03
14/8/2001 13:52
Page 44
SPOT STENTING
reference segment evaluated by IVUS, 73% of the lesions needed upsized balloons (final balloon-to-artery ratio 1.30 0.17) even after achieving an acceptable angiographic result. The success rate of IVUS-guided PTCA was 99%. This angiographic oversized balloon angioplasty, IVUS-guided, resulted in a large final minimal lumen diameter without increased rates of significant dissections or ischemic complications. The Washington Hospital Center reported pilot work on IVUS-guided balloon angioplasty utilizing balloons sized according to the mediato-media diameter as determined by IVUS. The endpoint used in this study was quite ambitious. The authors aimed to achieve a minimal lumen cross-sectional area 70% of the average vessel cross-sectional area, with no lumencompromising dissections. Crossover to stenting was needed in 61% of lesions. Final lumen area in the PTCA group was 6.0 2.0 mm2, with no incidence of abrupt vessel closure. Target lesion revascularization was needed in 17% of lesions. Frey et al reported on a total of 269 patients (358 lesions) who were randomized to IVUS-guided intervention and angiographyguided intervention in the SIPS trial.27 Stenting was performed in about 50% of lesions in both groups. Major adverse cardiac events (MACE) (myocardial infarction, urgent revascularization, death) during hospitalization were fewer with the IVUS-guided interventions. Based on these concepts, we modified the IVUS-guided PTCA approach to include the spot stenting technique. The basis of this approach is that it is quite common, in a long lesion, for balloon angioplasty not to achieve an optimal result throughout the entire length of the lesion. Stents may be utilized to treat the segment where an optimal angioplasty result was not achieved. This approach allows achieving the best lumen enlargement while utilizing the shortest possible stent. A stent will be deployed where lumen dimensions do not meet prespecified IVUS criteria. In contrast to traditional stenting, where a lesion is covered from a proximal normal segment to a distal normal segment, the concept
44
behind this approach tends to minimize stent length. Avoiding the treatment of long lesions with long stents has the goal of minimizing two potential problems: the high restenosis rates associated with long stents, and the pattern of diffuse in-stent restenosis. This technique does not depart from the aim of optimizing the final lumen and covering dissections with a stent. The concept of optimizing inflow and outflow is still valid. The only difference compared to the past is that dissections and results following balloon angioplasty are evaluated by IVUS. The lumen measurements based on IVUS will allow us to determine if a result is adequate or not, without the need to place a stent on any segment lacking a perfect angiographic result. IVUS-guided PTCA with spot stenting is a synergistic strategy utilizing PTCA, stents and IVUS for the treatment of long lesions, particularly if located in small vessels. This is not a method which seeks to compare the results of lesions treated with PTCA against those which receive a stent. It is a technique combining PTCA and stenting, with the objective of achieving a predetermined IVUS luminal result while restricting stent length. This approach is based on the premise that IVUS guidance for the coronary intervention will allow us to: (1) maximize the probability of achieving a prespecified criterion of lumen enlargement with balloon angioplasty, therefore minimizing or removing the need for stenting; and (2) identify the particular segment or segments of a lesion where the luminal result is not optimal, so as to be able to focally implant a stent only at that specific site. One assumption of this strategy is that the late loss following an optimal angioplasty will be lower compared to the one following implantation of a long stent. This approach allows a reduction in restenosis by the attainment of an optimal minimum luminal diameter (MLD) with angioplasty while limiting the stent length.
579_Stenting_ch.03
14/8/2001 13:52
Page 45
OUR EXPERIENCE
Our experience We tested this approach in a prospective study performed between April 1997 and June 1999, which included 146 consecutive patients with 173 lesions. The flow chart for this study is shown in Figure 3.1. The operator evaluates by visual estimate if the lesion to be treated is a long lesion which needs this approach. In general, this decision is taken if the lesion is too long to be treated with a single inflation of a 20 mm long balloon. Long lesions (15 mm) are initially approached with PTCA, utilizing a balloon-toartery ratio of 1 : 1. At the discretion of the operator, IVUS is performed prior to balloon dilatation, and the size of the first balloon is selected according to the IVUS media-to-media measurements. This means that the first step is to perform a preintervention IVUS evaluation. If this initial IVUS assessment is not possible or the operator prefers to defer this first IVUS evaluation, the lesion is first dilated with a balloon sized according to angiography. If extensive calcium is present, rotational atherectomy (Rotablator) can be performed before PTCA. If during balloon dilatation the balloon does not completely expand at 10–12 atm, a cutting balloon can be used. A cutting balloon is indicated if the IVUS study shows a fibrotic or moderately calcified lesion. If, after initial PTCA balloon dilatation, the IVUS criteria are met in all segments of the lesion, the procedure is considered complete. Criteria for success based on IVUS evaluation are: (1) achievement of a lumen cross-sectional area 50% of the vessel crosssectional area at the lesion site; or (2) a minimum true lumen cross-sectional area
5.5 mm2. These success criteria are defined independently of the presence of a dissection, as long as the true lumen cross-sectional area is adequate and meets our prespecified lumen cross-sectional area criterion, and thromolysis in myocardial infarction (TIMI) grade 3 flow is present. If the IVUS criteria are not met, the operator may consider using a bigger balloon or higher pressure, according to lesion morphology
and the IVUS vessel diameters. If balloon upsizing is not possible, a stent is implanted focally only in the segment or segments of the lesion where the IVUS criterion has not been achieved, taking care to use the shortest stent length necessary to obtain an optimal result. IVUS is performed at the end of the procedure to ensure achievement of IVUS success criteria and to document final lumen dimensions. Clinical, angiographic and procedural characteristics of the lesions treated with this approach are shown in Tables 3.1 and 3.2. Measurements were performed with quantitative angiography (QCA) using the QCA-CMS (Medis, Leiden, The Netherlands) by operators not involved in the procedure. These lesions had an average reference vessel diameter of 2.96 0.50 mm and a lesion length of 25.8 8.2 mm. Ninety-one per cent of the
Long lesion
PTCA with B/V ratio 1 :1 by IVUS (media to media)
IVUS criteria: CSA 5.5 mm2 or lumen area 50% of target lesion VA
Criteria not met Criteria met: procedure is complete Larger balloon or higher pressure
Criteria not met
Place a stent only in segments where IVUS criteria not met
Figure 3.1 Flow diagram of IVUS-guided PTCA with spot stenting.
45
579_Stenting_ch.03
14/8/2001 13:52
Page 46
SPOT STENTING
Number of patients Age (years) Male gender Hypertension Diabetes mellitus Hypercholesterolemia Current and previous smoker LVEF (%) Previous MI Multivessel disease Unstable angina pectoris
146 62 10 134 (92%) 82 (56%) 16 (11%) 83 (57%) 86 (59%) 61 12 75 (51%) 109 (75%) 46 (32%)
LVEF, left ventricular ejection fraction; MI, myocardial infarction.
Table 3.1 Baseline characteristics.
lesions approached were complex (type B2 and C). Of the 173 lesions treated, 63 lesions achieved IVUS criteria of success with PTCA alone, while 110 lesions required spot stenting. The vessels involved and the location of the lesion within the vessel had no influence upon whether a stent would eventually be required. Type B1 lesions were more likely to be treated with PTCA alone. The rotablator was adjunctively utilized in 16% of cases overall. The average final balloon-to-artery ratio used was 1.2 0.2, with an average pressure of 14 3.7 atm. The average stent length utilized in the lesions which did not meet IVUS criteria following PTCA (n 110) was 16.9 6.5 mm. This aggressive balloon sizing produced an acute gain of 2.03 0.76 mm. The acute gain was 1.60 0.64 mm for the lesions which were treated with PTCA alone, and 2.28 0.71 mm for the lesions which received a stent. This strategy of IVUS-guided PTCA allowed us to maximize the gain with simple balloon dilatation. It is interesting to note that the acute gain of 1.60 mm achieved with IVUS guidance in the group treated with PTCA alone was similar to
46
the acute gain achieved in the stent arms of the BENESTENT28 and STRESS trials,29 1.40 mm and 1.72 mm, respectively, which used angiographic-guided stenting. In the group of patients requiring additional stenting, we were able to maintain a total stent length much shorter than the lesion length measured with QCA (Figure 3.2).
Case examples We would like to illustrate the spot stenting approach by presenting and discussing two typical cases, which were treated according to this strategy. An example of a typical lesion approached with IVUS-guided PTCA and spot stenting is shown in Figure 3.3. This is a 36.4 mm long lesion located in an obtuse marginal branch. The initial balloon of 3.0 mm was selected according to the visual estimate of an operator with extensive IVUS experience. We used the statement ‘extensive IVUS experience’ in order to help understand why the first balloon selected was oversized compared to the usual practice of angiographic guidance; QCA measurement of this artery showed a reference vessel size of 2.17 mm. This decision shows how frequently
Percentiles plot 100 80 Percentile
Patients
Lesion length
60
Length of stented segment
40 20 0 5 10 15 20 25 30 35 40 45 50 55 Length (mm)
Figure 3.2 Frequency–distribution curve of lesion length versus stented segment length. Contrary to most trials, the final stent length is shorter than the angiographic lesion length.
579_Stenting_ch.03
14/8/2001 13:52
Page 47
CASE EXAMPLES
Number of lesions RCA LAD LCx Proximal Mid Distal Modified ACC/AHA class: B1 B2 C Reference diameter (mm) MLD (mm) Diameter stenosis (%) Lesion length (mm) DCA Rotablator Balloon-to-artery ratio Maximal inflation pressure (atm) Post-MLD (mm) Post-diameter stenosis (%) Number of deployed stents Total deployed length of stents (mm) Slotted tube stent Coil stent
Total
Stent
Balloon
p
173 54 (31%) 88 (51%) 31 (18%) 66 (38%) 86 (50%) 21 (12%)
110 28 (26%) 62 (56%) 20 (18%) 42 (38%) 60 (55%) 8 (7%)
63 26 (41%) 26 (41%) 11 (18%) 24 (38%) 26 (41%) 13 (21%)
0.041 0.06 1.00 1.00 0.11 0.014
10 (16%) 6 (10%) 47 (75%) 2.91 0.53 0.79 0.40 74 14 26.0 8.1 1 (2%) 9 (14%) 1.2 0.2 13 4.0 2.37 0.54 22 13 – – – –
0.030 1.00 0.10 0.34 0.85 0.95 0.83 0.42 0.67 0.62 0.004 0.001 0.001 – – – –
16 (9%) 6 (6%) 16 (9%) 10 (9%) 141 (82%) 94 (86%) 2.96 0.50 2.99 0.48 0.78 0.44 0.77 0.47 74 15 74 15 25.8 8.2 25.7 8.2 6 (4%) 5 (5%) 28 (16%) 19 (17%) 1.2 0.2 1.2 0.2 14 3.7 15 3.4 2.80 0.66 3.04 0.59 11 15 4.2 12 – 1.1 0.4 – 16.9 6.5 – 101 (92%) – 8 (7%)
RCA, right coronary artery; LAD, left anterior descending artery- LCx, left circumflex artery; ACC, American College of Cardiology; AHA, American Heart Association.
Table 3.2 Baseline angiographic characteristics and procedural data.
angiography may underestimate the vessel size. In fact, the IVUS media-to-media measurements (Figure 3.4) indicated a vessel diameter of 2.7 mm. This means that the operator oversized the balloon even according to IVUS measurements. Following the initial balloon dilatation, the angiographic result seen in Figure 3.4 appears acceptable. The IVUS evaluation pointed out that at the center of the lesion the criteria for success were not met (b). A decision to implant a
3.0 mm stent 18 mm long was then taken. Stenting produced an acceptable result in segment (b), while the proximal and distal areas could be safely left with an optimal PTCA result (Figure 3.5). Of note is a small dissection only demonstrated by IVUS in Figure 3.5a. The mean stent length utilized in this 36 mm long lesion demonstrates the concept of spot stenting utilizing a combination of PTCA and stenting during the treatment of the same
47
579_Stenting_ch.03
14/8/2001 13:52
Page 48
SPOT STENTING
Figure 3.3 Case 1. Baseline angiogram. A long lesion is present in an obtuse marginal branch with an angiographic reference size of 2.17 mm.
lesion. Another illustrative example is shown in Figure 3.6. We see a 34.3 mm long lesion in the mid left anterior descending (LAD) on a vessel 3.28 mm in reference size by QCA. The operator initially performed angioplasty utilizing a 3.5 mm cutting balloon with multiple overlapping inflations throughout the lesion length. The subsequent angiogram, shown in Figure 3.7, shows an acceptable angiographic result with small extraluminal dissections. At this time, IVUS evaluation was performed in order to confirm or disprove that this angiographic result was acceptable. Figure 3.7a–d summarize the most relevant IVUS images of the pull-back. The first information listed refers to the size of the vessel. Proximally, this artery had a reference size by IVUS of over 4 mm in diameter; the mid and distal parts of the vessel had sizes slightly less than 3.5 mm. Aware of this information, the operator could have used a larger balloon proximally if this result was not acceptable. As shown in Figure 3.7a, the area stenosis proximally is only 45%. This result is therefore acceptable,
48
and no bigger balloon or stenting is necessary at this level. Slightly more distally, there is a 68% area stenosis despite the use of a balloon of appropriate size (Figure 3.7b). This means that this residual lesion should be stented. The IVUS evaluation allowed placement of a 4.0 mm stent 15 mm long. It may be asked why the operator did not use a 4.0-mm balloon before deciding to proceed with a stent. The answer to this question is that the residual area stenosis and the plaque burden at the lesion site were quite large and unlikely to suggest that a simple angioplasty with a 0.5-mm larger balloon would have made much difference. In addition, the threshold for performing stent implantation in a vessel with a reference size over 3.5 mm is quite low, due to the low restenosis rate in large vessels. The same line of reasoning applies to the other segment shown Figure 3.7c. The final result is shown in Figure 3.8. Figure 3.2 summarizes the frequency–distribution curve depicting the relationship between lesion length and stent length with the spot stenting approach. These curves are not overlapping. This finding is different from our usual experience, in which stent length matches lesion length. In previous studies such as the BENESTENT I and II and STRESS trials28–30 and in many other stent trials, stent length almost always exceeds lesion length. With the spot stenting approach, stent length is actually less than the lesion length (16.9 6.5 mm versus 25.7 8.2 mm). This is an important concept to consider, since there is now evidence to support the view that the length of the deployed stent and the number of stents implanted are implicated as contributing factors to increased restenosis rates.23,24 Based on these notions, stents were limited to the shortest length that allowed the achievement of an adequate lumen. This strategy was not associated with a higher risk of complications. The procedural success rate was 92%. Acute and subacute thrombosis occurred in 0.7% and 1.4% of cases respectively, Q-wave myocardial infarction in 1.4%,
579_Stenting_ch.03
14/8/2001 13:52
Page 49
CASE EXAMPLES
a
a
b
b c
c
Figure 3.4 Case 1. Post balloon angioplasty. 3.0 mm 10 atm. (a) Lumen CSA 2.7 mm2. Vessel CSA 5.4 mm2. Area stenosis 50%. Media-to-media diameter 2.4 2.7 mm. (b) Lumen CSA 2.0 mm2. Vessel CSA 4.6 mm2. Area stenosis 57%. Media-tomedia diameter 1.9 2.7 mm. (c) Lumen CSA 2.9 mm2. Vessel CSA 4.0 mm2. Area stenosis 28%. Media-to-media diameter 2.3 2.3 mm.
49
579_Stenting_ch.03
14/8/2001 13:53
Page 50
SPOT STENTING
a
a
b
b
c
c
Figure 3.5 Case 1. Final angiogram and IVUS images. Crossflex LC 3.0 mm 18 mm, 20 atm. (a) Lumen CSA 2.9 mm2. Vessel CSA 5.7 mm2. Area stenosis 50%. Media-to-media diameter 2.7 2.7 mm. (b) Lumen CSA 5.0 mm2. Strut-to-strut diameter 2.7 2.7 mm. (c) Lumen CSA 2.9 mm2. Vessel CSA 3.6 mm2. Area stenosis 21%. Media-to-media diameter 1.9 2.5 mm.
50
579_Stenting_ch.03
14/8/2001 13:53
Page 51
PROCEDURAL SAFETY
Figure 3.6 Case 2. Baseline angiogram. LAD mid. Reference vessel diameter: 3.28 mm. Lesion length: 34.3 mm.
and emergency and in-hospital CABG in 0.7%; no patient died during the hospital stay.
Selected lesion examples The lesions presented in Figures 3.9 to 3.12 are typical examples of long stenosis which are best suited for the approach of spot stenting.
Procedural safety Historically, balloon angioplasty performed with ‘oversized balloons’ without IVUS guidance has been reported to be associated with poor outcome.31,32 In addition, placing a stent without fully ‘covering’ the lesion has been viewed as dangerous because of the risk of acute and suba-
cute stent thrombosis due to the potential flow disturbance. However, when IVUS is used to guide the intervention, any flow-limiting dissection can be more accurately assessed and a more educated decision can be made regarding this particular segment should be left untreated. The rate of major procedural complications in this study does not differ significantly from what has been reported with traditional coronary stenting in simpler and more focal lesions. In the STRESS trial, Q-wave myocardial infarction occurred in 2.9% of patients, and emergency bypass surgery was done in 2% of patients.29 Therefore, it seems that this approach does not increase the incidence of major procedural complications or subacute events, despite treating a more complex lesion subset.
51
579_Stenting_ch.03
14/8/2001 13:53
Page 52
SPOT STENTING
a
b a b
c
d
c
d
Figure 3.7 Case 2. Post cutting balloon. 3.5 mm 12 atm. (a) Lumen CSA 9.7 mm2. Vessel CSA 17.4 mm2. Area stenosis 45%. Media-to-media diameter 4.3 5.2 mm. (b) Lumen CSA 3.3 mm2. Vessel CSA 10.2 mm2. Area stenosis 68%. Mediato-media diameter 3.6 3.8 mm. (c) Lumen CSA 4.4 mm2. Vessel CSA 13.6 mm2. Area stenosis 68%. Media-to-media diameter 3.9 4.5 mm. (d) Lumen CSA 5.8 mm2. Vessel CSA 8.8 mm2. Area stenosis 34%. Media-to-media diameter 3.2 2.6 mm.
52
579_Stenting_ch.03
14/8/2001 13:53
Page 53
PROCEDURAL SAFETY
a
b
a b c
c d
d
Figure 3.8 Case 2. Final angiogram and IVUS images. 2 Crown 4.0 mm 15 mm, 12 atm (a) Lumen CSA 10.6 mm2. Vessel CSA 17.8 mm2. Area stenosis 41%. Media-to-media diameter 4.4 5.2 mm. (b) Lumen CSA 10.0 mm2. Strut-to-strut diameter 3.4 3.6 mm. (c) Lumen CSA 9.2 mm2. Strut-to-strut diameter 3.2 3.8 mm. (d) Lumen CSA 6.7 mm2. Vessel CSA 10.4 mm2. Area stenosis 36%. Media-to-media diameter 3.5 3.8 mm.
53
579_Stenting_ch.03
14/8/2001 13:53
Page 54
SPOT STENTING
Figure 3.9 Case 3. Baseline. A diffuse diseased lesion located in the proximal and mid right coronary artery.
Figure 3.10 Case 3. Final result following implantation of 4 mm NIR stent 16 mm long in the proximal right coronary artery. All the other segments of the lesions were successfully dilated with PTCA. The haziness present distally to the implanted stent when evaluated with IVUS did not represent a reduction in lumen to suggest the implantation of an additional stent.
(a)
b a
Haziness (b)
Minimal intimal tear
54
579_Stenting_ch.03
14/8/2001 13:53
Page 55
LONG-TERM OUTCOME
Baseline
Figure 3.11 Case 4. Baseline. A distal left anterior descending coronary artery with diffuse disease.
Implications for management of dissections after coronary interventions Traditionally, dissections after PTCA have been considered a risk factor for acute closure. This concept applies also to coronary stenting, where even small edge dissections are usually stented because of the fear of subacute stent thrombosis. However, inducing a dissection is an integral part of lumen enlargement with PTCA, and not all dissections should be judged to be equally
malignant events. A dissection may predispose to an adverse event when it compromises the lumen, leading to subsequent vessel closure. There is no doubt that if a dissection is associated with a decrease in TIMI flow, stenting becomes mandatory. However, when a dissection is associated with a TIMI 3 flow, further evaluation beyond angiographic assessment should be considered. IVUS interrogation or coronary flow measurements are tools useful for this evaluation. A recent study that compared the degree of agreement between angiography and IVUS reported a large discrepancy between these two modalities, particularly when dissections are present.33 With the IVUS-guided PTCA with spot stenting strategy, residual dissections, which were evaluated by IVUS, were present and left untreated in 29% of lesions (82% type B), both in the angioplasty-alone group and in the spot stenting group. These dissections, which were mostly type B, were all associated with TIMI 3 flow, and met the IVUS criterion to leave at the dissection site a residual lumen at least 50% of the vessel area. These dissections, which were left without additional stenting, did not produce an increased risk of acute or subacute adverse events.
Long-term outcome The lesions treated with the IVUS-guided spot stenting approach had a mean vessel diameter of 2.96 mm and a mean length of 25.8 mm, an incidence of binary restenosis of 29%, a target lesion revascularization (TLR) rate of 29%, and a late MACE rate of 33% (11 7.9-month follow-up interval); these are encouraging outcome data compared to what have been reported in the literature with PTCA or stenting long lesions.10,19,21 This approach allows lumen optimization while limiting stent length. This goal is achieved without an increase in procedural complications such as acute or subacute vessel closure. The long-term outcome appears favorable, thanks to the combination of a large lumen achieved with simple balloon dilatation
55
579_Stenting_ch.03
14/8/2001 13:53
Page 56
SPOT STENTING
(b)
(a)
a b Dissection
(a)
(b) Dissection
Figure 3.12 Case 4. IVUS evaluation following angioplasty with 3.0-mm balloon (10 atm).
and with a minimal usage of long stents which may lead to excessive intimal hyperplasia. The major procedural and clinical findings utilizing this technique of IVUS-guided balloon angioplasty assisted by spot stenting are as follows: (1) treatment of long lesions with this technique is associated with a higher procedural success rate than that of the historical controls treated with PTCA, and a similar success rate to those reported with stenting;34–36 (2) complication rates do not increase; and (3) long-term follow-up data suggest that the angiographic
56
restenosis rate and the need for TLR with this approach are better compared to PTCA alone or stenting applied to these types of lesion. Studies which reported a favorable long-term outcome with a strategy of stenting the full lesion length dealt with vessels with a large reference diameter37,38 or used only TLR, myocardial infarction or death as the long-term endpoint. The large reference vessel diameter is known to be an important factor that counteracts the negative effect of lesion length or stent length.39,40 An evaluation limited to TLR or
579_Stenting_ch.03
14/8/2001 13:54
Page 57
PATTERN OF RESTENOSIS
i)
ii)
other major cardiac events without an angiographic follow-up are known to give an optimistic assessment of the long-term results of coronary interventions.41
Pattern of restenosis a b
Figure 3.13 Case 4. Final result following implantation of two stents. (a) ACS RX Duet 3.0 13 mm. (b) ACS RX Duet 3.0 8 mm.
A
One of the main problems following the implantation of long stents is the pattern of restenosis. Diffuse in-stent restenosis and total occlusion are known to be associated with a high incidence of target vessel revascularization following a second intervention.42 Studies have reported that the use of a long stent was associated with a pattern of diffuse in-stent restenosis.24,43 For this reason, it is important not only to try to minimize the restenotic events but also, if restenosis occurs, to try to avoid the pattern of diffuse restenosis or total occlusion.
B
Figure 3.14 (A) Case 5. Baseline. A total occlusion of a right coronary artery with diffuse disease. (B) Case 5. IVUS-guided balloon sizing. After balloon angioplasty. PTCA + cutting balloon (final procedure before stenting). 3.75 mm, 10 atm. 57
579_Stenting_ch.03
14/8/2001 13:54
Page 58
SPOT STENTING
(i)
(ii)
(iii)
C
Figure 3.14 continued After balloon angioplasty. (C) Case 5. Lumen evaluation with IVUS. (i) Lumen CSA 6.7 mm2. Vessel CSA 13.2 mm2. (ii) Lumen CSA 4.0 mm2. Vessel CSA 13.2 mm2. (iii) Lumen CSA 4.5 mm2. Vessel CSA 8.8 mm2.
58
579_Stenting_ch.03
14/8/2001 13:54
Page 59
PATTERN OF RESTENOSIS
3.75 mm
16 atm
D
E
Figure 3.14 continued (D) Case 5. Implantation of a single 15-mm long stent. Final result. (E) Case 5. Follow-up result. Six-month follow-up.
59
579_Stenting_ch.03
14/8/2001 13:55
Page 60
Preintervention angiogram i)
ii)
QCA
iv)
IVUS
iii)
Figure 3.15 Case 6. A long lesion in mid right coronary artery. Notice the large discrepancy between the IVUS and angiographic reference vessel size. QCA: Ref 2.67 mm; MLD 0.98 mm; lesion length 49.2 mm. IVUS: media-to-media 4.1 mm; balloon size 3.75 mm.
(a)
(c)
a b
c (b)
Dissection
Figure 3.16 Case 6. Result following IVUS-guided PTCA. (a) Lumen 3.5 mm2. (b) Lumen 7.3 mm2. (c) LCSA 5.6 mm2.
60
579_Stenting_ch.03
14/8/2001 13:56
Page 61
Stent
Stent: DART 16 mm
After balloon angioplasty
After spot stenting
Figure 3.17 Case 6. Following a single 16-mm stent implantation with a 4-mm balloon.
(a)
Stent
(c)
a
b
c
LCSA 8.1 mm2
LCSA 6.6 mm2
(b)
Dissection LCSA 10.2 mm2
Figure 3.18 Case 6. Final result with IVUS evaluation.
61
579_Stenting_ch.03
14/8/2001 13:56
Page 62
SPOT STENTING
Lesion Stent restenosis Focal (10 mm) Diffuse (10 mm) Total occlusion
27 12 (44%) 15 (56%) 0
Table 3.3 Pattern of stent restenosis.
The 27 restenotic lesions in our experience of spot stenting had a diffuse pattern in 15 lesions (56%). The other 12 restenotic lesions (44%) had a focal pattern and, interestingly, no total occlusion occurred (Table 3.3). This is the reason why we expect that the long-term outcome of patients treated with this modality will be superior among patients who reach an endpoint. The incidence of a further restenotic event is likely to be less for the group of patients with a lower incidence of diffuse in-stent restenosis.
Contraindications There are formal or technical contraindications to this technique. We do not see the advantage of the more complex approach of spot stenting when the long lesion is located on a vessel with an angiographic reference size of 3.5 mm or larger. The restenosis rate of long stents implanted on vessels with a large reference diameter is low, and the difference compared to a
62
short stent is not large enough to justify a more complex and expensive approach.39,40 The most practical strategy for a long lesion located on a vessel with a reference diameter of 3.5 mm or larger is direct stenting with full lesion coverage. An area of concern is when the operator is not confident with the interpretation of the IVUS images. The need to rely on the judgment concerning the evaluation of IVUS findings is a key element for the success of this procedure. In particular, the decision not to stent a dissection depends on the correct measurement of the true residual lumen. A mistake in this evaluation may leave untreated an occlusive dissection which may cause late stent thrombosis. In a situation of uncertainty or inadequate IVUS image quality, such as the one related to the presence of nonuniform rotational artifacts, the operator may use doppler coronary flow reserve or measurement of pressure gradients with calculation of the fractional flow reserve to evaluate if a final result is adequate.
Conclusions IVUS-guided balloon angioplasty assisted by spot stenting allows safe treatment of long lesions. This strategy requires utilization of stents in the majority of cases; most of the stents utilized are shorter than the original length of the lesion. Procedural complications are low, and long-term outcome appears to be superior to the results achieved in historical controls, which utilize PTCA alone, or stenting where the lesion is covered from normal segment to normal segment.
579_Stenting_ch.03
14/8/2001 13:56
Page 63
REFERENCES
References
1. Ellis S, Roubin G, King SI et al. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol 1989; 63:30–34. 2. Tenaglia A, Zidar J, Jackman J et al. Treatment of long coronary artery narrowings with long angioplasty balloon catheters. Am J Cardiol 1993; 71:1274–1277. 3. Meier B, Gruentzig AR, Hollman J et al. Does length or eccentricity of coronary stenoses influence the outcome of transluminal dilatation? Circulation 1983; 67:497–499. 4. Ellis SG, Roubin GS, King SB 3rd et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77:372–379. 5. Detre KM, Holmes DR Jr, Holubkov R et al. Incidence and consequences of periprocedural transluminal coronary angioplasty registry. Circulation 1990; 82:739–750. 6. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 1988; 77:361–371. 7. Bourassa MG, Lesperance J, Eastwood C et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991; 18:368–376. 8. Pepine CJ, Hirshfeld JW, MacDonald RG et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation 1990; 81:1753–1761. 9. Ryan TJ, Bauman WB, Kennedy JW et al. Guidelines for percutaneous transluminal angioplasty: a report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (Subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 1993; 22:2033–2054. 10. Hirshfeld JW Jr, Schwartz JS, Jugo R et al.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol 1991; 18:647–656. Cannon AD, Roubin GS, Hearn JA et al. Acute angiographic and clinical results of long balloon percutaneous transluminal coronary angioplasty and adjuvant stenting for long narrowings. Am J Cardiol 1994; 73:635–641. Bertrand ME, Lablanche JM, Leroy F et al. Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). Am J Cardiol 1992; 69:470–474. Warth DC, Leon MB, O’Neill W et al. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24:641–648. Baim D, Hinohara T, Holmes D et al. Results of directional coronary atherectomy during multicenter preapproval testing. Am J Cardiol 1993; 72:6E–11E. Hinohara T, Rowe MH, Tcheng JE et al. Effect of lesion characteristics on outcome of directional coronary atherectomy. J Am Coll Cardiol 1991; 17:1112–1120. Robertson G, Selmon M, Hïnohara T et al. The effect of lesion length on outcome of directional coronary atherectomy. Circulation 1990; 82:III-623. Appleman YE, Piek J, Redekop WK et al. Excimer laser angioplasty versus balloon angioplasty in longer coronary lesions: a multivariate analysis. Circulation 1995; 92:I-74. Foley DP, Appleman YE, Piek JJ. Comparison of angiographic restenosis propensity of excimer laser coronary angioplasty and balloon angioplasty in the Amsterdam Rotterdam (AMRO) trial. Circulation 1995; 92: I-477. Kobayashi Y, De Gregorio J, Kobayashi N et al. Comparison of immediate and follow-up results of the short and long NIR stent with
63
579_Stenting_ch.03
14/8/2001 13:56
Page 64
SPOT STENTING
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
64
the Palmaz–Schatz stent. Am J Cardiol 1999; 84:499–504. Roguin A, Grenadier E, Peled B et al. Acute and 30-day results of the serpentine balloon expandable stent implantation in simple and complex coronary arterial narrowings. Am J Cardiol 1997; 80:1155–1162. Williams IL, Thomas MR, Robinson NM et al. Angiographic and clinical restenosis following the use of long coronary Wallstents. Cathet Cardiovasc Interv 1999; 48:287–293. Antoniucci D, Valenti R, Santoro GM et al. Preliminary experience with stent-supported coronary angioplasty in long narrowings using the long Freedom Force stent: acute and sixmonth clinical and angiographic results in a series of 27 consecutive patients. Cathet Cardiovasc Diagn 1998; 43:163–167. Kastrati A, Elezi S, Dirschinger J et al. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999; 83:1617–1622. Kobayashi Y, De Gregorio J, Kobayashi N et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651–659. Stone GW, Hodgson JM, St Goar FG et al. Improved procedural results of coronary angioplasty with intravascular-ultrasound guided balloon sizing. Circulation 1997; 95:2044–2052. Abizaid A, Mehran R, Pichard AD et al. Results of high pressure ultrasound-guided ‘over-sized’ balloon PTCA to achieve ‘Stentlike’ results. J Am Coll Cardiol 1997; 29(suppl A):280A. Frey AW, Muller Ch, Hodgson J, Roskamm H. Fewer acute major adverse cardiac events (MACE) by ultrasound guided interventions: findings from the strategy of intracoronary ultrasound guided PTCA and stenting (SIPS) trials Eur Heart J 1997; 18(suppl):862 (abstract). Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331:489–495. Fischman DL, Leon MB, Baim DS et al. A ran-
30.
31.
32. 33.
34.
35.
36.
37.
38.
domized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331:496–501. Serruys PW, van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease. Lancet 1998; 352:673–681. Roubin GS, Douglas JS, King SB et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty. Circulation 1988; 78:557–565. Nichols AB, Smith R, Berke AD et al. Importance of balloon size in coronary angioplasty. J Am Coll Cardiol 1989; 13:1094–1100. Ozaki Y, Violaris A, Kobayashi T et al. Comparison of coronary luminal quantitation obtained from intracoronary ultrasound and both geometric and videodensitometric quantitative angiography before and after balloon angioplasty and directional atherectomy. Circulation 1997; 96:491–499. Ozaki Y, Violaris AG, Hamburger J et al. Short- and long-term clinical and quantitative angiographic results with the new, less shortening Wallstent for vessel reconstruction in chronic total occlusion: a quantitative angiographic study. J Am Coll Cardiol 1996; 28:354–360. Gambhir DS, Sudha R, Trehan V et al. Immediate and six-month outcome of self-expanding Wallstent for long lesions in native coronary arteries. Indian Heart J 1997; 49:53–59. De Scheerder IK, Wang K, Kostopoulos K et al. Treatment of long dissections by use of a single long or multiple short stents: clinical and angiographic follow-up. Am Heart J 1998; 136:345–351. Mehran R, Hong M, Lansky A et al. Vessel size and lesion length influence late clinical outcomes after native coronary artery stent placement. Circulation 1997; 96:1520 (abstract). Kornowski R, Bhargava B, Fuchs S et al. Procedural results and late clinical outcomes after percutaneous interventions using long ( or 25 mm) versus short (20 mm) stents. J Am
579_Stenting_ch.03
14/8/2001 13:56
Page 65
REFERENCES
Coll Cardiol 2000; 35:612–618. 39. Hong MK, Park SW, Mintz GS et al. Intravascular ultrasonic predictors of angiographic restenosis after long coronary stenting. Am J Cardiol 2000; 85:441–445. 40. Rozenman Y, Mereuta A, Schechter D et al. Long-term outcome of patients with very long stents for treatment of diffuse coronary disease. Am Heart J 1999; 138:441–445. 41. Baim DS, Kuntz RE. Appropriate uses of angiographic follow-up in the evaluation of
new technologies for coronary intervention. Circulation 1994; 90:2560–2563. 42. Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872–1878. 43. Lee SG, Lee CW, Hong MK et al. Predictors of diffuse-type in-stent restenosis after coronary stent implantation. Cathet Cardiovasc Intervent 1999; 47:406–409.
65
579_Stenting_ch.03
14/8/2001 13:56
Page 66
579_Stenting_ch.04
14/8/2001 14:01
Page 67
4 Ostial and bifurcation disease Alexander JR Black, Jean Fajadet, Jean Marco
Overview Advances in angioplasty equipment and adjunctive medical therapy have been associated with improved immediate and long-term outcomes. However, the treatment of ostial and bifurcation lesions continues to be problematic, with reduced procedural success rates and an increased need for repeat procedures during long-term follow-up. With the exception of aorto-ostial disease, which presents its own unique challenges in terms of accurate visualization and precise instrumentation, these situations share a common pathologic basis, largely related to the likelihood of plaque shift with resultant axial redistribution, which results in the so-called ‘snow-plough’ effect.1,2 A systematic approach to management in these situations requires an understanding of the different possible ‘permutations’ of lesion morphologic type and the likely outcomes after intervention according to these anatomic subtypes. Ideally, a clear rationale for therapeutic decision-making will be based on this kind of information, indicating the need for side-branch protection, the appropriateness of debulking, and whether to deploy one, two (or more) stents. As well as requiring more attention to overall strategic considerations, bifurcation and aorto-ostial lesions commonly pose greater technical challenges, with the potential need to use two guidewires, balloons or stents demanding a higher degree of technical skill in the case of bifurcation disease, and difficulties in guide catheter manipulation
and stent positioning adding to the complexity of aorto-ostial intervention. The likelihood of a higher rate of in-hospital major adverse coronary events (MACE) and a higher restenosis rate when compared to non-bifurcation/ostial lesions must be taken into account if percutaneous intervention is chosen ahead of alternative treatment strategies.
Classification systems for bifurcation/ostial lesions Bifurcation lesions These can be classified according to the angulation of the bifurcation and the specific location of the plaque burden (Figures 4.1–4.7). Angulation between the branches of the bifurcation is an important issue in terms of side-branch access and the likelihood of significant plaque shift, and the relationship of the amount of plaque material with respect to the proximal main, distal main and side-branches will dictate the likely consequences of any plaque shift which occurs. Both of these issues will influence the resultant treatment strategy and must be consciously considered in every case. Notwithstanding these issues, we are currently using a reasonably standard algorithm in the majority of cases (Table 4.1): • Y-shaped lesions—The angulation between the side-branch and distal main branch is less than 70°. Access to the side-branch is usually
67
579_Stenting_ch.04
14/8/2001 14:01
Page 68
OSTIAL AND BIFURCATION DISEASE
Figure 4.1 Type 1 lesion involving main branch and side-branch.
Figure 4.2 Type 2 lesion sparing ostium of side-branch.
Figure 4.3 Type 3 lesion proximal to branch.
Figure 4.4 Type 4 lesion involving both distal with sparing of main branch proximally.
Figure 4.5 Type 4a lesion involving main branch distal to side-branch only.
Figure 4.6 Type 4b lesion with sparing of main branch and involvement of side-branch ostium only.
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 Step 9 Step 10
Wire all side-branches 2.25 mm in diameter Dilate the side-branch before the main branch is stented Kissing balloon inflation is always performed after main branch stenting, and again if the side-branch is stented Stent the main branch Use the T-technique, stenting into the main branch first ‘Jail’ the side-branch wire with the main branch stent The side-branch may be stented first (see text) Side-branch stenting should be provisional ‘Modified’ Y-technique?—only in cases of type 4b lesions Never use the ‘culotte’ or ‘V’ techniques
Table 4.1 Suggested scheme for bifurcation stenting.
68
579_Stenting_ch.04
14/8/2001 14:01
Page 69
APPROACH TO TREATMENT
easy, but plaque shifting is also more pronounced. • T-shaped lesions—The angulation between the side-branch and distal main branch is more than 70°. Access to the side-branch is usually more difficult, and plaque shifting is less important. This angulation is usually reduced after both branches of the bifurcation have been wired, possibly changing the properties of a T-shaped lesion to those of a Y-shape (Figure 4.7). The distribution of plaque material around the point of bifurcation may predict the response to balloon/stent instrumentation and enable more appropriate selection of treatment strategy: • Type 1 lesions—These are defined as ‘true’ bifurcation lesions involving the main branch proximal and distal to the bifurcation and the ostium of the side-branch (Figure 4.1).
• Type 2 lesions involve the main branch at the bifurcation site but not the ostium of the sidebranch (Figure 4.2). • Type 3 lesions are located in the main branch, proximal to the bifurcation. These are also considered ‘bifurcation’ lesions, because they are frequently associated with a deterioration of the ostium of one or both distal branches after balloon percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting due to the ‘snow-plough’ effect (Figure 4.3). • Type 4 lesions are located at the ostium of each branch of the bifurcation in the absence of lesions in the proximal part of the bifurcation (Figure 4.4). If only one branch is involved, they can be subclassified as follows; the treatment of ‘branch vessel ostial lesions’ is discussed in the appropriate section. Type 4a: ‘Main branch ostial lesion’ (Figure 4.5). Type 4b: ‘Side-branch ostial lesion’ (Figure 4.6).
Ostial lesions These can be divided into three categories, with differing pathologies and behaviour according to site:
90°
• aorto-ostial native coronary • aorto-ostial graft • branch vessel ostial disease.
90°
70°
The last category shares some of the properties of bifurcation disease, with the possibility of plaque shift (types 4a and 4b above), whereas aorto-ostial disease presents unique challenges, with difficult visualization and resistance to dilatation.
Approach to treatment Figure 4.7 A ‘T’-shaped lesion (>70° between branch and distal main vessel) may become ‘Y’-shaped (70°) after wiring.
Bifurcation lesions Side-branch occlusion has long been recognised as a complication of coronary angioplasty,3,4 and
69
579_Stenting_ch.04
14/8/2001 14:01
Page 70
OSTIAL AND BIFURCATION DISEASE
early strategies for dealing with this problem evolved into the double guidewire and balloon technique.5 Additional measures such as ‘debulking’ have been reported to improve outcome.6,7 With the advent and increased application of coronary stenting together with refinements in stent and delivery equipment design, a variety of technical approaches have been proposed to deal with this problem.8–11 When faced with such an array of possibilities, the interventionist must select the most appropriate management strategy for each individual case. Several issues must be addressed.
Does the side-branch need protection? In a study of 175 patients (182 lesions), Aliabadi et al12 reported side-branch occlusion in 43 of 223 side-branches, the majority (67%), following high-pressure balloon inflation. By multivariate analysis, the presence of >50% ostial narrowing of side-branches that arose from within or just beyond the diseased portion of the parent vessel was a powerful predictor (odds ratio 40, p < 0.0001) of subsequent closure, accounting for 80% of the observed cases. It is worth noting that at 9-month follow-up, there was no difference in combined clinical events between those patients with and without side-branch occlusion. Fischman et al13 evaluated the fate of side-branches 1 mm in diameter (n 66 of 57 stent placements in 167 consecutive lesions). Of 60 side-branches patent after initial balloon angioplasty, 3 subsequently occluded after stent placement; all 3 had 50% ostial stenosis at baseline. At 6-month follow-up, all were patent. Does the side-branch need balloon dilation? In general, this will depend on the size (>2–2.5 mm) and distribution of the branch, the initial angiographic result after stenting of the main vessel, and any ischemic consequences resulting from compromised flow. Does the side-branch need a stent? Al Suwaidi et al14 reported the results of stenting
70
for ‘true bifurcation’ (type 1) stenoses, where both parent and branch vessels were >2.0 mm diameter by visual estimate. Angiographic success occurred in 75 of 77 (97.4%) instances where the side-branch was dilated through the struts of the parent vessel stent and not stented, and 51 of 54 (94.4%, p NS) cases where the side-branch was stented (‘Y’ n 19, ‘T’, n 31). At 1-year follow-up, there were no significant differences between patients receiving one versus two stents with respect to survival, myocardial infarction (MI), coronary angioplasty bypass graft (CABG) or repeat revascularization; however, the authors noted a trend to better long-term outcome in patients receiving only a single stent. Moreover, MACE during 1 year of follow-up was significantly more frequent in patients who had undergone a ‘Y’-type bifurcation stenting strategy, occurring in 86.3% of this group compared with only 30.3% in those who had undergone ‘T’ stenting (p 0.004). Pan et al15 reported a series of 70 patients undergoing bifurcation stent implantation, 47 receiving a single stent in the parent vessel, and 23 receiving a stent to each branch in a ‘T’ configuration. There was no significant difference in procedural success (89% versus 91% respectively, p NS); however, major cardiac events at 18-month follow-up were more frequent in patients receiving stents to both branches (56% versus 25%, p < 0.05). A similar study by Yamashita et al16 reported a series of 92 patients undergoing bifurcation stenting, comparing those who received a stent to each branch (n 53) with those receiving a single stent to only the parent vessel with balloon angioplasty of the side-branch (n 39). In-hospital MACE were only reported in patients who received stenting to both vessels, with no events in the single-stent group (13% versus 0%, p < 0.05). Six-month angiographic restenosis (62% versus 48%), target lesion restenosis (TLR) (38% versus 36%) and MACE (51% versus 38%), although numerically greater for patients receiving stents to both vessels, were not significantly different.
579_Stenting_ch.04
14/8/2001 14:01
Page 71
PRACTICAL APPROACH
Ostial lesions True ostial lesions are less frequent but can be technically demanding, with a significantly increased complication rate after balloon angioplasty compared with non-ostial locations. A spectrum of different anatomic locations can be covered by this definition, including aorto-ostial lesions (native vessel or graft ostial location), as well as branch ostial lesions which can be further subdivided into major branch ostial lesions (ostial left anterior descending (LAD) or circumflex) and secondary branches such as diagonal or obtuse marginal branches. Initial attempts to deal with this problem by balloon dilation alone were marked by a high rate of primary failure in addition to increased rates of restenosis following successful procedures.17 The main technical advances which have been explored in an attempt to achieve an improvement in outcome have been debulking devices and coronary stents. The use of debulking, by either directional atherectomy, rotational atherectomy or laser, was compared with a historical series of balloon-only angioplasties by
Baseline
Sabri et al,18 who noted an improvement in acute gain following the use of debulking devices, and a suggestion of reduced immediate complication rates. This finding has been confirmed in other studies;19 however, restenosis rates have been unacceptably high.20,21 Rocha-Singh,22 in an early report of stenting for aorto-ostial disease, reported a favorable binary restenosis rate of 27.8% at 6-month follow-up in 42 patients receiving Palmaz–Schatz stents for aorto-ostial disease. More recently, the use of cutting balloon angioplasty has been advocated;23 however, is it likely that this technology will need to be used adjunctively with stenting except in anatomic situations where plaque shift into adjacent branches is undesirable (e.g. ostial left circumflex (LCX), proximal diagonal).24
Practical approach Case examples that illustrate some of the points of this chapter are included (Figures 4.8–4.13 (bifurcation angioplasty), Figures 4.14–4.19 (ostial disease)). It must be emphasized,
Final result
Figure 4.8 Case 1 The small sub-branch of the obtuse marginal is considered too small to warrant protection and is occluded after stenting the main branch (arrows) without clinical sequelae.
71
579_Stenting_ch.04
14/8/2001 14:01
Page 72
OSTIAL AND BIFURCATION DISEASE
however, that each case encountered will need to be assessed according to its specific clinical and anatomic characteristics, within the framework of the general guidelines offered.
Bifurcation lesions If the side-branch is small in diameter or distribution, it may be reasonable to concentrate on the
main branch without specific attention to the side-branch (Figure 4.8). More significant sidebranches will require protection and probably balloon dilatation, for which we had previously practiced ‘provisional’ kissing inflation (Figures 4.9–4.11). Our current practice is to perform kissing balloon inflation in all cases of bifurcation disease (Figures 4.11–4.13), following stent implantation but also after initial branch vessel
A
Baseline Final result
B
Figure 4.9 Case 2 Stent to LAD with balloon to diagonal, no final kissing balloon inflation. Note plaque shift into diagonal ostium after stenting LAD (inset A) treated by balloon inflation through stent struts (inset B) followed by low pressure ‘non-kissing’ balloon inflation in LAD—final result in right panel.
Baseline
Final result
Figure 4.10 Case 3 Bifurcation left main disease predominantly involving ostium of LAD (type 2)—after left main LAD stenting, there is plaque shift into the ostium of the LCX (inset) which is corrected by balloon inflation in the LCX with alternate (‘non-kissing’) balloon inflation without stenting the LCX.
72
579_Stenting_ch.04
14/8/2001 14:01
Page 73
PRACTICAL APPROACH
A
B Baseline – Type 2 Y-shaped lesion
C Final result
Figure 4.11 Case 4 Stent to type 2 lesion LAD, with marked plaque shift into diagonal (inset A), with residual stenosis origin of diagonal after ‘non-kissing’ inflation diagonal (inset B), followed by kissing balloon inflation LAD/diagonal (inset C).
Baseline – Type 1 lesions D1 and D2 A
C
B
D
Final result
Figure 4.12 Case 5 Complex type 1 lesion involving proximal LAD and first and second diagonal branches. Both diagonal branches are wired first, followed by the LAD (inset A). The two diagonal branches are stented first in ‘T’ fashion (inset B), followed by ‘kissing balloon’ inflations to the LAD and each diagonal separately (inset C, D).
73
579_Stenting_ch.04
14/8/2001 14:01
Page 74
OSTIAL AND BIFURCATION DISEASE
A
B
Baseline
C
D
Final result
Figure 4.13 Case 6 Kissing stent (T-type). Complex type 1 lesion. A dissection plane is noted in the ostial segment of the diagonal (inset A, arrowed) after stent implantation in the LAD. The diagonal is rewired through the LAD stent and dilated (inset B) and stented (inset C) before a final ‘kissing’ inflation (inset D). The final result is satisfactory in both branches.
dilation in most cases. As a general approach to the management of bifurcation lesions, we suggest the following 10 steps: 1. Wire all side-branches 2.25 mm in diameter or if there is ostial disease in significant side- branches 2 mm in diameter. Cross the most difficult part of the lesion first. 2. Dilate the side-branch before the main branch is stented, unless its ostium is completely normal and remains normal after balloon inflation in the main branch. 3. Kissing balloon inflation can be performed before main branch stenting, and is always performed after main branch stenting, and again if the side-branch is stented.
74
4. Stent the main branch even if the result of balloon dilatation is satisfactory. 5. Use the T-technique, stenting into the main branch first in most cases. 6. ‘Jail’ the side-branch wire with the main branch stent, unless a decision has been made to stent the side-branch first. 7. The side-branch may be stented first (modified T-technique) if the origin of the sidebranch remains 90° after wiring, with significant ostial disease or moderate–severe calcification, or if there is a significant dissection in the side-branch after main/sidebranch kissing inflation, which might compromise our ability to wire or stent the side-branch after the main branch has been stented.
579_Stenting_ch.04
14/8/2001 14:01
Page 75
PRACTICAL APPROACH
8. Side-branch stenting should otherwise be provisional, depending on the result after kissing inflation into the main/side-branch. 9. Consider a ‘modified’ Y-technique (stenting into the distal side and main branches only), only in cases of type 4b lesions where the proximal segment remains completely normal after balloon inflation. Avoid or minimize stenting back into the proximal segment. 10. Never use the ‘culotte’ or ‘V’ techniques, in view of increased adverse outcomes with these techniques and a lack of any benefit in terms of technical success.
Ostial lesions (Table 4.2) Native vessel aorto-ostial disease It is important to determine the degree of calcification, as this will impact on the likely success of balloon dilation and the choice of overall strat-
egy—if available, consider the use of intravascular ultrasound (IVUS) when calcification is not evident angiographically, and use rotational atherectomy if there is >90° circumferential calcification. When rotational atherectomy is used, we recommend a stepped-burr approach, aiming for a burr/artery ratio of 0.7–0.8. In general, vessels >2.5 mm in diameter will then be stented with a slotted tube stent. Positioning of the stent with respect to the aortic margin of the lesion is of critical importance, as distal placement will not cover the segment most at risk of recoil, and proximal placement will put the stent struts at risk of trauma from the guiding catheter. After stent implantation, we recommend flaring the proximal end of the stent with an oversized balloon. Given the need for a much more conservative strategy when dealing with left main than with right coronary disease, the overall strategy differs somewhat between the left and right coronary arteries:
Aorto-ostial Left main Always stent Rotational atherectomy if any calcification CABG if heavy calcification, multi-vessel disease or impaired left-ventricular function Right coronary Rotational atherectomy if > mild calcification CABG if heavy calcification or poor left ventricular function Graft Always stent Rotational atherectomy if severe calcification Branch vessel LAD DCA for ‘Y’ shaped lesions Rotational atherectomy if calcified Stent for ‘T’ shape Circumflex Avoid plaque shift into LAD—DCA if Y-shaped DCA, directional coronary atherectomy.
Table 4.2 Suggested scheme for ostial stenting.
75
579_Stenting_ch.04
14/8/2001 14:01
Page 76
OSTIAL AND BIFURCATION DISEASE
• Ostial left main: if non-calcified, we suggest balloon and stent; may consider direct stent (Figure 4.14), DCA stent, or cutting balloon stent. If there is mild–moderate calcification, consider rotational atherectomy and stent; if heavily calcified or in the presence of multivessel coronary disease or impaired left ventricular (LV) function, consider CABG. • Ostial right coronary artery (RCA) lesions: if non-calcified or mildly calcified, treat as for non-calcified LCA, although stenting is less ‘mandatory’ if there is a good result following debulking. Consider a direct stent strategy for non-calcified lesions (Figure 4.15). If there is heavy calcification, consider rotational atherectomy for single-vessel disease, and CABG if there is multivessel disease with impaired LV function. • Guide catheters to consider for left main include a standard or short-tip left Judkins (if using femoral access), extra-backup shape or AL2. For RCA ostial disease, consider a shorttip right Judkins, AR1 or AR2, or AL1 if there is superior take-off. • Initial angiographic views suggested are either 10–20° LAO or shallow RAO with mild caudal angulation for the LCA, and 30° LAO or lateral for the RCA.
A
Bypass graft aorto-ostial disease Generally, these lesions are difficult to dilate and elastic, and are less calcified than native aortoostial lesions (Figure 4.16). Elastic recoil is a major problem, and stenting with or without prior debulking by rotational atherectomy will be needed. Our practice is to reserve atherectomy for cases with marked visible calcification. If the graft is diffusely diseased and anastamosed to the LAD or if there are other grafts in need of intervention, consider redo-CABG, especially if mammary conduits are available. Guide catheter selection will depend on the placement of the aortic anastamosis—the multipurpose catheter is useful if there is a downward take-off of the graft; otherwise consider a right Judkins or Hockey stick. Branch ostial disease This is a much more frequent problem, and is complicated by marked elastic recoil in the target vessel and also by the possibility of plaque shift into adjacent vessels. For ostial LAD lesions (Figures 4.17 and 4.18), consider atherectomy (rotational if mild–moderately calcified, directional if not) stenting, especially for Y-shaped lesions, where there is a higher risk of plaque shift into the ostium of the LCX. If the LAD is <3 mm in diameter, or in the case of long
C
B
Figure 4.14 Case 7 Non-calcified critical ostial left main stenosis treated by direct stent. (A) Left main ostial lesion; (B) Zoom of the ostial lesion; (C) After direct stenting.
76
579_Stenting_ch.04
14/8/2001 14:02
Page 77
PRACTICAL APPROACH
Baseline
Final result
Figure 4.15 Case 8 An extremely tight ostial RCA lesion (circled) is treated by direct stenting. The proximal border of the stent (markers arrowed) is positioned in the aorta just proximal to the ostium of the RCA.
lesions, or significant calcification, consider referral for CABG. For ostial LCX, it is important to avoid plaque shift into the LAD (Figure 4.19). For this reason, atherectomy will be necessary, but may not be possible if there is marked tortuosity of the take-off of the LCX from the left main. It is possible that the use of a cutting balloon without adjunctive stenting may have a role, although more data are awaited. For more peripheral ostial lesions, the principles outlined above for bifurcation lesions apply;
however, it is important to recognize the special case of ostial diagonal disease with a normal LAD, where there is a risk of plaque shift and consequent need for instrumentation of the LAD which results in a significant risk of restenosis (?in-stent) with potential long-term consequences. In this case, consideration should be given to maximization of medical therapy as a first choice, although the cutting balloon may have a potential role in this situation when more data concerning its use are available.
77
579_Stenting_ch.04
14/8/2001 14:02
Page 78
A
D
B
C
Baseline
Final result
Figure 4.16 Case 9 (A–D) Ostial vein graft lesion (circled, A). The tip of the guiding catheter is arrowed (inset B).
A
B
Baseline D
C
Final result Result post-DCA
Figure 4.17 Case 10 Ostial LAD disease (A, arrowed) treated by DCA (B) with improvement in MLD (C) and a satisfactory result after balloon inflation in LAD without stenting and without protection of the LCX with a guidewire (D).
78
579_Stenting_ch.04
14/8/2001 14:02
Page 79
ACKNOWLEDGMENT
A B
Baseline
C
Final result
Figure 4.18 Case 11 Ostial LAD disease (A, circled) with a long segment of residual disease in the proximal LAD after DCA (B) treated by stenting.
Conclusion
Acknowledgment
The overall approach to treatment, as in all areas of interventional cardiology, must be based on simplicity, speed, safety and efficacy (immediate and long-term patency), while keeping in mind cost-effectiveness and the comparison of the results of percutaneous coronary interventions (PCI) with cardiac surgery. The goal should be to offer the most appropriate treatment for any given patient without necessarily being obliged to dilate every lesion that is present.
We acknowledge with thanks the work of Thierry Lefèvre, Yves Louvard and Marie Claude Morice done for the PCR Course book 2000, from which Figures 4.1–4.7 have been modified.
79
579_Stenting_ch.04
14/8/2001 14:02
Page 80
A
Baseline: RAO cranial
LAO caudal
C B
D
E
F
Final result (RAO cranial)
(LAO caudal)
Figure 4.19 A moderately calcified ostial LCX stenosis (A) is treated first by rotational atherectomy (1.75-mm burr, B) with a minor improvement in lumen diameter (C). Stenting into the LCX (D) resulted in plaque shift to the LAD (not shown), requiring kissing balloon inflation into the LAD and LCX (E) to achieve a satisfactory final result (F).
579_Stenting_ch.04
14/8/2001 14:02
Page 81
REFERENCES
References
1. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94:35–43. 2. Ahmed JM, Mintz GS, Weissman NJ et al. Mechanism of lumen enlargement during intracoronary stent implantation. An intravascular ultrasound study. Circulation 2000; 102:7–10. 3. Meier B, Greuntzig AR, King SB 3rd et al. Risk of side branch occlusion during coronary angioplasty. Am J Cardiol 1984; 53(1):10–14. 4. Arora RR, Raymond RE, Dimas AP et al. Side branch occlusion during coronary angioplasty: incidence, angiographic characteristics, and outcome. Cathet Cardiovasc Diagn 1989; 18(4):210–212. 5. Oesterle SN, McAuley BJ, Buchbinder M, Simpson JB. Angioplasty at coronary bifurcations: single-guide, two-wire technique. Cathet Cardiovasc Diagn 1986; 12(1):57–63. 6. Dauerman HL, Higgins PJ, Sparano AM et al. Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesions. J Am Coll Cardiol 1998; 32(7): 1845–1852. 7. Brener SJ, Leya FS, Apperson-Hansen C et al. A comparison of debulking versus dilatation of bifurcation coronary arterial narrowings (from the CAVEAT I Trial), Coronary Angioplasty Versus Excisional Atherectomy Trial-I. Am J Cardiol 1996; 78(9):1039–1041. 8. Colombo A, Gaglione A, Nakamura S, Finci L. ‘Kissing’ stents for bifurcational coronary lesion. Cathet Cardiovasc Diagn 1993; 30(4):327–330. 9. Carrie D, Karouny E, Chouairi S, Puel J. ‘T’shaped stent placement: a technique for the treatment of dissected bifurcation lesions. Cathet Cardiovasc Diagn 1996; 37(3): 311–313. 10. Fort S, Lazzam C, Schwartz L. Coronary ‘Y’ stenting: a technique for angioplasty of bifurcation stenoses. Can J Cardiol 1996; 12(7):678–682.
11. Chevalier B, Glatt B, Royer T, Guyon P. Placement of coronary stents in bifurcation lesions by the ‘culotte’ technique. Am J Cardiol 1998; 82(8):943–949. 12. Aliabadi D, Tilli FV, Bowers TR et al. Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol 1997; 80(8):994–997. 13. Fischman DL, Savage MP, Leon MB et al. Fate of lesion-related side branches after coronary artery stenting. J Am Coll Cardiol 1993; 22(6):1641–1646. 14. Al Suwaidi J, Berger PB, Rihal CS et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol 2000; 35(4):929–936. 15. Pan M, Suárez de Leso J, Medina A et al. Simple and complex stent strategies for bifurcated coronary arterial stenosis involving the side branch origin. Am J Cardiol 1999; 83(9): 1320–1325. 16. Yamashita T, Nishida T, Adamian MG et al. Bifurcation lesions: two stents versus one stent—immediate and follow-up results. J Am Coll Cardiol 2000; 35(5):1145–1151. 17. Mathias DW, Mooney JF, Lange HW et al. Frequency of success and complications of coronary angioplasty of a stenosis at the ostium of a branch vessel. Am J Cardiol 1991; 67(6):491–495. 18. Sabri MN, Cowley MJ, DiScisacio G et al. Immediate results of interventional devices for coronary ostial narrowing with angina pectoris. Am J Cardiol 1994; 73(2):122–125. 19. Safian RD, Freed M, Reddy V et al. Do excimer laser angioplasty and rotational atherectomy facilitate balloon angioplasty? Implications for lesion-specific coronary intervention. J Am Coll Cardiol 1996; 27(1): 552–559. 20. Koller PT, Freed M, Grines CL, O’Neill WW. Success, complications, and restenosis following rotational and transluminal extrac-
81
579_Stenting_ch.04
14/8/2001 14:02
Page 82
OSTIAL AND BIFURCATION DISEASE
tion atherectomy of ostial stenoses. Cathet Cardiovasc Diagn 1994; 31(4):255–260. 21. Eigler NL, Weinstock B, Douglas JS Jr et al. Excimer laser coronary angioplasty of aortoostial stenoses. Results of the excimer laser coronary angioplasty (ELCA) registry in the first 200 patients. Circulation 1993; 88(5 Pt 1):2049–2057. 22. Rocha-Singh K, Morris N, Wong SC, Schatz RA, Teirstein PS. Coronary stenting for treatment of ostial stenoses of native coronary
82
arteries or aortocoronary saphenous venous grafts. Am J Cardiol 1995; 75(1):26–29. 23. Muramatsu T, Tsukahara R, Ho M et al. Efficacy of cutting balloon angioplasty for lesions at the ostium of the coronary arteries. J Invas Cardiol 1999; 11(4):201–206. 24. Colombo A, Adamian M. Cutting balloon angioplasty of ostial coronary lesions: do we need the stent support? J Invas Cardiol 1999; 11(4):231–236.
579_Stenting_ch.05
14/8/2001 14:05
Page 83
5 Left main disease Alexander JR Black, Jean Fajadet, Jean Marco
Overview Left main coronary artery disease is found in 3–5% of patients undergoing cardiac catheterization for ischemic chest pain, congestive heart failure or cardiogenic shock. Revascularization by coronary artery bypass grafting (CABG) has been proven to improve survival and is generally the preferred therapeutic option. Various studies of balloon angioplasty for left main disease have been marked by poor short- and long-term outcomes.1–9 The results of stenting of unprotected left main stenosis have now been reported for a number of series, showing acceptable procedural results and reasonable survival, although the results are strongly influenced by patient selection.10–18
Classification systems The main issues to be addressed when considering left main stenting concern: • The presence or absence of calcification. • The localization of the plaque material: ostial, mid, or distal. In the case of distal stenoses, the degree of involvement of the individual ostia of the LAD and circumflex needs to be identified (Figure 5.1). Lesions are classified as either ‘true’ or ‘false’ bifurcation lesions, the latter because of the absence of plaque material in the origin of one side-branch,1 or because of an occluded or very small sidebranch.2
(a)
(b)
(c)
(d)
(e)
Figure 5.1 (a) Ostial (b) Mid-shaft (c) True bifurcation (d) False bifurcation type 1 (e) False bifurcation type 2 (negligible myocardial territory supplied).
• The amount of myocardium jeopardized by each major branch. • The presence of impaired left ventricular (LV) function. • The likely consequences of procedural failure.
Approach to treatment Given the serious consequences of left main occlusion, a decision to recommend percutaneous coronary intervention (PCI) in this situation must be based on a clear understanding of the ratio of risk to benefit. The operator must take into account angiographic and other clinical characteristics that influence procedural risk, in the context of each patient’s specific clinical situ-
83
579_Stenting_ch.05
14/8/2001 14:05
Page 84
LEFT MAIN DISEASE
ation. It is essential to define the anatomy of the lesion: is it ostial, mid-shaft, or distal? Is there any evidence of calcification? The vessel must be visualized in a non-foreshortened view to assess its length accurately—if length of the left main is less than 8 mm (Figure 5.2, Case 1), do not proceed unless it is planned to stent into one of the distal branches, or it is planned to rely on atherectomy without stenting. The extent of myocardium potentially jeopardized by the procedure must be estimated, and considered in the presence of overall and regional LV function. A precise idea of the different stages of the stenting procedure must be thought through before wiring the left main. It is particularly important to exercise caution in patients with reduced left ventricular ejection fraction (LVEF) and multivessel disease—the increased risk associated with PCI in these cases may indicate a need to reconsider the possibility of surgical treatment. Finally, we recommend that an angiographic result that is less than perfect should never be accepted.
Literature review In a recent study of left main stenting in a population of 42 consecutive patients with unpro-
6.7 mm
Figure 5.2 Case 1 In this case, the left main is 8 mm, and does not allow any stent placement, so we did not proceed the planned percutaneous intervention.
84
tected left main stenosis and normal LV function, Park et al19 presented excellent results, with a procedural success rate of 100%, clinical recurrence at 6-month follow-up of 17%, and angiographic restenosis of 22%. Only one patient died in this series, 2 days after elective bypass surgery for treatment of in-stent restenosis. The paper describes a series of patients with low surgical risk. In our published series of 115 consecutive patients who underwent stenting of unprotected left main up to the end of December 1999,18 the acute results in the subgroup of 76 patients with ‘relatively’ low surgical risk appear satisfactory, with one death from ventricular arrhythmia, and two procedure-related non-Q myocardial infarctions (MIs). There were no other procedural or in-hospital complications. During follow-up, six patients required target lesion revascularization, five treated with repeat left main angioplasty and one with CABG surgery. Our results are very similar to those of the series reported by Silvestri et al,20 which compared the immediate and mid-term results of a group of patients considered to be good candidates for bypass surgery with a group considered to be poor candidates: there were 4 deaths out of 47 high-risk surgical patients and 0 out of 93 low-risk patients at 1-month follow-up. Ellis et al21 have reported the results of a multicenter registry of percutaneous treatment of unprotected left main coronary stenosis in 107 patients from 25 centers. Ninety-one patients were treated electively, and 16 patients were treated for acute myocardial infarction (AMI). In the group of patients with AMI, technical success was achieved in 75%, and survival to hospital discharge was 31%. In elective patients, technical success was achieved in 98.9%; the inhospital mortality rates were 5.9% in patients considered to be good candidates for CABG, and 30.4% in patients not candidates for CABG. Inhospital mortality was strongly correlated with LVEF (p 0.003). Patients who had elective stenting, and who were considered to be good potential candidates for CABG, had an in-
579_Stenting_ch.05
14/8/2001 14:05
Page 85
LESIONS AMENABLE TO PERCUTANEOUS TREATMENT
hospital survival of 98% and a 9-month eventfree survival of 86% 5% when LVEF was >40%, compared with 67% and 22% 12% respectively when LVEF was <40%. Long-term freedom from death, infarction or bypass surgery was strongly correlated with ejection fraction (p < 0.001) and was inversely related to presentation with progressive or rest angina (p < 0.001).
‘Debulking’ before unprotected left main coronary artery stenting The use of stents to treat distal bifurcation lesions is technically challenging and may be associated with a higher risk of late complications. Directional coronary atherectomy (DCA) before stenting has been proposed in this setting; data from the ULTIMA registry22 showed a restenosis rate of 20% in 26 distal left main lesions treated by DCA. The results in general for the use of ‘debulking’ are encouraging. Bramucci et al23 have reported the results of adjunctive stent implantation following DCA in patients with coronary artery disease, with a 6.8% angiographic restenosis rate and a low incidence of events at follow-up. Comparable results were reported in the Stenting after Optimal Lesion Debulking (SOLD) study by Moussa et al:24 in a series of 90 lesions in 71 patients who underwent DCA followed by stenting. It was found that plaque removal prior to stenting led to optimization of lumen gain with an acceptable rate of procedural complications and a low loss index at 6-month angiographic follow-up, resulting in a low restenosis rate (11%). In the case of left main intervention, Park25 reported better 6-month outcomes after directional atherectomy and stenting compared to stenting alone in 110 patients undergoing elective percutaneous procedures for unprotected left main stenosis. The angiographic restenosis rate after directional atherectomy and stenting was 9.3% with target lesion revascularization (TLR) of 9%, compared to a restenosis rate of 20% with 11.2% TLR in the stent group. More
recently, his group have presented a subset of 77 patients who underwent left main PCI DCA using ultrasound guidance.26 Acute results in terms of post-procedural reference diameter and MLD were similar; restenosis appeared to be less frequent in the group receiving DCA. When the outcome was stratified by reference diameter, it appeared that the benefit from DCA was more marked in vessels 3.6 mm. On this basis, they suggest considering a debulking strategy for smaller vessels and stenting alone for those
3.7 mm. A bigger series recently published by Kosuga et al27 describes the outcome of 101 patients undergoing DCA for unprotected left main disease. Adjunctive balloon angioplasty was only performed in 30% of patients, and stenting after debulking as a ‘bailout’ strategy in 13%. Although the follow-up results cannot be compared directly with those following stenting, the low incidence of procedural complications supports the safety and practicability of this technique for treating unprotected left main disease.
Lesions amenable to percutaneous treatment Good indications for operators experienced in PCI • Emergent clinical situations such as acute left main occlusion. • Surgically high-risk or inoperable patients with major comorbidity such as advanced chronic obstructive lung disease or dialysisdependent renal failure. • Patients with left main stenosis and multivessel diffuse disease with anatomic characteristics which may preclude satisfactory placement of grafts. • Low-risk patients with good ventricular function and the left main stem anatomically suitable for stenting: ostial and mid-shaft location.
85
579_Stenting_ch.05
14/8/2001 14:05
Page 86
LEFT MAIN DISEASE
Controversial indications, operators experienced in left main PCI only • Low-risk patients with good ventricular function and the left main stem anatomically suitable for stenting: ostial and mid-shaft location. • Patients with preserved left ventricular (LV) function (LVEF > 40%) and distal bifurcation lesions involving the ostium of the left anterior descending artery (LAD) or the left circumflex artery (LCX). • Low-risk patients with good ventricular function who desire not to have bypass surgery. • Patients with preserved LV function, left main stem anatomically suitable for stenting and multivessel disease who are good candidates for CABG but have anatomic characteristics such as lack of calcium, short lesion length, location in large-caliber vessel and lack of involvement of a branching vessel which appear suitable for percutaneous interventions.
Contraindications These may be ‘relative’, depending on clinical need: • Patients with reduced LV function (LVEF < 40%). • Good candidates for CABG with distal bifurcation lesion and reduced LVEF. • Good candidates for CABG with distal bifurcation lesion and occluded right coronary artery. • Patients with multivessel disease with reduced LV function and anatomic characteristics suitable for coronary artery bypass surgery. • Heavily calcified left main disease. • Short (<8 mm) left main stem.
86
Practical approach to left main lesions Once a decision to proceed with angioplasty has been made, consideration needs to be given to equipment selection.
Guiding catheter selection Ostial disease The main issue is to minimize any mechanical effects of the guiding catheter such as temporary occlusion resulting in ischemia or possible trauma resulting in dissection. For these reasons, a 6 Fr catheter is recommended, and the use of a catheter shape that is less prone to deep intubation of the left main will result in a lower risk of traumatic complications. Amplatz-shaped guides should be absolutely avoided, and from the femoral approach, the Judkins left shape is the best choice. Bifurcation lesions A T-stenting approach with kissing balloon inflation is recommended. Even with the currently available larger-lumen 6 Fr catheters, it is not possible to advance two balloons 3.0–3.5 mm in diameter simultaneously, and catheters of at least 7 Fr will be needed unless the LAD and/or LCX are unusually small in diameter. Furthermore, the use of 7 Fr catheters enables the use of larger burrs for rotational atherectomy if needed. For more complex procedures that require the use of rotational atherectomy, burrs of more than 2.00 mm in diameter, or for directional atherectomy, a guiding catheter of 8 Fr or 9 Fr, will be needed. In the case of bifurcation lesions, support is the main issue, and ‘extra-backup’ shapes, Amplatz left, and, more recently, some of the specifically available longer-tip radial catheters are the best choice. Mid-shaft lesions For mid-shaft lesions, backup is a less critical issue; however, it makes sense to use shapes that
579_Stenting_ch.05
14/8/2001 14:05
Page 87
SPECIFIC ANATOMIC SUBSETS
provide a reasonable amount of backup (in 6 Fr rather than 7 Fr) if the ostium is free from significant disease.
Guidewire For left main stenting procedures, the choice of guidewire is of minor importance – a routine guidewire that provides good backup support is normally used. The only exception is following rotational atherectomy, when the wire should be exchanged for one that has better backup support to place the stent.
Dilation process Predilation of the lesion in the left main setting has been generally considered mandatory to facilitate stent delivery. In our experience, predilation is usually performed with short (<20 s) and repeated balloon inflations with an inflation pressure of >15 atm to limit the duration of myocardial ischemia. It is useful to observe the guidewire movement with myocardial contraction during balloon inflation to establish the effect of ischemia on myocardial function. It is necessary to deflate the balloon immediately if the systolic blood pressure falls to <80 mmHg or if there is a reduction of distal guidewire movement. The technique of direct stenting is not generally recommended. Nevertheless in carefully selected, non-calcified lesions, using the current generation of low-profile stents, preliminary results are acceptable. We have performed in excess of 25 direct stenting procedures out of our current total of 168 unprotected left main stenting procedures as at April 2001. Plaque debulking using rotational atherectomy should be used in patients with heavily calcified plaques to facilitate balloon expansion and stent deployment.
Specific anatomic subsets (Tables 5.1a and 5.1b). In all cases it is essential that the stent be perfectly deployed. We recommend that the initial placement of the stent as well as its deployment be performed under continuous fluoroscopic guidance, and that a cineangiographic or acquisition run be performed after deployment. This should be reviewed carefully (using step-frame with magnified or zoomed images): do not accept a less than ‘perfect’ result.
Left main ostial lesion (Figure 5.3, Case 2) It is important to choose an appropriately shaped guiding catheter that does not risk traumatizing or occluding the coronary ostium (6–7 Fr) (Figure 5.3a). The lesion is predilated with short inflations at high pressure. The left main ostium is next covered with a stent protruding 0.5–1 mm into the ascending aorta, advancing the guidewire sufficiently to disengage the catheter from the left coronary ostium (Figure 5.3b). If the left main is of sufficient length, use a 13–15-mm stent, which is easier to deploy precisely than a very short stent in this situation. Position the stent accurately and deploy it as above at >16 atm for <20 s. Postdilate at high pressure with the proximal half balloon in the ascending aorta (Figure 5.3c) to flare the proximal part of the stent.
Left main mid-shaft lesion (Figure 5.4, Case 3) Assess the length of the left main in the least foreshortened view: if <8 mm (i.e. shorter than available stent lengths), stenting is not advisable, and CABG or DCA without stenting will need to be considered. If the left main length is >8 mm, stenting can be performed as follows (Figure 5.4a). First, wire
87
579_Stenting_ch.05
14/8/2001 14:05
Page 88
LEFT MAIN DISEASE
Bifurcation lesions ‘True’ Ostial lesions
Comments
Mid-shaft lesions
Involving ostia of both branches
Must be >8 mm
‘False’ No significant involvement of side-branch ostium
Occluded branch or negligible myocardial territory
Use the simplest possible technique
Set-up
6 Fr guide: try not to occlude ostium; avoid amplatz left guides
6 Fr EBU/AL
Guide 7 Fr with good backup EBU/AL
Guide 7 Fr with good backup (may need kissing balloon/stent)
6 Fr EBU/AL
Wire
Distal LAD
LAD
Both branches alternately or kissing
Wire both branches
Only wire major branch
Predilate
Short inflation, high pressure
Short inflation 15 s at 18 atm
Both branches alternately
Only dilate involved branch
Only dilate major branch
Stentc
Cover ostium by 0.5–1 mm; recommend 13–15-mm stent if possible
Deploy stent, >16 atm for <20 s
Deploy stent in main branch (LAD), jailing wire in side-branch
Stent involved branch
Stent major branch only
Film/acquire the result and review it at high magnification: it is imperative that the stent is perfectly deployed Postdilate
High pressure, into aorta to flare stent
Never accept an unsatisfactory result
Table 5.1a
88
If needed 20 atm with shorter balloon
T-stent/Kissing balloon (consider provisional stent if small SB)
Provisional SB balloon stent only
SB jailed: not dilated unless ischemic complications
579_Stenting_ch.05
14/8/2001 14:05
Page 89
SPECIFIC ANATOMIC SUBSETS
‘Special cases’
LVEF < 40% or occluded RCA
Heavily calcified lesions
Left main RCA other sites
Comments
Refer for CABG if operable; only do PCI if absolute C/I for surgery
Refer for CABG if operable; if not, rotational atherectomya with large burrs
Mandatory pretreatment with adequate antiplatelet Rx
Set-up
IABP ready;b BP >120 before wiring LM
Guide 8 Fr; IABP ready;c BP >120
Stent the RCA first, then left-sided lesions as right →→→
Wire
Distal LAD
Exchange rota wire for better support
Predilate
Undersized branch balloon, 15 s at 18 atm. Wait 1 min
Appropriatesize balloon (by 0.5 mm) at low (8 atm) pressure
Stentc
Ensure uninflated balloon passes freely before stenting, >16 atm for <20 s
Ensure uninflated balloon passes freely before stenting, >16 atm for <20 s
Postdilate
Postdilate as for ostial or mid-shaft lesions
Left main LAD or LCX lesions
Dilate LM, stent SB, stent LM, then stent MB through LM stent
Never accept an unsatisfactory result a Before rotational atherectomy, we suggest the use of intracoronary ISDN (3 mg) or GTN (200 µg), verapamil (125–250 µg) adenosine to limit the no-reflow phenomenon. Advance burr for no more than 30 s for each run. b Counterpulsation must be available in the catheterization laboratory for every case. c Place stents precisely under continuous fluoroscopic guidance (i.e. do not remove foot from fluoro pedal!). RCA, right coronary artery; C/I, contraindication; BP, blood pressure; LM, left main; MB, main branch; SB, side-branch.
Table 5.1b
89
579_Stenting_ch.05
14/8/2001 14:05
Page 90
LEFT MAIN DISEASE
a
d
Pre-Stent
b
c
Final Result
Figure 5.3 Case 2 (a) Left main ostial lesion (b) Accurate stent positioning (c) High pressure post-dilatation (d) Final result.
(a) Figure 5.4 Case 3 (a) Pre stent (b) Post direct stenting.
the major branch, and then predilate the lesion with an undersized balloon to avoid distal dissection. In carefully selected non-calcified lesions, direct stenting might be performed. A short inflation (10–15 s) at high pressure (16–18 atm) is then performed (Figure 5.4b)
90
(b)
prior to stent deployment as above. If the stent is not perfectly deployed, postdilate at higher pressure (20 atm) with the same balloon (if it is a current-generation balloon which will not exceed the stent length) or using a shorter balloon with a bigger diameter.
579_Stenting_ch.05
14/8/2001 14:05
Page 91
SPECIFIC ANATOMIC SUBSETS
Distal bifurcation lesion ‘True’ distal lesion involving both bifurcation branches (Figure 5.5, Case 4, see also Chapter 4) As a ‘kissing’ balloon inflation will be used, it is necessary to choose a larger-lumen guiding catheter ( 7 Fr). Both branches are wired and pre-dilated alternately, and the stent is deployed in the major branch, leaving the (‘jailed’) wire in the side-branch (Figure 5.5a). The wire from the stented branch is then used to rewire the nonstented branch through the stent just deployed, and the ‘jailed’ wire from the non-stented branch is removed and used to rewire the stented branch. Following predilation through the stent struts, a second stent is deployed (‘T’ technique) in the non-stented side-branch (Figure 5.5b). Finally, both branches are dilated using the kissing balloon technique (Figure 5.5c ), using alternately high and low pressures in the two balloons to avoid excessive stretching of the proximal left main when both balloons are inflated at the same time. ‘False’ distal lesions • Involving only one branch (see also Chapter 4, ‘type 2’): We recommend that wires be placed in both branches, although it is usually
only necessary to predilate and stent the involved major branch. The wire in the sidebranch is left as protection, in case of dissection or plaque shift that necessitates ‘provisional’ intervention to the side-branch— if so, both branches should be postdilated and/or stented using the kissing balloon and/or kissing stent technique. • With negligible myocardial territory or occlusion of one of the branches: Use the simplest possible technique. Only the involved major branch is wired, predilated and stented. The side-branch is jailed in the stent struts. There are certain situations where the risk of left main intervention is considerably increased. As well as applying this information to selection criteria, it may be necessary to modify the practical approach to carrying out the procedure. These situations include those where there is significant impairment of LV function or occlusion of the right coronary artery, or concomitant disease in the branch coronary vessels (left coronary or right coronary), and are covered in Table 5.1. In the case of left main disease in inoperable elderly patients with diffuse multivessel disease, it is recommended that only the left main be stented unless there is a clear ‘culprit’ lesion in the distal branches.
a
b
c Pre-Stent
Final Result
Figure 5.5 Case 4 Stent is deployed in the major branch leaving the (‘jailed’) wire in the side branch (a). Following predilation through the stent struts, a second stent is deployed (‘T’ technique) in the non-stented side branch (b). Finally both branches are dilated using the kissing balloon technique (c).
91
579_Stenting_ch.05
14/8/2001 14:05
Page 92
LEFT MAIN DISEASE
References
1. Cohen MV, Gorlin R. Main left coronary artery disease. Clinical experience from 1964–1974. Circulation 1975; 52:275–285. 2. Conley MJ, Ely RL, Kisslo J et al. The prognosis spectrum of left main stenosis. Circulation 1978; 57:947–952. 3. Varnauskas E, for the European Coronary Surgery Study Group. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1998; 319:332–337. 4. Farinha JB, Kaplan MA, Harris CN et al. Disease of left main coronary artery: surgical treatment and long-term follow-up in 267 patients. Am J Cardiol 1978; 42:124–128. 5. Loop FD, Lyttle BW, Cosgrove DM et al. Atherosclerosis of the left main coronary artery: 5 year results of surgical treatment. Am J Cardiol 1979; 44:195–201. 6. Carraciolo EA, Davis KB, Sopko G et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2325–2334. 7. O’Keefe JH, Hartzler GO, Rutherford BD et al. Left main coronary angioplasty: early and late results of 127 acute and elective procedures. Am J Cardiol 1989; 64:114–147. 8. Eldar M, Schulhoff RN, Hertz I et al. Results of percutaneous transluminal coronary angioplasty of the left main coronary artery. Am J Cardiol 1991; 68:255–256. 9. Crowley ST, Morrison DA. Percutaneous transluminal coronary angioplasty of the left main coronary artery in patients with rest angina. Cathet Cardiovasc Diagn 1994; 33: 103–107. 10. Lopez JJ, Ho KKL, Stoler RC et al. Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices: immediate angiographic results and intermediate term follow-up. J Am Coll Cardiol 1997; 29:345–352. 11. Laham RJ, Carrozza JP, Baim DS. Treatment
92
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
of unprotected left main stenoses with Palmaz–Schatz stenting. Cathet Cardiovasc Diagn 1996; 37:77–80. Colombo A, Gaglione A, Nakamura S, Finci L. ‘Kissing’ stents for bifurcational coronary lesion. Cathet Cardiovasc Diagn 1993; 30: 327–330. Macaya C, Alfonso F, Iniguez A et al. Stenting for elastic recoil during coronary angioplasty for the left main coronary artery. Am J Cardiol 1992; 70:105–106. Sathe S, Sebastian M, Vohra J, Valentine P. Bail-out stenting for left main coronary artery occlusion following diagnostic angiography. Cathet Cardiovasc Diagn 1994; 31: 70–72. Garcia-Robles JA, Garcia E, Rico M et al. Emergency coronary stenting for acute occlusive dissection of the left main coronary artery. Cathet Cardiovasc Diagn 1993; 30:227–229. Karam C, Fajadet J, Cassagneau B et al. Results of stenting of unprotected left main coronary artery stenosis in patients at high surgical risk. Am J Cardiol 1998; 82(8):975–978. Kosuga K, Tamai H, Ueda K et al. Initial and long-term results of angioplasty in unprotected left main coronary artery. Am J Cardiol 1999; 83(1):32–37. Black A, Cortina R, Bossi I et al. Unprotected left main coronary artery stenting. Correlates of midterm survival and impact of patient selection. J Am Coll Cardiol 2001; 37(3): 832–838. Park SJ, Park SW, Hong MK et al. Stenting of unprotected left main coronary artery stenoses: immediate and late outcome. J Am Coll Cardiol 1998; 31:37–42. Silvestri M, Barragan P, Sainsous J et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000; 35(6):1543–1550. Ellis SG, Tamai H, Nobuyoshi M et al. Contemporary percutaneous treatment of
579_Stenting_ch.05
14/8/2001 14:05
Page 93
REFERENCES
unprotected left main coronary stenoses. Initial results from a multicenter registry analysis 1994–1996. Circulation 1997; 96:3867–3872. 22. Marso SP, Steg G, Plokker T et al. Catheterbased reperfusion of unprotected left main stenosis during an acute myocardial infaction (the ULTIMA experience). Unprotected Left Main Trunk Intervention Multi-center Assessment. Am J Cardiol 1999; 83(11):1513–1517. 23. Bramucci E, Angoli L, Merlini PA et al. Adjunctive stent implantation following directional coronary atherectomy in patients with coronary artery disease. J Am Coll Cardiol 1998; 32(7):1855–1860.
24. Moussa I, Moses J, Di Mario C et al. Stenting after optimal lesion debulking (SOLD) registry. Angiographic and clinical outcome. Circulation 1998; 98(16):1604–1609. 25. Park SJ. Interventional Cardiology 2000 Symposium in Aspen, Colorado, USA. 26. Park SJ. Angioplasty Summit 2001, Seoul, Korea. 27. Kosuga K, Tamai H, Ueda K et al. Initial and long-term results of directional coronary atherectomy in unprotected left main coronary artery. Am J Cardiol 2001; 87(7):838–843.
93
579_Stenting_ch.05
14/8/2001 14:05
Page 94
579_Stenting_ch.06
14/8/2001 14:08
Page 95
6 Small vessel stenting Flavio Airoldi, Carlo Di Mario, Remo Albiero, Antonio Colombo
Introduction Since the first year after introduction of balloon angioplasty, percutaneous revascularization of coronary vessels with small luminal reference diameter has been associated with lower rates of procedural success and higher incidence of inhospital events. Many studies indicated that a small lumen size is one of the most important predictors of restenosis after plain old balloon angioplasty.1–3 Shunkert et al4 recently reported a retrospective analysis of their experience between 1994 and 1996 and showed that percutaneous revascularization procedures of coronary vessels with reference diameter <2.5 mm were associated with lower rates of procedural success (92% versus 95%, p 0.006) and higher rates of in-hospital major events (3.4% versus 2.0%; p 0.03) when compared to larger vessels. However, it should be noted that such differences were observed only among patients with non-stented lesions, while the lesions treated with stent implantation (only 18% of the lesions located in small arteries) had no differences in procedural success rate regardless of the vessel reference diameter. Based on these findings, they suggested that the current practice to limit the use of stents to vessels larger than 2.5 mm requires re-evaluation. Recent improvements in antiplatelet therapy and techniques of stent implantation as well as the availability of a new generation of flexible stents premounted on low-profile balloons have broadened the indications for coronary stenting,
allowing the treatment of distal vessels and secondary branches. As compared to conventional balloon angioplasty, coronary stenting reduces restenosis and target lesion revascularization rates in arteries with an angiographic reference diameter equal to or greater than 3.0 mm.5,6 The benefit of stenting in coronary arteries with a smaller angiographic diameter is still unclear, and stent implantation in such vessels is not a generally accepted practice, despite the poor results of standard balloon angioplasty. This chapter reviews the results of the preliminary studies of stent implantation in small vessels and analyzes the possible advantages provided by the use of dedicated stents.
Mechanisms of restenosis after stenting in small vessels Intracoronary ultrasound has shown that, after stenting, restenosis is entirely due to intimal proliferation.7,8 Conversely, restenosis after balloon angioplasty with or without adjunctive ablative techniques is mainly due to late wall recoil and intimal hyperplasia, accounting for 30–40% of the late lumen loss. A linear relationship has been demonstrated between acute gain and late loss, which means that the net gain is always increased by the achievement of a larger initial lumen (‘the bigger the better’) and that the absolute lumen loss caused is similar in arteries of different diameter.9 The greater initial post-
95
579_Stenting_ch.06
14/8/2001 14:08
Page 96
SMALL VESSEL STENTING
procedural lumen obtained in large vessels allows easier accommodation of intimal hyperplasia; in smaller vessels, in contrast, a similar hyperplasia can lead to the development of a critical lumen reduction. In other words, the same absolute volume of neointimal proliferation is more likely to induce >50% diameter stenosis in small coronary arteries. The relatively greater lumen reduction can also be explained by the increased injury induced by a high degree of vessel stretch, by an inappropriately high metal density with stents designed for larger vessels, or by the presence of higher plaque burden and more diffuse disease.
Technique of stenting small vessels Various techniques of stent deployment and different types of stent have been evaluated to identify the best strategy to optimize the initial results and minimize the extent of neointimal proliferation in small vessels and consequently reduce restenosis rate. As discussed below, a consensus has yet to be reached over the ideal balloon size and dilatation pressure, imaging guidance modality and stent length. Highpressure dilatation has been advocated to ensure optimal stent expansion and lumen enlargement.10,11 However, one may argue that the degree of vessel trauma and the excessive wall stretch induced by an aggressive stent expansion may induce a greater proliferative response. Data from different studies seem to indicate that high inflation pressure does not influence the long-term outcome. A less aggressive dilatation strategy in small vessels did not result in lower restenosis in the STRESS trial.12 Schulen et al13 have recently reported a prospective randomized comparison between highpressure (16.7 2.2 atm) and low-pressure (10.9 2.2 atm) dilatation in 574 lesions, and no difference in immediate and long-term angiographic and clinical results was observed. Akiyama et al14 observed that the balloon-to-
96
artery ratio was not predictive of restenosis, while the final cross-sectional area (CSA) within the stent was a predictor of restenosis independent of vessel size. The same conclusions have been drawn by Ziada et al,15 who performed successful stenting and intravascular ultrasound (IVUS) in a series of 234 arteries with a reference diameter of 3.0 0.5 mm, and found the minimal lumen area by ultrasound to be more accurate than other angiographic measurements of the procedural results (qualitative angiography (QCA) final minimum lumen diameter or percentage residual diameter stenosis) in predicting need for revascularization. Balloon oversizing with IVUS guidance to increase stent expansion in small vessels has been evaluated by Stone et al.16 This study included 220 vessels with a reference diameter of 2.9 0.5 mm according to the QCA evaluation, and a media-to-media diameter of 3.9 0.5 mm at IVUS examination. In all cases, a postdilatation at 16 atm was performed to expand the stent to the media–adventitial border, using balloons with focal technology which grow 0.5 mm larger centrally within the stent (Radiance FACT), protecting the stent edges. Interestingly, both target vessel revascularization (TVR) and restenosis rates were low and similar in the group of arteries with an angiographic diameter <3.0 mm and in the group of arteries >3.0 mm (12.7% versus 12.0%, p NS for TRV rates, and 25.9% versus 26.1%, p NS for restenosis rate), supporting the hypothesis that a larger final lumen area may provide better late outcomes. IVUS-guided percutaneous transluminal coronary angioplasty (PTCA) with spot stenting has also been proposed for treatment of long lesions located in small vessels. In 109 lesions with a reference diameter <3.0 mm, the procedural success rate (96%) was higher than historical success rates reported with traditional balloon angioplasty and similar to success rates reported with traditional coronary stenting performed with complete coverage of the diseased segment (from the proximal normal segment to the distal
579_Stenting_ch.06
14/8/2001 14:08
Page 97
RETROSPECTIVE ANALYSIS
normal segment).17 In particular, a residual dissection with a large true lumen confirmed by ultrasound did not seem to increase the risk of abrupt closure or subacute stent occlusion. Long-term follow-up data of this consecutive series of patients treated with ultrasound-guided spot stent implantation matched with patients treated with conventional angiographic-guided stent implantation suggest that the angiographic restenosis rate (17.4%) obtained with this approach is better than the restenosis rate observed in lesions with similar length and vessel size treated with conventional PTCA alone or with traditional stenting. The advantage of this approach is to avoid covering long segments in small vessels with multiple stents, since the length and the number of stents implanted have been shown to be factors promoting an increased restenosis rate and associated with malignant patterns of diffuse restenosis.18
Retrospective analysis Most of the information we have about the results of coronary stenting in small vessels derives from retrospective analysis of historical series or from retrospective evaluation of subgroups of patients randomized in prospective studies addressed to other purposes. Few data are available from prospective analyses, and the final results of ongoing prospective case–control randomized studies have not been published. Akiyama et al, in the already mentioned study,14 observed that patients who underwent stent implantation in small vessels had a shortterm outcome (1 month) similar to the outcome of patients who underwent stenting in larger arteries (subacute thrombosis rates of 1.5% in vessels <3.0 mm and 1.4% in vessels >3.0 mm, p NS), but stenting in small vessels was associated with a higher restenosis rate compared to stenting in larger arteries (32.6% and 19.9% respectively, p 0.0001) at 6-month follow-up. The low incidence of stent thrombosis in small vessels in this study is in agreement with other
reports,19–21 and may be explained by the aggressive stent expansion, under ultrasound guidance in 70% of cases, together with post-procedure double antiplatelet therapy. Several studies have compared the results of treatment of small vessels with standard balloon angioplasty and coronary stenting. Savage et al22 have analyzed the subgroup of 311 patients from the STRESS I and II trials with a vessel diameter measured by QCA <3.0 mm. Palmaz–Schatz stents were implanted in de novo lesion in patients with stable angina. The average reference diameters in these arteries before treatment were 2.69 mm and 2.64 mm in the stent and in the PTCA groups, respectively. Immediate success was higher in the stent group (100% versus 92% in the PTCA group, p NS), and no difference in acute vessel closure was observed. Long-term angiographic follow-up showed a significant reduction of restenosis rate in the 163 patients treated with stent implantation, in comparison with the 168 patients randomized to standard PTCA (34% versus 55% incidence of >50% diameter stenosis at 6-month angiographic followup; p < 0.001). A larger meta-analysis was performed by Azar et al,23 based on the data from 1099 patients enrolled in the BENESTENT-1 and in the STRESS-I and STRESS-II trials. Coronary arteries were grouped according to their reference diameter into four categories: smaller than 2.60 mm, between 2.60 and 2.80 mm, between 2.8 and 3.00 mm, and greater than 3.00 mm. The restenosis rate for stenting was significantly lower in the latter three categories (27%, 27% and 18%) in comparison to PTCA (49%, 40% and 34%), while in the smallest arteries (<2.60 mm) the restenosis rate after stenting was higher (42%) and similar to the restenosis rate observed after balloon angioplasty (38%, p NS). However, the results of Savage and Azar must be considered with a note of caution, as the patient population was highly selected for clinical and angiographic characteristics (for example, all lesions had to be shorter than
97
579_Stenting_ch.06
14/8/2001 14:08
Page 98
SMALL VESSEL STENTING
10 mm). Furthermore, since a reference diameter <3.0 mm was an exclusion criterion on these trials, the real existence of such a large group of small arteries can be questioned. The ability to accommodate a 3.0-mm stent with no increased incidence of dissection or vessel rupture (100% technical success in the stent group) suggests that, in most instances, QCA might have underestimated the true vessel diameter. In other words, the angiographic evaluation employed in these studies is not able to distinguish between a truly small vessel and a larger artery with a diffuse plaque burden, affecting also the reference segment. This important methodological aspect has been highlighted in studies in which vessel size was evaluated with QCA as well as with IVUS. In our experience, in 365 vessels with angiographic lumen diameter <3.0 mm in all cases (mean angiographic diameter of 2.65 mm) consecutively treated with stent implantation, the average vessel diameter (media-to-media) as measured by IVUS was 3.64 mm. This discrepancy was even higher if the lesions were located in the proximal segment of the vessel or in arteries of diabetic patients.24 These findings explain previous angiographic observations showing that, even in apparently normal arteries, the reference diameter becomes smaller with the increase in age and number of risk factors for coronary artery disease. For example, diabetic patients have a small reference diameter as a consequence of higher plaque burden and more diffuse disease. These observations may explain why the results documented by Savage et al and Azar et al have not been duplicated in other studies. For instance, in a series of lesions located in vessels <3.0 mm, Fernandez-Ortiz et al25 reported a high risk (41% at 6 months) of restenosis after stenting, with no significant difference from restenosis occurring after standard PTCA (40.8%). The randomized trial DESTINI compared elective stenting and a strategy of aggressive QCA and doppler-guided balloon angioplasty, and separately analyzed the 203 lesions with a reference diameter <2.75 mm. The need for
98
target lesion revascularization (TLR) was 16.8% in the optimal angioplasty group and 25.6% in the group treated with elective stenting.26 It must be noted, however, that even in this small vessel subset, an optimal result could be obtained in less than 50% of cases with PTCA alone. A comparison between stenting and balloon angioplasty in small vessels has also been evaluated in a subset of patients with chronic total occlusions in the TOSCA (Total Occlusion Study of Canada) study.27 The authors reported an improvement in acute angiographic results (92% for stenting versus 84% balloon angioplasty, p 0.036). Yet, at 6-month follow-up, only a slight and statistically non-significant difference in restenosis rate was observed between the two groups (53% and 63% for stenting and angioplasty, respectively; p NS). Also in the setting of acute myocardial infarction, stenting small vessels does not appear beneficial. The cumulative effect of lesion length and small vessel size on restenosis rate after stenting has been confirmed by Lansky et al28 in a recent sub-analysis of data from the Primary Angioplasty in Myocardial Infarction (PAMI) stent randomized trial: after primary PTCA or stenting for acute myocardial infarction, restenosis rates increased with longer lesions. Among arteries with reference diameter <2.75 mm, restenosis rates were slightly but not significantly higher in the conventional angioplasty group than in the stent group for lesions shorter than 20 mm (39% versus 33% for lesions <10 mm in the POBA and in the stent groups respectively, p NS, and 38% versus 28% for lesions 10–20 mm in the POBA and in the stent groups respectively, p NS). In lesions >20 mm (n 119), the angiographic follow-up showed an unacceptable high restenosis rate after stenting, being 80% in stented vessels compared to 22% in the POBA group (p < 0.05). These results should discourage the operators from performing an elective complete coverage of the stenotic segment in such lesions.
579_Stenting_ch.06
14/8/2001 14:08
Page 99
INITIAL RESULTS OF RANDOMIZED TRIALS
Prospective evaluations Analysis of pooled data of randomized trials addressing different lesion groves cannot substitute for a true specifically designed trial for small vessels. Few prospective studies of coronary stenting in vessels <3.0 mm have been performed, and most of these studies are still in progress or definitive results are pending. Koning et al29 have published results of primary stenting in small arteries (mean reference diameter 2.66 mm) using the Palmaz-Schatz stent manually crimped on low compliant or non-compliant balloons of 2.5 mm or non-compliant balloons of 2.75 mm. Stent deployment was successful in all cases, with only one case of subacute thrombosis. At 6-month angiographic follow-up, the restenosis rate was 30%. Fished et al30 evaluated the results of coronary stenting in 135 small vessels (reference diameter 2.55 mm) using the beStent, a slotted tube stent with an unique serpentine design, available in small sizes, meant to be implanted in 2.5–3.0-mm-diameter arteries. Immediate angiographic success was obtained in 99% of cases. Long-term results have been assessed only with clinical follow-up, and target vessel revascularization (TVR) occurred in 12.6% of patients. In the Hospital San Raffaele and Centro Cuore Columbus, Milan, we evaluated the angiographic results of elective implantation of dedicated stents in small vessels, comparing two different stents with a slotted tubular design: the NIR 5-cells and the MINI stent.31 No difference was observed in immediate quantitative coronary angiography results. Owing to the low angiographic control at 6 months, performed only in 35% of patients and mainly for recurrence of symptoms or signs of ischemia, an unacceptably high restenosis rate was observed in both groups (60% with NIR and 50% with MINI). This incidence could reflect a bias in patient selection, as the follow-up population consisted mainly of symptomatic patients. A larger patient population and a more complete
angiographic follow-up are required to obtain the true incidence of restenosis.
Initial results of randomized trials Three large trials have specifically addressed the benefit of the use of stents in small vessels. Since the data have not been published, the information available remains insufficient to draw firm conclusions. The opposite outcome of these trials requires in-depth knowledge of patient and procedural characteristics to explain the cause of the difference. In the BESMART trial, 381 patients were enrolled in 21 French centers. One-two lesions were treated per patient. The protocol mandated the use of a single 15-mm-long beStent mounted on a 2.5-mm balloon and discouraged the use of balloons larger than 2.5 mm both for post-dilatation in the stent group and for treatment in the PTCA arm. The investigators strictly adhered to the protocol, enrolling lesions with an average reference diameter of 2.24 mm and lesion length of 9.4 mm, similar in the PTCA and stent groups, and using a 2.5-mm balloon in 96% of the lesions of the PTCA group and 99% of the stent group. Crossover to stenting in the PTCA arm was equal to 24%. Intention-to-treat analysis showed a striking difference in favor of the stent group, with TLR in 13% versus 25% of the PTCA arm and binary restenosis rates of 22.7% versus 48.5% in the PTCA arm, both statistically significant differences. The Medtronic beStent was used in another randomized trial of similar size (352 patients with single lesion and stable angina in vessels with a reference diameter of 2.3–2.9 mm). Despite the fact that the initial clinical data showed a trend to a reduction of adverse events at 30 days (3.9% in the stent group and 8.8% in the PTCA group), the angiographic restenosis rate was similar in the two groups, with 32.4% in the PTCA arm and 28.0% in the stent
99
579_Stenting_ch.06
14/8/2001 14:08
Page 100
SMALL VESSEL STENTING
group.32 In the ISAR-SMART trial, 404 patients with average reference vessel diameter of 2.4 mm were randomized to PTCA or single Multilink stent implantation: restenosis rate was similar in the two groups (35.7% in the stent group and 37.5% in the PTCA group), and TLR was higher (non-significantly) in the stent group (20.1% versus 16.5% in the PTCA group). A possible criticism of all these trials is the deliberate attempt to avoid balloon upsizing if, after the initial dilatation, the vessel size is larger than expected from the preintervention angiogram. Furthermore, these trials are a sort of BENESTENT trial of small vessels, with inclusion criteria such as single lesion, stable angina, and lesions to be covered by a single 15-mm stent. Therefore, these results cannot be applied to longer lesions.
Dedicated stents Stent design and strut geometry have been thought to influence the proliferative response of the intima after stenting. The stents used in most of the previous studies were designed to achieve an optimal plaque scaffolding and wall coverage in vessels in the range of 3.0–4.5 mm. Implantation of these stents in small arteries can lead to a higher metal density, a potential stimulus for an excessive proliferative response. Two different lines of evidence support this hypothesis. The first one is that in our experience,14 using a cutoff reference diameter of 3.0 mm, the effect of coil stents on restenosis is similar to that of slotted tube stents only in small vessels (32.6% versus 27.7%) and not in larger arteries (32.1% versus 16.7%), suggesting that the negative properties of the coil stents (higher recoil and plaque prolapse) are counterbalanced by the more favorable metal-to-vessel surface ratio. The second line of evidence comes from a study in small (<3.0-mm) porcine coronary arteries, in which vascular remodeling and neointimal formation were evaluated at 1 month after the deployment of different types of stent.33 Vessel histology indicated that neointimal area corre-
100
lated positively with strut thickness (r 0.42, p < 0.0001). Moreover, the neointimal area was greater in stents with 0.15-mm strut width (2.54 1.17 mm2) than in stents with 0.9-mm strut width (1.34 0.59 mm2, p < 0.0001) leading to a greater in-stent area reduction (50% versus 30%, p < 0.0001). The superiority of the second generation of stents seems to be confirmed by a recent paper by Hamasaki et al,34 in which the authors compared the short- and long-term results of three different strategies for the treatment of small vessels: balloon angioplasty, stenting with a Palmaz-Schatz and stenting with the ACS Multilink Duett 2.5 mm. The results indicate that, in spite of a similar MLD after the procedure (2.43 mm after Palmaz–Schatz stenting and 2.36 mm after Multilink implantation), the restenosis rate (RR) and the TLR rate were significantly lower in the group treated with the Multilink stent (RR 23%, TLR 13%) in comparison to balloon angioplasty (RR 56%, TLR 40%, p < 0.001) and to Palmaz–Schatz stenting (RR 31%, TLR 19%, p < 0.001). Stents with modular design (Bard XT) have also been proposed for vessels <3.0 mm. The clinical and the 6-month angiographic results have been compared to slotted tubular stents in the EXTRA trial involving 338 lesions. Even though the angiographic restenosis rates were comparable for modular and slotted tubular stent design (41% and 32% respectively, p NS), a significantly increased incidence of Q-wave myocardial infarction within 6 months was noted in the modular stent group (5% versus 0%, p 0.004).35 Recently, new stents specifically dedicated to small vessels have been developed. They are characterized by a slotted tube design that allows complete wall coverage and stent expansion in small-diameter vessels with a different design of the stent produced from the same steel cylinder with laser cutting. The original diameter of the cylinder, however, is the same for small and large vessel design (>1.5 mm). The Biodiv Ysio stent for small vessels is an exception to this
579_Stenting_ch.06
14/8/2001 14:08
Page 101
CONCLUSIONS
the lesion in the distal segment of the main vessels or in the side-branches and IVUS can be useful to distinguish true small vessels from diffusely diseased large arteries with a reduced angiographic reference diameter, conditions which require different strategies. The current available data on treatment of small vessels indicate that stenting is safe, but registry data, data gathered from randomized trials in large vessels, and the conflicting results of recent randomized trials in small vessels, do not provide sufficient evidence of improved long-term outcome compared with conventional angioplasty. We believe that stent implantation in arteries smaller than 3.0 mm should be limited to the cases of suboptimal results of conventional
manufacturing procedure, as the stent is carved from a cylinder of 1.0 mm. This explains the easier crimpability and the very low profile (0.74 mm for the 2.5 mm, 0.64 mm for the 2.0-mm premounted stents, the smallest profile available of balloon-mounted stents), properties associated with the presence of phosphorylcholine coating supposed to improve the stent biocompatibility and reduce thrombogenicity. The most common stents for small vessels are listed in Table 6.1.
Conclusions Definition of small vessels must be limited to arteries with a true small diameter. Location of
Stent
Range (mm)
Lengths (mm)
Characteristics
Be-Stent Medtronic, Mn, USA Mini Cordis, J&J Inc., NJ, USA BX Velocity Cordis, J&J Inc., NJ, USA NIR 5-cellsa
2.5–3.0
8–15–25
Slotted tubular stent
2.25–3.25
11–15–26
Slotted tubular stent
2.25–3.00
8–13–18–23–28
Slotted tubular stent
2.0–2.5
19
Laser cut from a metal sheet rolled and welded
NIR 7-cells Boston Scientific-Medinol Ltd, Israel S540 Medtronicnt AVE, Inc., USA ACS Multilink Duett RXTristar Guidant/Advanced Cardiovascular System, CA,USA Jostent Flex—small vessel (Jomed International A, Sweden) Diamond flex AS Phytis Medical Services BioDivysio PC coated stent Biocompatibles Ltd, UK
2.5–3.5
9–16–25–32
2.5
8–12–14–18–23
Slotted tubular stent
2.5–3.0
8–13–18–23
Slotted tubular stent
2.0–3.0
9–16–26–32
Slotted tubular stent
2.5–3.0
12–16–20
2.0–3.0
11–15–18–28
Slotted tubular stent, available with carbon-coated surface Slotted tubular stent, carved from a 1.0-mm cylinder, Phosphorylcholine-coated
a
Not yet commercially available.
Table 6.1
101
102 BeStent, Medtronic, Mn, USA
SISA32
Mini-Crown Cordis, J&J Inc., NJ, USA NIR-7 cell, Boston Scientific-Medinol Ltd, Israel
Asia-Pacific40 Mini-Crown registry Park et al41
Controlled prospective
Prospective randomized trial (POBA versus stent)
Australia, Asian countries South Korea
USA
France
218
120
100
128
381
404
440
352
138
Patients
Vessel size
1–3–2.99
<3.0
<3.0
2.25–3.00
Average reference diameter 2.4 mm <3.0
2.2–2.7
2.3–2.9
2.75
(mm)
100% technical success
Bailout stenting in 10% of cases in POBA group
93% technical success in stent group, 60% success in POBA group, bailout stenting in 37% of cases. By intention-to-treat analysis: 95% technical success in stent group, 93% success in POBA group (p NS) Not available
Interim analysis: 99% technical success in stent group, 96% success in POBA group (p NS)
Interim analysis: 98% technical success in stent group, 96% success in POBA group (p NS)
Interim analysis: overall technical success 97.9%
97% technical success
Immediate results
Table 6.2 Clinical, angiographic, and procedural variables identified as risk factors for restenosis.
Biodiv Ysio PC coated stent, Biocompatibles Ltd, UK
Prospective randomized trial (POBA versus stent)
Mini-Crown, Cordis, J&J Inc., NJ, USA
Savage et al39
Sophos42
Prospective registry
BeStent, Medtronic, Mn, USA
BESMART38
Spain
Worldwide
Italy
Country
At 6-month-follow-up: 31% restenosis rate in stent group, 36% restenosis rate in POBA group (p NS) At 6-month-follow-up: 20.6% restenosis rate in vessels with reference diameter <3.0 mm
Not available
Not available
TLR: 20% in stent group and 16% in POBA group (p NS) Binary restenosis rate: 37.5% in both groups (p NS). TLR: 13% in stent group and 25% in POBA group (p < 0.01) Binary restenosis rate: 23% in the POBA group and 48% in the POBA group (p < 0.01). Crossover to stenting in the POBA 24%
Binary restenosis rate: 32% in the POBA group and 28% in the POBA group (p NS) Not available
Not available
Long-term results
14/8/2001 14:08
Prospective randomized trial (POBA versus single stent) Prospective randomized trial (POBA versus stent)
ACS Multilink Duett
ISAR-SMART
Prospective randomized trial (POBA versus stent)
BeStent, Medtronic, Mn, USA
Prospective randomized trial (POBA versus stent)
Prospective registry
Study design
RAP36 Restenosis in arterias pequenas
Stenting in small arteries
Mini-Crown, Cordis, J&J Inc., NJ, USA
Microscope
Stent employed
579_Stenting_ch.06 Page 102
579_Stenting_ch.06
14/8/2001 14:08
Page 103
CONCLUSIONS
balloon angioplasty, using short stents to cover segments with severe dissections or persistent significant residual stenosis. In the near future, the indications for stenting small coronary arter-
ies may be broadened by improvements in stent technology or development of effective antiproliferative treatments (brachytherapy, cell cycle inhibitors).43–46
103
579_Stenting_ch.06
14/8/2001 14:08
Page 104
SMALL VESSEL STENTING
References
1. Ellis S, Roubin G, King S et al. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal angioplasty. Am J Cardiol 1989; 63:30–34. 2. Kuntz RE, Safian RD, Carrozza JP et al. The importance of acute lumen diameter in determining restenosis after coronary atherectomy, or angioplasty. Circulation 1992; 86: 1827–1835. 3. Elezi S, Kastrati S, Neumann FJ et al. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875–1880. 4. Schunkert H, Harrel L, Palacios F. Implications of small reference vessel diameter in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 1999; 34: 40–48. 5. Serruys PW, de Jagere P, Kiemeneij F et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489–495. 6. Fishmann DL, Leon MB, Baim DS et al. A randomized comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:496–501. 7. Dussailant GP, Mintz GS, Pichard AD et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26:720–724. 8. Mudra H, Regar E, Klauss V et al. Serial follow-up after optimized ultrasound guided deployment of Palmaz–Schatz stents: in stent neointimal proliferation without significant reference segment response. Circulation 1997; 95:363–370. 9. Hoffmann R, Mintz GS, Dussaillant AD et al. Patterns and mechanism of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94:1247–1254.
104
10. Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676–1688. 11. Karrillon GJ, Morice MC, Benveniste E et al. Intracoronary stent implantation without ultrasound guidance and with replacement of anticoagulation by antiplatelet therapy: 30 day clinical outcome of the French Multicenter Registry. Circulation 1996; 94:1519–1527. 12. Savage MP, Fishman DL, Rake R et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries; stent restenosis study (STRESS investigators). J Am Coll Cardiol 1998; 31:307–311. 13. Schulen H, Hausleite J, Giehrl W et al. High versus low balloon pressure for stent deployment in small (<3.0 mm) coronary arteries. One year result of a randomized trial. Circulation 1998; 98(suppl I):I-828 (abstract). 14. Akiyama T, Moussa I, Reimers B et al. Angiographic and clinical outcome following coronary stenting of small vessels. A comparison with coronary stenting of larger vessels. J Am Coll Cardiol 1998; 32:1610–1618. 15. Ziada KM, Kapadia SR, Belli G et al. Impact of vessel size and procedural results on long term outcome following coronary stenting. J Am Coll Cardiol 2000; 35:1043–1117 (abstract). 16. Stone GW, Bailey S, Roberts DK et al. A prospective multicenter trial of the safety, feasibility and efficacy of ultrasound guided maximal stenting to the media–adventitial border final late clinical and angiographic results from the OSTI-2 study. J Am Coll Cardiol 2000; 35:1108–1192 (abstract). 17. Moussa I, De Gregorio J, Di Mario C et al. The use of intravascular ultrasound and spot stenting for the treatment of long lesion and small vessels. J Invas Cardiol 1999; 11:47–55. 18. Kobayashi Y, De Gregorio J, Kobayashi N et al. Stented segment length as independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651–659.
579_Stenting_ch.06
14/8/2001 14:08
Page 105
REFERENCES
19. Moussa I, Di Mario C, Reimers B et al. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 1997; 29:6–12. 20. Baim D, Cutlip DE, Zhang Y et al. Characteristics and predictors of stent thrombosis from the stent anticoagulation regimen study (STAR). Circulation 1997; 96(suppl I):I-3655. 21. Morice MC, Bradai R, Lefevre T et al. Stenting small coronary arteries. J Invas Cardiol 1999; 11:337–340. 22. Savage MP, Goldberg S, Hirshfeld JW et al. Clinical and angiographic determinants of primary coronary angioplasty success. J Am Coll Cardiol 1991; 17:22–28. 23. Azar AJ, Detre K, Goldberg S et al. A metaanalysis of the clinical and angiographic outcomes of stent vs PTCA in the different vessel sizes in the Benestent and Stress I/II trials. Circulation 1995; 92(suppl I):I-475 (abstract). 24. Moussa I, Moses J, De Gregorio J et al. The discrepancy between quantitative coronary angiography and intravascular ultrasound in determining true vessel size: a homogeneous or a selective phenomena. J Am Cardiol 1999; 39(suppl I):I-1159 (abstract). 25. Fernandez-Ortitz A, Perez-Vitzcayno MJ, Goicolea J et al. Should we stent small coronary vessels? Comparison with conventional balloon angioplasty. Eur Heart J 1997; 18(suppl):286 (abstract). 26. Di Mario C, Moses J, Anderson T et al. Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by on-line quantitative angiography and intracoronary doppler. Circulation 2000; in press. 27. Title LM, Buller CE, Catellier D et al. Efficacy of stenting vs balloon angioplasty in small diameter (<3.0 mm) total coronary occlusions: a Total Occlusion Study of Canada sub-study. Circulation 1998; 98(suppl I):I-3362 (abstract). 28. Lansky A, Stone GW, Mehran R et al. Impact of vessel size and lesion length on outcomes after primary stenting vs primary angioplasty in acute myocardial infarction: results from Stent PAMI. Eur Heart J 1999; 20(suppl):3332 (abstract).
29. Koning R, Chan C, Eltchaninoff H et al. Primary stenting of de novo lesions in small coronary arteries: a prospective, pilot study. Cathet Cardiovasc Diagn 1998; 45:235–238. 30. Fished A, Friend CA, Allan RM et al. Favourable acute and six month follow-up results after coronary stenting using the small bestent in 2.5–3.0 mm arteries. Circulation 1998; 98(suppl I):I-3361 (abstract). 31. Airoldi F, Di Mario C, Anzuini A et al. Small vessel stenting with two different dedicated stents. Eur Heart J 1999; 20(suppl):2052 (abstract). 32. Doucet S, Schalig MJ, Hilton D et al. The SISA trial: a randomised comparison of balloon angioplasty and stent to prevent restenosis in small arteries. J Am Coll Cardiol 2000; 35:8 (abstract). 33. Carter AJ, Foster M, Bailaey LR et al. Vascular remodelling and neointimal formation depend on stent design and strut geometry in small coronary arteries. Circulation 1998; 98(suppl I):I-980 (abstract). 34. Hamasaki N, Nosada H, Kimura T et al. Stenting for small vessels using new generation flexible stent: comparison of balloon angioplasty and Palmaz–Schatz stent. J Am Coll Cardiol 1999; 39(suppl):I-81 (abstract). 35. Caputo RP, Gianbartolomei A, Simons A et al. Small vessels stenting: comparison of modular vs slotted tube design. Six month results from the EXTRA trial. J Am Coll Cardiol 2000; 35:1130–1189 (abstract). 36. Gargïa E, Gomez-Recio M, Pasalodos J et al. Interim results of the RAP-randomized study stent vs balloon in small vessels. Eur Heart J 1999; 20(suppl):2062 (abstract). 37. Douchet S, Shalig MJ, Hilton D et al. The SISA study: a randomized comparison of balloon angioplasty and stent to prevent restenosis in small arteries. J Am Coll Cardiol 2000; 35: 79–84 (abstract). 38. Koning R, Khalife K, Gilard M et al. The BESMART study: in hospital clinical and angiographic results. Eur Heart J 1999; 20(suppl):2053 (abstract). 39. Savage MP, Fishman DL et al. A randomized comparison of elective stenting and balloon angioplasty in the treatment of small coronary arteries. Circulation 1999; 100(suppl I):I-2651 (abstract).
105
579_Stenting_ch.06
14/8/2001 14:08
Page 106
SMALL VESSEL STENTING
40. Muller D, Lansky A, Kaul U et al. Small native coronary vessel stenting: results from the AsiaPacific Mini-Crown registry. Circulation 1999; 100(suppl I):I-2653 (abstract). 41. Park SW, Lee CW, Hong MK et al. Randomized comparison of coronary stent placement with optimal balloon angioplasty for treatment of lesion in small coronary arteries. Circulation 1999; 100(suppl I):I-717 (abstract). 42. Serruys PW, Buller C, Bonnier JJRM et al. Quantitative angiographic results of the phosphorylcholine coated stent in the SOPHOS study. Eur Heart J 1999; 20(suppl):I525 (abstract). 43. Albiero R, Adamian M, Kobayashi N et al. Short- and intermediate-term results of 32P radioactive -emitting stent implantation in
106
patients with coronary artery disease. The Milan dose–response study. Circulation 2000; 101:18–26. 44. Terstein PS, Massullo V, Jani S et al. Threeyear clinical and angiographic follow-up after intracoronary radiation. Results of a randomized clinical trial. Circulation 2000; 101: 360–365. 45. Axel DI, Kunert W, Göggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96:636–645. 46. Herdeg C, Oberhoff M, Karsch KR. Antiproliferative stent coatings: taxol and related compounds. Semin Interv Cardiol 1998; 3: 197–199.
579_Stenting_ch.07
16/8/2001 10:33
Page 107
7 Direct stenting Sanjay Prasad, Ameet Bakhai, Ulrich Sigwart
Introduction In recent years, as randomized trials have demonstrated improved outcomes with stenting, compared to balloon angioplasty, routine stent implantation has become the preferred option.1,2 Significant problems were encountered with firstgeneration balloon-expandable stents, which tended to be bulky and difficult to deliver, and either had to be hand crimped onto a balloon or were unreliably adherent to their delivery catheters. In these circumstances, balloon predilatation was considered necessary and important to permit easy, safe passage of the stent delivery system across the stenosis. With secondgeneration stents, many of these problems have been overcome through improvements in crossing profile and stent bonding.3,4 The crossing profile of the current-generation stents, at less than 1.25 mm, is significantly lower than that of the first-generation Palmaz–Schatz delivery system (1.65 mm). Interventional cardiologists have since striven to identify ways of reducing both the complexity and costs to the patients, and healthcare providers, of coronary interventions.5,6 In addition, particularly with complex cases, there has been a need to reduce exposure time to radiation and the amount of contrast agent used. One such approach to enable this is direct stenting, which refers to the technique of coronary stent implantation without initial balloon predilatation of the coronary lesion.7,8 Direct stenting has been shown in some studies to have an improved or equivalent clini-
cal outcome compared to the pre-dilatation strategy, often with reduced procedural costs.4,9 In part, this may be due to the observation that aggressive pre-dilatation is more commonly associated with extensive dissection which is reduced by directly sealing off any dissection plane, and reducing the associated exposure of platelet-activating and cell proliferative substances. Other potential advantages of direct stenting are reductions in ischemia, equipment cost, radiation dose, procedural time, and radiographic contrast use. Preliminary observations suggest that the strategy of direct stenting is applicable with modern stents in up to about 40–60% of all coronary interventions.10,11 With increasing safety and economic data being gathered by randomized trials and prospective registries, this may become the method of choice in eligible lesions.
Theoretical background Studies in laboratory models by Edelman12 and Rogers et al13 have suggested that, by avoiding balloon dilatation before stenting, the extent of vessel injury and the subsequent restenotic response may be reduced. A pre-dilating balloon that is longer than the stent delivery balloon is also likely to create intimal damage outside the target segment for stenting. Thus, direct stent placement without unnecessary adjunctive balloon inflations may reduce the response to vessel wall injury.10,14
107
579_Stenting_ch.07
16/8/2001 10:33
Page 108
DIRECT STENTING
Technique for direct stenting The implantation technique for direct stenting is not dissimilar to standard techniques for stent deployment, except that there is no balloon predilatation. Standard guide catheters and guidewires have been used in the published trials. In many of the published studies from the early 1990s, 8 Fr guide catheters were used. More recently, there has been a shift towards 6 Fr guide catheters via the femoral artery and 5-Fr via the radial artery. Although the initial series utilized a protected over-the-wire system, this rapidly evolved to the unprotected rapidexchange system. With newer stent delivery systems, the risk of stent dislodgement has been minimized. Maximal guide catheter support is, however, crucial for this technique. As the antegrade flow (due to the larger profile) is often abolished as soon as the stent delivery unit is located in the stenotic area, auxiliary landmarks for accurate placement are important. These must be identified prior to advancing the stent to the lesion. Generally, once optimal stent placement has occurred, deployment is achieved using highpressure balloon inflation pressures of around 14–16 atm.15 If stents have failed to cross the target lesions, standard pre-dilatation with a balloon is performed, followed by a further attempt to cross with the stent.
Requirements for direct stenting Stent systems considered for direct stenting must exhibit a number of features above minimal requirements. First, and most important, the quality of bonding to the delivery balloon is crucial. As additional axial push in situations of high friction may be required to cross the target lesion, the firm seating of the stent is a major challenge. The same challenge may occur if the stent system has to be withdrawn following unsuccessful attempts to cross. Stent emboliza-
108
tion under such circumstances may have catastrophic sequelae. With the advent of ‘heat bonding’, the previously recommended avoidance of negative balloon pressures has become obsolete; on the other hand, even minimal pressurization of the delivery balloon before deployment is to be avoided, as it may interfere with the bonding process. Stent manufacturers have recognized that the stent delivery balloon should match the length of the unexpanded stent as closely as possible to reduce the potential for edge dissections with high-pressure stent deployment. Given the unpredictable nature of the target lesion composition, high and even very high deployment pressures may become necessary to deploy the stent optimally, and this factor has influenced manufacturers in the design and compliance of the stent delivery balloon. Requirements regarding the stent itself include low profile and minimal friction caused by the struts of the stents, particularly at each end of the stent. A rounded cross-sectional profile and smooth, polished surface may be beneficial. Coating of stent struts with pyrolitic carbon or other similar compounds has been advocated as one possible means of reducing friction. More importantly, any protrusion of individual struts, caused by either bending of the stent or trauma, may lead to an inability to cross; therefore, engineers have gone to considerable lengths to design newer stents to minimize this. Standard medical therapy, including the use of pretreatment with aspirin and clopidrogrel, as well as heparin during the procedure and, if required, a glycoprotein IIb/IIIa receptor antagonists is recommended.
Outcome data for direct stenting: review of evidence base Since the early experience in the mid-1990s, direct stenting has now increased in frequency and currently accounts for more than one-third
579_Stenting_ch.07
16/8/2001 10:33
Page 109
OUTCOME DATA FOR DIRECT STENTING: REVIEW OF EVIDENCE BASE
of stent implantations in many centers. Early, small-scale studies suggested a role for direct stenting as a potential new therapeutic approach in the treatment of coronary artery stenoses.7,8 Briguori et al10 retrospectively analyzed their results on direct stenting in a single high-volume center (non-randomized). Stents implanted by the direct technique without pre-dilatation were the NIR stent (46%), ACS Multilink Duet (36%), AVE GFX and Palmaz-Schatz (1.5%), and CrossFlex stents (6.5%). Direct stenting was successful in 94% of cases. Reasons for switching to the traditional method in the remaining 6% were either the inability to optimally place the stent or dissection. In all these patients, the stent could be successfully withdrawn, without loss or damage, and, after pre-dilatation, the same stent was successfully deployed. A downward occlusive dissection occurred in two patients, necessitating prolonged balloon inflation and additional stenting. There were no in-hospital deaths, myocardial infarctions (MIs) or emergency bypass operations. During the first month of follow-up, no patients had subacute stent thrombosis or major adverse cardiac events. In the direct stenting group, there were significant reductions in the procedure time (by 30%), radiation exposure time (by 25%), contrast dye and cost (by 41%), compared to a similar control group undergoing conventional stenting (Table 7.1). The cost saving in part was because, on average, the number of
balloons used was 1.0 for direct stenting compared to 1.7 for conventional stenting. This study suggested that direct stenting was safe and helpful in reducing procedure times, costs and radiation exposure without increasing the risk of complications to patients. Of all patients who underwent coronary stent implantation, about 32% were considered suitable for direct stenting by two independent senior cardiologists. Oemrawsingh et al undertook a prospective observational study of direct stenting.16 Although this included clinical and angiographic follow-up to 6 months, there was no conventional stenting control group for comparison. The Jostent Flex (JF) stent was used in 50 patients with stable or unstable angina with de novo stenoses 15 mm long in one or two native coronary arteries. The 16-mm JF stents were mounted on balloons with optimal diameters of 3.0 or 3.5 mm. Direct stenting was successful in 90% of stenoses, and angiographic success (30% residual stenosis) was achieved in 96% of these. No stent loss or damage occurred. At 6 months, 78% of patients were free of angina, with no deaths. Although angiographic restenosis (50%) was present in 24% of target lesions, revascularization was performed in only 8%. The mean minimal lumen diameter increased from 1.1 0.4 to 2.6 0.4 mm (p 0.001) after stent placement, and was 1.8 0.6 mm (p 0.001) at 6 months.
Direct stenting Procedure time (min) Radiation exposure time (min) Contrast dye used (ml) Balloons and devices Catheterization and laboratory costs (Euros) Total costs (Euros)
45 21 12 9 183 96 697/50 608/338 1305/363
Pre-dilatation 64 46 16 10 255 110 1128/25 1082/778 2210/803
Table 7.1 Retrospective between patients undergoing direct stenting and conventional stenting.
109
579_Stenting_ch.07
16/8/2001 10:33
Page 110
DIRECT STENTING
These results were comparable to reports with conventional stenting techniques.1,2,17,18 Chan et al19 prospectively studied 158 consecutive cases of attempted direct stenting over a 1-year period. Of the group, 71% of procedures were undertaken for unstable angina, 24% for stable angina and 5% for acute MI. Vein grafts accounted for 6% of target vessels. Preprocedure Thrombolysis in Myocardial Infarction (TIMI) flow grades were 3 in 91.7% and 0 in 1.3%. The majority of lesions were American Heart Association/American College of Cardiology (AHA/ACC) grade B (61%; 27% grade A; 12% grade C). Stents included were the NIR, NIR Primo and the ACS Multilink RX Duet. Stents were successfully deployed in 98% of cases. Pre-dilatation was required in 1.3%. In one case, the deployed stent could not be expanded and the stent was opened by rotablation. Apart from this case, TIMI 3 flow was achieved in all other cases. Post-stentdeployment balloon dilatation was required in 34%. No deaths or referral for urgent bypass surgery occurred. Mean and procedural duration was 33 19 min. Screening time was 7 6 min. These times compared favorably to a matched group undergoing conventional stenting (11 7 and 47 18 min, p 0.005) or coronary angioplasty only (10 6 and 40 12 min, p 0.005). Subacute stent thrombosis occurred in two cases (1.3%) and creatine kinase elevation was noted in five patients. Wilson et al20 retrospectively analyzed the Mayo Clinic Coronary Intervention database over a 4-year period and compared the immediate and late outcomes after direct stenting (777 patients) with conventional balloon dilatation followed by stenting (3176 patients). Similar procedural success rates of around 96% were achieved. Multivariate analysis showed no significant differences for in-hospital rates of death, MI or revascularization. At 6 months, outcomes were similar despite patients at higher risk in the direct stent group (higher frequency of previous coronary artery bypass grafts (CABGs), vein graft interventions and thrombus at the
110
treatment site). MI and mortality rates at 6 months were 2.4 and 1.9% versus 2.2 and 2.8% in the direct versus pre-dilation groups respectively. In the direct stenting group, procedural costs were lower, with less utilization of contrast agents and equipment, and shorter procedure (1.3 versus 1.4 h) and fluoroscopy (25 versus 20 min) times. With direct stenting, the authors also noted fewer residual dissections. However, this was a retrospective analysis without randomization. Taylor et al reported a retrospective, singlecenter Australian experience.21 Of 467 consecutive percutaneous intervention (PCI) cases, direct stenting was used in 20% (based on interventionist preference). Of the lesions tackled by direct stenting, 37% were type A, 59% type B and 4% type C. A successful outcome was achieved in 98 of the 102 patients, with 3 patients requiring pre-dilatation. Distal complications were encountered in 5 patients—3 had a distal dissection, 1 had embolization of debris causing a procedural MI, and 1 had a distal dissection requiring multiple stents. This low incidence of complications correlated well with the 5.9% seen in their conventional PCI cases, although patients in the two groups were unmatched, and outcomes were restricted to predischarge events. In addition, the effectiveness of direct stenting has been reinforced by intravascular ultrasound (IVUS) studies,22 showing that, in selected lesions, IVUS results could be comparable to those expected with conventional stenting.
Clinical and economic comparison of stenting with and without pre-dilatation While the above studies were useful, their application is limited due to case selection bias. To provide more evidence to allow licensing indications to be amended, randomized safety and feasibility studies have been performed prospectively in conjunction with stent-device manufacturers.
579_Stenting_ch.07
16/8/2001 10:33
Page 111
CLINICAL AND ECONOMIC COMPARISON OF STENTING
The key randomized trials comparing direct stenting without pre-dilatation against conventional stenting with pre-dilatation include the SLIDE, NIR, BET and DIRECTO trials. The SLIDE trial (Select Lesion Indication for Direct Stenting) was a prospective, 2 : 1, randomized evaluation of the ACS Multilink RX Duet coronary stent system in the elective treatment of patients with de novo and restenotic native coronary artery lesions using a predilatation versus no pre-dilatation (direct stenting) implantation strategy.23 It aimed to define the procedural success rate and medium-term efficacy of the two strategies. The primary endpoint was procedural success defined as the attainment of a final result of 30% in-stent residual stenosis of the target site, using the assigned treatment in the absence of major adverse cardiac events (MACE), at 30 days. Secondary endpoints included total procedure time, cost, and target site revascularization at 6 months. Patient exclusion criteria were: age 75 years, onset of angina 6 months, vessel flow TIMI grade 3, visible calcium, severe angulation, and lesion length 23 mm. Target vessels were between 3.0 and 4.0 mm in diameter. Patients had recent-onset angina (6 months) and were enrolled in 26 centers in Europe and Canada. Two hundred and forty-one patients were enrolled in the direct stenting group and 120 in the pre-dilatation group (group B). Patient demographics are shown in Table 7.2. Procedural success in the direct stenting group was 93.4% (Table 7.3). In eight patients (3.3%) there was a crossover from direct stenting to pre-
dilatation, due to failure to cross the lesion. In the one patient in whom a stent was not deployable, removal of the delivery system was accomplished without stent loss. There was no significant difference in postprocedural residual stenosis (Table 7.3), although minimal luminal diameters were larger in the direct stenting group. In this prospective, rigorous evaluation, direct stenting compared to pre-dilatation showed a trend towards reduced procedural (30 versus 35 min, p 0.063) and fluoroscopy (5 versus 6 min, p 0.056) times, with significantly fewer cases requiring multiple balloons (1.2% versus 15.8%, p 0.01). The SLIDE trial thus showed that, in a defined population, direct stenting was safe, with a high procedural success and a low 6-month adverse event rate. Laarman et al24 evaluated the AVE GFX II stent in a prospective study of 250 patients, with 266 procedures. Direct stenting was successful in 85% of procedures with success after predilation in 39 of the remaining 40 (15%) of procedures. Complex, long and left circumflex artery lesions incurred higher adverse events. Temporary and permanent stent loss occurred in 4 and 5 procedures respectively. Post-procedural MI occurred in 1.6% as did sub-acute thrombosis. At 6 months death occurred in 2.0%, target lesion related MI in 3.2% and overall repeat revascularisation in 9.7% (PCI 4.0%). The NIR Future trial4 was also a multicenter randomized study, and enrolled patients with stable or unstable angina, or documented silent ischemia and one or two lesions in vessels
N(%)
Direct stenting (n = 241)
Pre-dilatation (n = 120)
Diabetic Previous MI CCS III or IV
32 (13.3%) 97 (40.2%) 134 (55.6%)
18 (15.0%) 51 (42.5%) 65 (54.2%)
Table 7.2 Patient demographics in the SLIDE trial.
111
579_Stenting_ch.07
16/8/2001 10:33
Page 112
DIRECT STENTING
Death Q-wave MI Non-Q-wave MI CABG PTCA target lesion PTCA target vessel (not at the target lesion) Total major adverse cardiac events MLD pre-procedure MLD post-procedure % stenosis pre-procedure % stenosis post-procedure
Direct stenting n 241
Pre-dilatation n 120
p value
0.8% 0.0% 0.8% 0.4% 4.1% 0.4%
0.0% 0.0% 1.7% 2.5% 2.5% 0.0%
1.00 – 0.60 0.11 0.56 1.00
6.6%
6.7%
1.00
0.93 mm 2.94 mm 70.2% 10.4%
0.97 mm 3.04 mm 69.3% 10.2%
0.39 0.04 0.51 0.78
PTCA, percutaneous transluminal coronary angioplasty. MLD, mean luminal diameter.
Table 7.3 Provisional angiographic and 6 month clinical outcomes in the SLIDE trial.23
2.5 mm diameter. Included were native vessel, de novo or restenotic lesions with no more than mild calcification, to be treated by a 9-mm or 16-mm NIR Primo stent. Exclusion criteria included ostial lesions, marked proximal vessel calcification or tortuosity, TIMI grade 0 or 1 flow, acute MI within the previous 48 h, sidebranches 2.0 mm in diameter, in-stent restenosis, and thrombus occupying greater than 50% of the vessel lumen. Of the cohort of 81 patients, 42 were randomized to a direct stenting and 39 patients to a pre-dilatation strategy. Both groups were similar for baseline demographic, clinical and lesion characteristics. Primary endpoint data are shown in Table 7.4. Resource utilisation cost was significantly less in those with direct stenting than in those with pre-dilatation. In this small trial, no significant differences were seen in contrast use or fluoroscopy time, however procedural time was shorter in the direct stenting group.
112
Secondary endpoints are shown in Table 7.5. Major adverse events were uncommon, with no deaths at 1 month. One patient in each group sustained an MI requiring repeat target vessel revascularization in the patient with direct stenting. In three patients (7%), direct stent delivery was not possible, and in all cases the stents were removed without incident and then successfully deployed after pre-dilatation. In all patients, stent deployment was successfully achieved with 50% residual stenosis by qualitative angiography (QCA). Stent expansion with a residual stenosis of 30% diameter loss was achieved in 96% of those assigned to predilatation and in 98% of those assigned to direct stenting. Thus, in this study, direct stenting was associated with a reduced equipment cost, shorter procedural time with no cases of stent dislodgement, or failure of stent expansion, and with similar adverse events to stenting after pre-dilatation.
579_Stenting_ch.07
16/8/2001 10:33
Page 113
CLINICAL AND ECONOMIC COMPARISON OF STENTING
Outcome
Direct stenting Mean (median) SD
Pre-dilatation Mean (median) SD
p value
Equipment cost ($US) Contrast volume (ml) Fluoroscopy time (min) Procedure time (min)
1199 (976)526 192 (190) 62 7.6 (5.4) 7.9 26.2 (24.5) 17.5
1455 (1285) 401 226 (200) 88 7.9 (6.6) 4.3 29.2 (25.5) 10.8
0.001 NS NS 0.03
NS, not significant.
Table 7.4 Primary endpoint data in NIR Future trial.4
Danzi et al25 showed in their prospective randomized study of 122 patients that in single noncalcified lesions in native coronary vessels, procedural costs were significantly lower with direct stenting. Mean total procedure costs in the direct stenting group were $2398, compared with $3176 (p 0.001) in the pre-dilatation group. In the BET study9 Carrie et al randomised patients to the direct stenting or pre-dilation group. Procedural success rate of 98.3% was achieved in the direct stent group after a crossover to predilation group of 13.9%. At 6 months the composite events of death, angina, myocardial infarction, congestive heart failure, repeat PCI or coronary bypass grafting occurred in 5.3 and 11.4% of the direct and pre-dialtion groups respectively. In the Argentinean DIRECTO trial,26 preliminary data from the first 151 patients have been presented. The primary endpoint examined whether direct stenting prevented dissections and reduced the length of stents implanted, compared to a similar baseline group randomized to pre-dilatation. The NIR Primo stent was used. Direct stenting was successful in 89% of cases. Eight patients (11%) crossed over to predilatation without complications. As shown in Table 7.5, dissections requiring stents longer than pre-selected occurred more frequently in the pre-dilatation group. Direct stent-
ing, as previously shown, was also associated with fewer balloons, lower rate of CPK elevation and a trend towards shorter procedure times. Direct stenting appears to be a safe and feasible procedure for a large proportion of selected patients, resulting in shorter radiation times to both patient and operator, with a favorable economic outcome.
Direct stenting in acute coronary syndromes Primary angioplasty in acute coronary syndromes is an established intervention.27 Procedural success rates, in achieving TIMI grade 3 flow, have improved through greater stent implantation.28,29 So far there have only been limited studies specifically addressing direct stenting in acute coronary syndromes. Hamon et al30 prospectively studied 122 carefully selected patients with either unstable angina or acute MI. Direct stenting was successful in 96% of cases, with less than 30% residual stenosis both angiographically and by IVUS. In five cases (4%), they were unable to advance the stent across the stenosis. The stent was successfully retrieved in three of these cases, but in two patients there was peripheral embolization of the stent. The rate of tran-
113
579_Stenting_ch.07
16/8/2001 10:33
Page 114
DIRECT STENTING
Final stent length (mm) SD Pre-selected stent length (mm) SD Difference in pre-selected and final stent length (%) Dissections (%) Procedure time (min) SD Number of balloons SD Elevated CPK, n (%)
Direct stenting (N 73)
Pre-dilatation (N 78)
p value
15.31 5.5 15.31 5.5
16.31 7.6 15.29 5.8
0.7 NS
0 1 (1.4%) 29.0 15.4 1.31 0.55 4 (5.5%)
1.02 8 (10.3%) 33.7 17.1 2.20 0.6 11 (16.7%)
0.03 0.03 0.08 0.001 0.04
Table 7.5 Provisional outcome data from DIRECTO Trial.26
sient no-reflow was 2.5%, but in all three cases this was rapidly reversed with intracoronary injection of a glycoprotein IIb/IIIa receptor antagonist. There was one death at 48 h postprocedure, due to established cardiogenic shock. At 1-month follow-up, no additional coronary events were reported. Possible explanations for the low no-reflow rate seen here may be avoidance of the effects of balloon-induced extrusion of thrombus, distal embolization of atherosclerotic particles and further disruption of the protective plaque fibrous cap, together with improvements in adjunctive antiplatelet therapies such as a glycoprotein IIb/IIIa receptor antagonist.
Subset analysis There has been no specific study looking at whether the diabetic or elderly subgroups have similar outcomes with direct stenting. In most studies, about 30% of patients have had diabetes but numbers have been insufficient to show an increased rate of adverse outcomes. Few patients with multivessel disease have been studied. A potential advantageous role for direct stent-
114
ing has been described in short lesions in saphenous vein grafts, where, in conjunction with emboli-containment devices, less atheromatous embolic particulate debris after direct stent implantation was collected than with conventional stenting.14,31,32 The studies are small, but show promise.
Potential advantages of direct stenting 1. Reduced ischemic times. 2. Reduced endothelial denudation. 3. Lower rates of balloon-induced dissection and abrupt vessel closure. 4. Reduced rate of restenosis through reduced balloon trauma to arterial wall. 5. Shorter radiation exposure times. 6. Reduced use of contrast agents. 7. Shorter procedure times. 8. Reduced use of balloons. 9. Reduced resource utilization cost. Reduction in ischemic time may be clinically relevant in specific patient subgroups (e.g. left main disease, severe left ventricular dysfunction). Long-term data and studies are awaited to see if
579_Stenting_ch.07
16/8/2001 10:33
Page 115
WHEN TO DIRECT STENT AND WHEN TO PRE-DILATE?
these potential advantages improved clinical outcome.
translate
into
Disadvantages of direct stenting 1. Technically more demanding. 2. Patient selection critical. 3. Increased risk of ischemia if difficult stent deployment. 4. Potential for only partial stent deployment (e.g. due to lesion fibrosis, calcification, or balloon rupture). 5. Risk of stent loss and difficult stent retrieval. 6. Sequelae of peripheral stent embolization. 7. Potential for inaccurate stent placement if poor distal vessel opacification. 8. Greater guiding support required. 9. Potential by increased intimal injury due to initial stent and balloon passage. 10. Does not permit stand-alone balloon angioplasty. It should be noted that, even where there is adequate distal opacification at the start of a procedure, this may change once a bulky stent is advanced across a severe stenosis. This can assume importance where, for example, a sidebranch must be avoided and the ability to correctly place a stent is compromised. The most important factor, as in all angioplasty, is proper lesion, patient, guide cath and device selection. Stent design is therefore critical, and the device chosen should be crimped solidly and reliably on a low-profile delivery system with a high degree of flexibility and trackability to minimize complications. Care should also be given to the choice of guide catheter, as maximal guiding support may be needed. In early studies, Figulla et al7 reported an 80% success rate. Subsequent studies have achieved levels of success ranging from about 76%32 to 95%.25 A potential limitation of direct stenting may be a smaller cross-sectional luminal area com-
pared to traditional stenting, owing to less aggressive pre-dilatation and post-dilatation. IVUS can aid in the use of post-stent deployment dilatation to optimize stent expansion with minimal exit or entry dissections.33
When to direct stent and when to pre-dilate? Already, at many centers, one-third of stent implantations are achieved without balloon predilatation, and uptake is likely to increase.34 In all the above trials the patients randomized have constituted a highly selected group. Several of the studies have excluded certain types of lesions from randomization, including long, occluded or heavily calcified lesions or those in tortuous vessels, and ostial or left main lesions, and thus caution should be applied in extrapolating the current outcome data to patients with these angiographic features. By contrast, the studies have included patients with severe lesions with a mean stenosis of 70% in the NIR Future and SLIDE trials. The severity of the stenosis does not appear to be a reliable indicator for successful crossing and outcome with the stent, whereas the degree of lesion angulations may be more important.8,16
Lesion characteristics suitable for direct stenting 1. 2. 3. 4.
Non-occlusive. Length of stenosis 15 mm. Target vessel reference diameter 2.5 mm. Absence of moderate to severe coronary calcification. 5. No severe proximal tortuosity or angulation (45°). IVUS studies suggest that optimal results occur with a visual balloon/artery ratio of 1.1 to 1.2, in combination with implantation pressures of 12–16 atm, to reduce complications related to
115
579_Stenting_ch.07
16/8/2001 10:33
Page 116
DIRECT STENTING
oversizing stents.22 The target residual stenosis should be 20% or less. Direct stenting also has a useful role in saphenous vein grafts and restenotic lesions, where it is particularly important to reduce downstream microparticle embolization. With appropriate case selection, for the experienced interventionalist success rates of 95% or above are realistic when using second-generation premounted stents.
Lesion characteristics unsuitable for direct stenting 1. 2. 3. 4. 5. 6. 7. 8.
Total vessel occlusion. Severe proximal tortuosity. Calcified lesions. Bifurcation lesions. Suboptimal guide support. Marked vessel angulation. Important side-branch. Long lesions.
In practice there will be some instances where, in order to gauge artery size, the presence of sidebranches or bifurcation stenoses or lesion length, it will be necessary to undertake limited balloon pre-dilatation prior to selecting and accurately deploying a stent.
Is any one type of stent better for direct stenting? Stents used for direct stenting must have a low delivery profile, superior bonding to the balloon material and a precise one-to-one ratio of balloon to stent length. This latter feature is important in the context of the potential need for high-pressure balloon dilatation in case of rigid stenoses. Delivery balloons exceeding the stent lengths may augment the risk for edge dissection. The delivery balloon must also have high-pressure capability, preferably up to 20 bar and more. The specifications of various products should be examined.
116
At present, there is no head-to-head comparison between different types of stents; however, there are differences in stent profiles, metal to artery ratio, strut thickness and stent retention characteristics, that should be borne in mind. Trial set-ups are different, and drawing extensive inferences from reported success rates is inappropriate. The ideal stent for direct stenting should have a low profile, flexibility, trackability, visibility and secure attachment to the delivery catheter, together with the ease of recovery if delivery is unsuccessful. The delivery system should also minimize the amount of vessel dilated outside the stent and provide uniform stent expansion. The majority of reports have utilized tubular stents. The MultiLink Tetra stent (Guidant Corporation) is a 316L stainless steel multilinked corrugated ring pattern device with variable strut thickness. It incorporates features which facilitate stent retention and protect the stent edges while on the delivery system and which can allow the unexpanded stent to be retracted back into the guide catheter, usually once only. Currently, they are available in diameters from 2.5 to 4.0 mm, and in lengths from 8 to 38 mm. The Jostent Flex stent (Jomed AB) is a 316L stainless steel slotted tube device with a spiral link design and a strut thickness of 0.09 mm. The NIR stent (Boston Scientific) is a low-profile, flexible tubular stent. Profiles of these stents range from 1.1 to 1.2 mm. There is less experience with the higher-profile stents such as the Palmaz–Schatz (Cordis) and the Microstent (Medtronic). Coil stents have also been used but to a lesser extent and with less success, partly due to unreliable adherence of coil stents to their delivery balloons.35 At present, self-expanding stents such as the Wallstent (Boston Scientific) and the radius stent (Boston Scientific) have been tried but are not favored in this context, due to their higher profile, which makes delivery and vessel opacification difficult. Additionally, once delivered there are potential problems in entering the unexpanded stent with a dilating balloon.
579_Stenting_ch.07
16/8/2001 10:33
Page 117
POTENTIAL PROBLEMS OF DIRECT STENTING
High- or low-pressure inflations with direct stenting? In all the reported experiences of direct stenting, the deployment pressures used have been in the high range (14–16 atm). Using high-pressure inflation during initial deployment makes for a quicker, easier and, indeed, safer procedure, since the balloon has essentialy the same length as the stent. It reduces the need to return with additional non-compliant shorter balloons to as low as 4–6%, and generally occurs in vessels that demonstrate distal tapering.23,36 At this stage, high pressure inflations of an optimal diameter device suggest a sub-optimal outcome only in small vessel stenting where contradictory preliminary evidence has been seen.
Potential problems of direct stenting As with all interventional cardiology, an ounce of prevention is worth its weight in gold, and the key is to stay out of trouble rather than to get out of trouble. Proper case selection is therefore the key to good direct stenting. Nonetheless, problems will arise. Some of these are described below.
Unsuccessful stent delivery In the early studies,7,8 stent dislodgement on the delivery balloon system and stent loss were key concerns. This has been ameliorated to a large extent with the current generation of stents and stent delivery systems.34 Several systems, e.g. the MultiLink Tetra, now allow an unexpanded stent to be retracted back into the guide catheter (usually only once). MRI has been used to detect peripheral embolized stents. Overall, in the reported studies, the incidence of this problem currently appears to be low.
Suboptimal stent expansion postdeployment The commonest cause for this problem, where a stent fails to optimally expand after successful delivery, is calcified or fibrotic stenoses. Poststent-deployment dilatation should be undertaken where, angiographically or by IVUS, there is a residual stenosis greater than 20–30%. In practice, this problem is uncommon, and the best way to avoid it is proper case selection.
Risk of arterial trauma When passing a stent through an undilated stenosis, there is the risk of greater resistance than that encountered by trying to cross with a pre-dilatation balloon. For this reason, maximal guiding support is required. A trade-off is that more aggressive deep seating and manipulation of the catheter is often required than when balloon pre-dilatation is performed. This carries the risk of causing arterial trauma, and overzealous manipulation should be avoided. Again, in the reported series the incidence of arterial trauma as a problem is low.
Resistance on retracting unexpanded stent Some devices allow an unexpanded stent to be retracted back into the guide catheter where, for example, stent position is suboptimal. If, however, any resistance is felt at any time during lesion access, manufacturers recommend that the entire system be removed as a single unit.
Future directions with direct stenting One limitation of adopting direct stenting is the current lack of large-scale comparisons with predilatation with follow-up beyond 6 months. Further work is required to clarify the effect on vessel wall injury after direct stenting and
117
579_Stenting_ch.07
16/8/2001 10:33
Page 118
DIRECT STENTING
whether in humans potential advantages provide better long-term clinical outcome. Nonetheless, it is likely that, as experience with direct stenting increases, coupled with the advances in stent technology, an increasing proportion of patients will be potential candidates for direct stenting. The outcome of subset analysis to guide practice, particularly in diabetics, saphenous vein grafts, and small vessels, is awaited.
118
Conclusions In selected patients, a strategy of direct stenting is feasible and safe and is economically attractive, compared to the conventional approach of pre-dilatation followed by stenting. The current evidence base suggests a low incidence of associated adverse events and comparable outcome data in the acute 6-month setting to the later. The basic principle of correct lesion, patient and stent selection remains as important as ever.
579_Stenting_ch.07
16/8/2001 10:33
Page 119
REFERENCES
References
1. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489–495. 2. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496–501. 3. Ormiston JA, Ruygrok PN, Webster MW et al. Mechanical properties of five long stents compared. J Invasive Cardiol 1998; 10(suppl B): 35B 4. Ormiston JA, Webster MW, Ruygrok PN et al. A randomized study of direct coronary stent delivery compared with stenting after predilatation: the NIR future trial. On behalf of the NIR Future Trial Investigators. Catheter Cardiovasc Interv 2000; 50:377–381. 5. Cohen DJ, Breall JA, Ho KK et al. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol 1993; 22:1052–1059. 6. Cohen DJ, Breall JA, Ho KK et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation 1994; 89:1859–1874. 7. Figulla HR, Mudra H, Reifart N, Werner GS. Direct coronary stenting without predilatation: a new therapeutic approach with a special balloon catheter design. Cathet Cardiovasc Diagn 1998; 43:245–252. 8. Pentousis D, Guerin Y, Funck F et al. Direct stent implantation without pre-dilatation using the MultiLink stent. Am J Cardiol 1998; 82:1437–1440. 9. Carrie D, Khalife K, Citron B et al. Benefit Evaluation of Direct Coronary Stenting Study
10. 11.
12. 13.
14.
15.
16.
17.
18.
Group. Comparison of direct coronary stenting with and without balloon pre-dilation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group. Am J Cardiol 2001; 87(6):693–698. Briguori C, Sheiban I, De Gregorio J et al. Direct coronary stenting without pre-dilation. J Am Coll Cardiol 1999; 34:1910–1915. Herz I, Assali A, Solodky A et al. Coronary stenting without pre-dilatation (SWOP): applicable technique in everyday practice. Catheter Cardiovasc Interv 2000; 49:384–388. Edelman ER, Rogers C. Hoop dreams. Stents without restenosis. Circulation 1996; 94: 1199–1202. Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation 1996; 94:2909–2914. Herz I, Assali A, Solodky A et al. Coronary stent deployment without pre-dilation in acute myocardial infarction: a feasible, safe, and effective technique. Angiology 1999; 50: 901–908. Caixeta AM, Brito FS Jr, Rati M et al. High versus low-pressure balloon inflation during multilink trade mark stent implantation: acute and long-term angiographic results. Catheter Cardiovasc Interv 2000; 50:398–401. Oemrawsingh PV, Schalij MJ, Srimahachota S et al. Clinical and angiographic outcome of stent implantation without pre-dilatation using the Jostent Flex stent. J Invasive Cardiol 2000; 12:187–193. Kastrati A, Schuhlen H, Hausleiter J et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: sixmonth angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997; 96: 462–467. Antoniucci D, Valenti R, Santoro GM et al.
119
579_Stenting_ch.07
16/8/2001 10:33
Page 120
DIRECT STENTING
19.
20.
21.
22.
23.
24
25.
26. 27.
120
Restenosis after coronary stenting in current clinical practice. Am Heart J 1998; 135:510–518. Chan AW, Carere RG, Solankhi N et al. Coronary stenting without pre-dilatation in a broad spectrum of clinical and angiographic situations. J Invasive Cardiol 2000; 12:75–79. Wilson SH, Berger PB, Mathew V et al. Immediate and late outcomes after direct stent implantation without balloon pre-dilation. J Am Coll Cardiol 2000; 35:937–943. Taylor AJ, Broughton A, Federman J et al. Efficacy and safety of direct stenting in coronary angioplasty. J Invasive Cardiol 2000; 12(11):560–565. de la Torre Hernandez JM, Gomez I, Rodriguez-Entem F et al. Evaluation of direct stent implantation without pre-dilatation by intravascular ultrasound. Am J Cardiol 2000; 85:1028–1030. Chevalier B, Stables R, Riele JT et al. Safety and feasibility of direct stenting strategy with the ACS Multi-Link Duet stent: results from the SLIDE randomized trial. AHA 2000, New Orleans. Abstract 3529. Laarman G, Muthusamy TS, Swart H et al. Direct coronary stent implantation: safety, feasibility and predictors of success of the strategy of direct coronary stent implantation. Cathet Cardiovasc Interv 2001; 52(4):443–448. Danzi GB, Capuano C, Fiocca L et al. Stent implantation without pre-dilation in patients with a single, noncalcified coronary artery lesion. Am J Cardiol 1999; 84:1250–1253. Ballarino M. Multicenter randomised comparison of direct versus conventional stenting: the DIRECTO trial. Circulation 2000; 102:II–550. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J
Med 1993; 328:673–679. 28. Schomig A, Neumann FJ, Walter H et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997; 29:28–34. 29. Monassier JP, Hamon M, Elias J et al. Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction). Cathet Cardiovasc Diagn 1997; 42:243–248. 30. Hamon M, Richardeau Y, Lecluse E et al. Direct coronary stenting without balloon predilation in acute coronary syndromes. Am Heart J 1999; 138:55–59. 31. Webb JG, Carere RG, Virmani R et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34:468–475. 32. Savage MP, Douglas JS Jr, Fischman DL et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337:740–747. 33. Cotton JM, Kearney MT, Wainwright RJ. Shifting the balance: direct stenting a novel approach to improve the cost effectiveness of intra-coronary stenting. Eur Heart J 2000; 21:170. 34. Webb JG. Is the ‘direct’ approach best? J Invasive Cardiol 2000; 12:203–205. 35. Lohavanichbutr K, Webb JG, Carere RG et al. Mechanisms, management, and outcome of failure of delivery of coronary stents. Am J Cardiol 1999; 83:779–781. 36. Di Mario C, Stankovic G. Low or high pressure for stent deployment? not always ‘in medio stat virtus’. Catheter Cardiovasc Interv 2000; 50:402–405.
579_Stenting_ch.08
14/8/2001 14:10
Page 121
8 Treatment of chronic total coronary occlusions Christopher EH Buller, Jaap N Hamburger
Introduction Percutaneous transluminal coronary angioplasty (PTCA) has established itself as an important alternative to coronary artery bypass surgery in the treatment of coronary artery disease. A continuing development of tools and techniques has led to an increase in the number and complexity of cases performed annually.1 In the 1977–81 angioplasty registry compiled by the National Heart Lung and Blood Institute (NHLBI), total occlusions represented 2% of all lesions attempted; in the 1985–86 registry, this had increased to 10%. Following landmark studies, proving the benefit of intracoronary stents over plain balloon angioplasty, the routine use of intracoronary stents has widely increased the indications for PTCA.2–4 However, recanalization and maintenance of bloodflow through a previously chronically occluded coronary artery is still a major challenge. The relatively low procedural success rates5–8 and high recurrence rates9–11 made percutaneous attempts at recanalization of chronic occlusions a less popular indication for percutaneous coronary intervention. It was only after the introduction of improved guidewire technology12–14 and the demonstration of a positive influence of intracoronary stent implantation on long-term vessel patency15–17 that percutaneous treatment of chronic occlusions became an acceptable alternative for surgical treatment. Three randomized trials of primary stent placement versus balloon angioplasty alone, enrolling at least 100 patients, have
been reported (SICCO, GISSOC, and TOSCA-1). Though the trials varied in inclusion criteria, design, anti-thrombotic regimen, and endpoints, their results were substantially concordant in demonstrating reduced restenosis and reduced re-occlusion when a strategy of routine stenting of recanalized non-acute occlusions was followed. The key design features of these protocols and quantitative angiographic results are provided in Tables 8.1 and 8.2. Taken together, these data demonstrate that while routine primary stenting using the Palmaz–Schatz device produces superior 6-month angiographic results, there remains substantial room for improvement. Of particular concern were the absolute restenosis and reocclusion rates in the largest of these trials, TOSCA. Specifically, among the complex and often long lesions enrolled in TOSCA (Table 8.3), restenosis in the stent arm exceeded 50% and re-occlusion occurred in 10%. In conjunction with these angiographic results, the 1-year target vessel revascularization rate in these same stent-assigned patients was 19.8%, a rate comparable to that of the balloon angioplasty arm of stent trials in anatomically simpler cohorts.18 The stent restenosis rate observed in TOSCA 1 was attributable to previously validated and independent factors: large initial lumen gain, extended lesion length, extended total stent length, multiple stents and lesion-related thrombus. While the lesion complexity of CTOs cannot be changed, some potential for improved stent designs and improved stent deployment to
121
579_Stenting_ch.08
14/8/2001 14:10
Page 122
TREATMENT OF CHRONIC TOTAL CORONARY OCCLUSIONS
N First endpoint Study entry point Occlusion length Lesion thrombus Recent MI? Registry? Core laboratory? Stent Anti-thrombosis Angio F/U
SICCO
GISSOC
TOSCA
117 Restenosis After PTCA success 2 stents Excluded >14 days elapsed No No PS153 Warfarin/ASA 95%
110 Restenosis After PTCA success 2 stents Excluded >30 days elapsed No Yes PS153 Warfarin/ASA 88%
410 6-month patency After wire across Any length (1–7 stents) Included >72 h from ST Yes Yes HC PS153 Ticlid/ASA 96%
MI, myocardial infarction.
Table 8.1 Protocol designs.
PTCA
Baseline MLD Initial MLD Final MLD Late loss Loss index Restenosis Reocclusion
Stent
SICCO
GISSOC
TOSCA
SICCO
GISSOC
TOSCA
0.00 2.13 1.11 1.02 0.48 74% 26%
0.00 1.91 0.85 1.06 0.55 68% 34%
0.00 1.96 1.23 0.73 0.37 70% 20%
0.00 2.78 1.92 0.86 0.31 32% 16%
0.00 2.46 1.74 0.72 0.29 32% 8%
0.00 2.45 1.48 0.97 0.40 55% 11%
Table 8.2 Quantitative angiographic results.
reduce restenosis and re-occlusion rates exists. In addition to technological improvements, indications for attempting CTO recanalization may broaden substantially over the next several years to include a large reservoir of asymptomatic patients currently treated medically. It is now recognized that asymptomatic occluded infarct-related coronary arteries identified during convalescence from myocardial infarction are
122
associated with progressive left ventricular dilatation and dysfunction, reduced cardiac electrical stability, and higher long-term rates of cardiac death. The benefit of routinely seeking and opening such occlusions is being tested definitively in the NIH-NHLBI-funded Open Artery Trial (OAT) and its angiographic substudy TOSCA-2. This strategy, if proven effective, will increase greatly the number of
579_Stenting_ch.08
14/8/2001 14:10
Page 123
ARTERIAL ACCESS
TIMI 0 (%) Reference vessel size (mm) LAD target (%) Est lesion length (mm) Work length (mm) Thrombus score 1 (%) Abciximab (%) Multivessel procedure (%) Maximum pressure (atm) Crossover (%) 2 Stents (%) Stents deployed at target
PTCA
Stent
129 (62) 3.54 0.55 78 (38) 20.7 13.7 29.6 (21.9, 40.9) 54 (26) 7 (3) 70 (34) 9.9 3.2 20 (10) 9 (4) 0.1 (0–3)
134 (64) 3.61 0.57 76 (38) 20.5 11.5 31.4 (20.0, 46.5) 53 (26) 5 (3) 70 (35) 15.4 3.2 8 (4) 99 (49) 2.0 (0–7)
LAD, left anterior descending artery.
Table 8.3 Treatment variables—TOSCA 1.
non-acute coronary occlusions treated percutaneously. In this chapter we will discuss a practical approach to the technique of percutaneous recanalization of chronically occluded coronary arteries.
Arterial access A primary condition for a successful attempt at recanalization is an optimal visualization of the local anatomy. Typically, imaging of the proximal part of the occlusion only (i.e. the proximal stump) will not supply sufficient visual information to allow for reliable fluoroscopic guidance of a guidewire. Routinely puncturing both femoral arteries allows for the insertion of a second, smaller French size catheter in the contralateral coronary artery. By simultaneous bilateral injection of contrast medium into both coronary arteries, making use of the intercoronary artery collateral circulation and biplane coronary angiography, optimal information is
obtained about the anatomy of the missing segment.10 A monoplane fluoroscopy system could be used, provided that multiple views from different angles are made to control the alignment of the guidewire with the distal target lumen. Of importance is the use of a guiding catheter with optimal co-axial back-up support. Typically, this could be an Amplatz left-type guiding catheter for occlusions in the left or the right coronary artery. Alternatively, a Voda guiding catheter could be used for occlusions in the left coronary artery. The guiding catheter used should have a large enough lumen to accommodate the simultaneous introduction of two balloon catheters in case of presumed sidebranch involvement, which potentially necessitates treatment of a bifurcation lesion using a ‘kissing balloon’ technique. In addition, the size of the guiding catheter should also allow for the potential use of an intravascular ultrasound (IVUS) catheter, as the use of IVUS technology can be of value in optimizing the final result of the angioplasty procedure.
123
579_Stenting_ch.08
14/8/2001 14:10
Page 124
TREATMENT OF CHRONIC TOTAL CORONARY OCCLUSIONS
Guidewires The intrinsic capacity of a guidewire to cross a chronic coronary occlusion is dictated by its ‘steerability’ (the wire tip response to subtle torque movements), pushability (or wire tip stiffness) and ‘crossability’ (the interaction of the wire material with the occluding tissue). In the current decade, we have seen the clinical introduction of various dedicated guidewires and guidewire systems. Within the multitude of available chronic total occlusion wires, the following three major subgroups can be defined: 1. Active guidewires or guidewire systems. Examples are the laser guidewire (Spectranetics, CO, USA)19 and the activated guidewire,20 which were especially designed to cross lesions refractory to conventional guidewires. The results of several registries have suggested an advantage of the laser guidewire and the activated guidewire over conventional guidewires.21,22 However, this advantage was not sustained in a recently performed randomized trial.23 The most recent technical development in this category is the Safe-Steer TO Crossing System (IntraLuminal Therapeutics, Carlsbad, CA, USA). This system gives on-line spectroscopic information as acquired from the tip of the guidewire. As the spectroscopic signals from plaque and normal adventitia are distinctively different, this spectroscopic signal can be used for guidance of the guidewire through an occluded segment. 2. Metal tip ‘stiff’ guidewires. A typical representative in this group is the Miracle guidewire (Asahi Intec, Japan),13 with a short distal coil to resist wire tip entrapment in longer lesions, and supplied with a tip stiffness ranging from 3 g to 12 g. 3. Hydrophilic coated guidewires. Examples are the Choice PT or Choice Graphit guidewires (ranging from ‘Floppy’ to ‘Super Support’, Scimed, Mineapolis, MN, USA), the Shinobi wire (Cordis, Miami, FL, USA) and the Terumo Crosswire (in the USA:
124
Radiofocus, or Glidewire, with a 10-g tip stiffness) or the ‘Stiff wire’, with a tip stiffness of 40 g or 80 g (Terumo, Tokyo, Japan).14
Guidewire manipulation in chronic occlusions Conventional guidewires tend to follow a path of least resistance. Unfortunately, the subendothelium is usually softer than the intraluminal obstructing material. As a result, subintimal tracking of stiff guidewires resulting in coronary dissection is not uncommon. In a post-mortem study, Katsuragawa et al histologically identified approximately 100–200 µm diameter microchannels in occluded coronary segments.24 These microchannels would typically not be visible on coronary angiography, but would be large enough to carry a small-diameter, lowresistance guidewire. Assuming the potential presence of these microchannels, the tip of a balloon catheter could damage the entry point of the occlusion, thereby precluding additional attempts with different guidewires (e.g. stiffer guidewires) when needed. Thus, the importance of optimal guiding catheter support is determined by the intention to avoid using a balloon catheter for additional back-up support. An additional, typical histologic feature is the presence of a distal, fibrotic cap. The distal cap is presumably the initial lesion, which gave rise to the total occlusion. Therefore, a sensible approach would be to cross the occlusion using a steerable, small-diameter (0.014 inch), lowresistance (e.g. hydrophilic coated) guidewire. In addition, the wire tip should be stiff enough to create an entry point in the stump of the occlusion and to allow the penetration of the distal fibrotic cap into the distal parent lumen. In the presence of pre-existing microchannels, crossing of a chronic occlusion should not require any force. The appropriate technique is, rather, a careful ‘trial and error’ approach of steering and redirecting the guidewire until a
579_Stenting_ch.08
14/8/2001 14:10
Page 125
THE ADJUNCTIVE ANGIOPLASTY
channel connecting the stump with the distal parent lumen has been found. In this ‘microchannel scenario’, buckling of the guidewire means that the guidewire tip is in the wrong channel, or the tip is forced in a direction at an angle to the channel lumen. Applying additional force, or using a balloon for additional support to prevent the wire from buckling, would then only increase the risk of subintimal tracking and dissection. If, despite several such attempts, there is no wire progression, a guidewire with increased tip stiffness should be chosen. When the handling of the guidewire is based on steering, rather than pushing, the tip through the occlusion, while the alignment of the wire with the target lumen is continuously monitored, the risk of subintimal tracking and dissection is significantly reduced. If the tip stiffness of the guidewire is not sufficient to pierce the distal fibrotic cap, the wire tip will be deflected and, again, forced into a subintimal layer. Continued wire maneuvering could then cause the wire to perforate the adventitia, resulting in a wire exit. Although wire exits are usually benign, they have been associated with the occurrence of (late) tamponade, especially in the presence of co-medication with potent platelet aggregationblocking agents (IIb/IIIa receptor blockade, unpublished data). For this reason, the final maneuver of redirecting the guidewire tip through the distal fibrotic cap into the distal parent lumen is commonly the most critical part of the recanalization procedure. Without adequate visualization of the distal lumen, the operator will not be able to actively prevent the wire from choosing a subintimal pathway. The often very resistant nature of the distal part of an occlusion sometimes requires an exchange of the guidewire for a wire with increased tip stiffness. However, it should be stressed that as long as the guidewire has not yet crossed into the distal lumen, an exchange of guidewire should never be facilitated by using a balloon or probing catheter. The reasons for this dogma are obvious: if the wire has not yet crossed the occlusion because of a subintimal position, an
exchange catheter will sufficiently dissect the occluded segment as to preclude any additional guidewire attempts at recanalization. Second, and more urgent, in case of an undetected guidewire perforation, the introduction of an exchange catheter could alter a benign wire exit to a potentially life-threatening perforation of the coronary arterial wall, requiring pericardiocentesis. Therefore, prior to advancing any device, either an antegrade or retrograde injection of contrast medium should angiographically confirm the distal, intraluminal position of the guidewire.
The adjunctive angioplasty Once the guidewire has crossed the occlusion, the operator could choose to remove, rather than push aside, the material that obstructs the original lumen. The use of various ablative techniques, such as rotational or excimer laser atherectomy, has been suggested in this setting. However, a long-term clinical advantage over balloon angioplasty, as assessed in a prospective, randomized trial, has yet to be demonstrated.25,26 In contrast, a number of recent studies have shown a significant improvement in long-term clinical outcome following coronary stent implantation,16,17,27–30 the improvement typically being related to a reduction in 6-month restenosis and/or re-occlusion rates. The often complex nature of the disease frequently dictates the need for the use of long balloons and long or multiple stents. Whether the best long-term results are achieved when stent implantation is restricted to short, suboptimally dilated segments (‘spot stenting’31) or conversely with a full stent coverage of the entire lesion length (‘full metal jacket’) is still a matter of debate. Successful recanalization of chronic total occlusions is still plagued by recurrence rates in excess of those following dilatation of coronary stenosis. As restenosis is a function of the minimal lumen diameter, it is advisable to use a form of guidance to optimize the final result. As stent implantation has taken such a predominant
125
579_Stenting_ch.08
14/8/2001 14:10
Page 126
TREATMENT OF CHRONIC TOTAL CORONARY OCCLUSIONS
position in the recanalization procedure, IVUS is probably the most useful guidance tool for optimizing stent apposition and maximizing the stent minimal lumen area relative to the media-tomedia diameter at the site of stent implantation. Finally, it has been suggested that the recurrence rate following successful recanalization of chronic occlusions is predominantly determined by the occurrence of early reocclusion.32 Therefore, the additional value of a routine use of peri-procedural adjunctive medication, including potent platelet aggregation blocking agents (e.g. abciximab), followed by clopidogrel during the early follow-up period, needs to be assessed in a prospective study.
Conclusion
Figure 8.1 Chronic total occlusion of the left anterior descending artery. Simultaneous bilateral injection in the left anterior descending and the right coronary artery, showing both the proximal stump and the distal lumen (right inferior oblique view).
Figure 8.2 Chronic total occlusion of the left anterior descending artery. Simultaneous bilateral injection in the left anterior descending and the right coronary artery, showing both the proximal stump and the distal lumen (left inferior oblique view).
126
Percutaneous treatment of chronic total coronary occlusions has become a feasible and safe procedure. With the use of novel, dedicated guidewires, an operator technique of steering, rather than pushing, the guidewire through the occlusion, and a consequent monitoring of the proper alignment of the guidewire with the distal target lumen, the procedural success rates have increased to well over 80%. In an era of increasingly frequent interventions for non-acute coronary occlusions accompanied by increasing primary success rates, establishing a definitive and lasting initial result is of key importance. It is likely that IVUS-guided stent implantation and
579_Stenting_ch.08
14/8/2001 14:11
Page 127
CONCLUSION
Figure 8.3 Final result after multiple stent implantation and brachytherapy with -radiation.
Figure 8.4 Medium long-term result during 6 month angiographic follow-up.
periprocedural intravenous and long-term oral medication with platelet aggregation blocking agents will positively influence the long-term outcome. Whether the additional use of intracoronary brachytherapy with either - or -radiation will significantly reduce the excess
restenosis rates (and subsequent target vessel revascularization rates) typically associated with the long-term outcome of successful percutaneous recanalization of total occlusions needs to be studied in future controlled, clinical trials (Figures 8.1–8.4).
127
579_Stenting_ch.08
14/8/2001 14:11
Page 128
TREATMENT OF CHRONIC TOTAL CORONARY OCCLUSIONS
References
1. Windecker S, Meyer BJ, Bonzel T et al. Interventional Cardiology in Europe 1994. Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J 1998; 19(1):40–54. 2. Serruys PW, de Jaegere P, Kiemeney F et al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331:489–495. 3. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496–501. 4. Ruygrok PN, Serruys PW. Intracoronary stenting, from concept to custom. Circulation 1996; 94:882–890. 5. Holmes DR, Vlietstra RE, Reeder GS et al. Angioplasty in total coronary artery occlusion. J Am Coll Cardiol 1984; 3:845–849. 6. Meyer B, Gruentzig AR. Learning curve for percutaneous transluminal coronary angioplasty: skill, technology or patient selection. Am J Cardiol 1984; 53:65C–66C. 7. Kereiakes DJ, Selmon MR, McAuley BJ et al. Angioplasty in total coronary artery occlusion: experience in 76 consecutive patients. J Am Coll Cardiol 1985; 6:526–533. 8. Stone GW, Rutherford BD, McConahay DR et al. Procedural outcome of angioplasty for total coronary artery occlusion: an analysis of 971 lesions in 905 patients. J Am Coll Cardiol 1990; 15:849–865. 9. Serruys PW, Umans V, Heyndrickx GR et al. Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction; short-term and long-term results. Eur Heart J 1985; 6:2–12. 10. DiScascio G, Vetrovec GW, Cowley MJ, Wolfgang TC. Early and late outcome of percutaneous transluminal coronary angioplasty for sub acute and chronic total coronary occlu-
128
sion. Am Heart J 1986; 111:833–839. 11. Ivanhoe RJ, Weintraub WS, Douglas JS Jr et al. Percutaneous transluminal coronary angioplasty of chronic total occlusions: primary success, restenosis and long-term clinical follow-up. Circulation 1992; 85:106–115. 12. Hamburger JN, Gijsbers GHM, Ozaki Y et al. Recanalization of chronic total coronary occlusions using a laser guidewire: a pilot-study. J Am Coll Cardiol 1997; 30:649–656. 13. Kinoshita I, Katoh O, Nariyama J et al. Coronary angioplasty of chronic total occlusions with bridging collateral vessels: immediate and follow-up outcome from a large single-center experience. J Am Coll Cardiol 1995; 26: 409–415. 14. Lefevre T, Louvard Y, Morice MC et al. Treatment of chronic total coronary occlusion: a randomized study comparing two guidewire strategies. Eur Heart J 1998; 19:2674(A). 15. Sirnes PA, Golf S, Myreng Y et al. Stenting in chronic coronary occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996; 28:1444–1451. 16. Rubartelli P, Niccoli L, Verna E et al. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. J Am Coll Cardiol 1998; 32(1):90–96. 17. Buller CE, Dzavik V, Carere RG et al. Primary stenting versus balloon angioplasty in occluded coronary arteries the Total Occlusion Study of Canada (TOSCA). Circulation 1999; 100: 236–242. 18. Serruys PW, Sousa E, Belardi J et al. BENESTENT-II trial: subgroup analysis of patients assigned either to angiographic or clinical follow-up or clinical follow-up alone. Circulation 1997; 96(suppl I):I-653. 19. Hamburger JN, Serruys PW. Laser guidewire for recanalization of chronic total occlusions. In: Beyar, Keren, Leon, Serruys, eds. Frontiers in Interventional Cardiology. London: Martin Dunitz, 1997; 47–53.
579_Stenting_ch.08
14/8/2001 14:11
Page 129
REFERENCES
20. Rees MR, Michalis LK. Activated-guidewire technique for treating chronic coronary artery occlusion. Lancet 1995; 346:943–944. 21. Hamburger JN, Serruys PW, Gomes R et al. Recanalization of total coronary occlusions using a laser guide wire: the European TOTAL Surveillance Study. Am J Cardiol 1997; 80: 1419–1423. 22. Oesterle SN, Bittl JA, Leon MB et al. Laser wire for crossing chronic total occlusions— ‘learning phase’ results from the US TOTAL Trial. Cathet Cardiovasc Diagn 1998; 44: 235–243. 23. Serruys PW, Hamburger JN, Koolen JJ et al. Total occlusion trial with angioplasty by using laser guidewire. The TOTAL trial. Eur Heart J 2000; 21:1797–1805. 24. Katsuragawa M, Fujiwara H, Miyamamae M, Sasayama S. Histologic studies in percutaneous transluminal coronary angioplasty for chronic total occlusion: comparison of tapering and abrupt types of occlusion and short and long occluded segments. J Am Coll Cardiol 1993; 21:604–611. 25. Appelman YEA, Koolen JJ, Piek JJ et al. Excimer laser coronary angioplasty versus balloon angioplasty in functional and total coronary occlusions. Am J Cardiol 1996; 78(7):757–762. 26. Reifart N, Vandormael M, Krajcar M et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer laser, rotational atherectomy and balloon angioplasty comparison (ERBAC)
Study. Circulation 1997; 96(1):91–98. 27. Goldberg SL, Colombo A, Maiello L et al. Intracoronary stent insertion after balloon angioplasty of chronic total occlusions. J Am Coll Cardiol 1995; 26:713–719. 28. Ozaki Y, Violaris A, Hamburger JN et al. Short- and long-term clinical and quantitative angiographic results with the new, less shortening Wallstent for vessel reconstruction in chronic total occlusion: a quantitative angiographic study. J Am Coll Cardiol 1996; 28: 354–360. 29. Anzuini A, Rosanio S, Legrand V et al. Wiktor stent for treatment of total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience. J Am Coll Cardiol 1998; 31: 281–288. 30. Hancock J, Thomas MR, Holmberg S et al. Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries. Heart 79(1):18–23. 31. DeGregorio J, Kobayashi Y, Reimers B et al. Intravascular ultrasound guided PTCA with spot stenting. J Am Coll Cardiol 1998; 31(387A):896. 32. Violaris AG, Melkert R, Serruys PW. Longterm luminal renarrowing after successful elective coronary angioplasty of total occlusions: a quantitative angiographic analysis. Circulation 1995; 91:2140–2150.
129
579_Stenting_ch.08
14/8/2001 14:11
Page 130
579_Stenting_ch.09
14/8/2001 14:12
Page 131
9 In-stent restenosis Raluca Arimie, David P Faxon
Introduction The acceptance and widespread clinical application of coronary stents is the most important advance in interventional cardiology since the introduction of balloon angioplasty 20 years ago.1 It is estimated that up to 70% of percutaneous coronary interventions involve stents. The reasons for the increasing clinical use of coronary stents include: a more favorable and predictable acute angiographic result, even in unfavorable anatomy;2 high success in treating acute and threatened closure; improved longterm clinical outcomes through a reduction in restenosis; and ease of use and shortened procedure time. Currently, there is solid evidence from observational studies and randomized trials to support the use of coronary stents for the treatment of abrupt or threatened vessel closure during angioplasty, for primary reduction of restenosis in de novo focal lesions in vessels more than 3.0 mm in diameter, for focal lesions in saphenous vein grafts, for totally occluded vessels, and for the treatment of acute myocardial infarction (MI).3 The use of stents is not without complications. However, with improvements in stent design, deployment techniques, and pharmacological management, especially antiplatelet treatment, the rate of complications has fallen dramatically.2 Despite these improvements, the widespread use of stents in interventional cardiology has brought with it a new and serious
disease, in-stent restenosis. Restenosis can be defined using angiographic, clinical and histological criteria. The most frequently used angiographic definition of restenosis is a 50% or greater diameter narrowing 6–9 months after the procedure in the treated vessel segment. Clinical restenosis refers to the occurrence of clinical events related to restenosis in the vessel or lesion, leading to repeat revascularization of the vessel that was initially treated, called target vessel revascularization (TVR) or target lesion revascularization (TLR). By histological analysis, the main component of late lumen loss after stent implantation is intimal hyperplasia, unlike in non-stented vessels, where remodeling dominates. The average rate of instent restenosis is 20–30%, but varies greatly depending on clinical and angiographic factors.2
Restenosis versus pseudorestenosis Insights from intravascular ultrasound (IVUS) examinations suggest that stenosis recurrence is often due to inadequate initial balloon dilatation of the lesion (pseudorestenosis). Colombo et al were the first to show by IVUS studies that most of the angiographically satisfactory stent implantations were far from optimal, due to incomplete or asymmetrical stent expansion and the presence of significant disease of the proximal and distal reference segments.4,5 The optimal treatment for this type of in-stent restenosis is ade-
131
579_Stenting_ch.09
14/8/2001 14:12
Page 132
IN-STENT RESTENOSIS
A
B
D
C
E
Figure 9.1 An example of in-stent restenosis. A total occlusion of the proximal right coronary artery (A) was successfully dilated with three 20 mm stents (B). Three months later, diffuse in-stent restenosis developed (C), which was successfully treated by laser and balloon angioplasty (not shown). Three months later, restenosis occurred (D). By IVUS, the lesion was focal and located between the two stents. This focal stenosis was stented successfully (E) and no subsequent restenosis occurred.
quate dilatation with a properly sized balloon that is inflated to high enough pressure to ensure complete expansion (e.g. 12–16 atm). Since this problem is difficult to recognize by angiography, when it is suspected, documentation by IVUS before and after is critical to ensure adequate stent deployment (Figure 9.1).
132
Clinical predictors of in-stent restenosis A number of clinical, procedural and angiographic factors have been reported to be related to a subsequent risk of both in-stent restenosis and restenosis (Table 9.1). Kuntz et al defined the clinical predictors of restenosis after coronary stenting based on an extensive analysis of 5919 patients (6123 treated vessels) enrolled in
579_Stenting_ch.09
14/8/2001 14:12
Page 133
CLINICAL PREDICTORS OF IN-STENT RESTENOSIS
five prospective randomized multicenter stent trials. Clinical restenosis was defined as death, recurrent MI, or TVR. The overall rate of clinical restenosis was 14.0%. Angiographic restenosis (50% diameter stenosis) occurred in 25.4% of the angiographic follow-up group (1344 patients with 6–9 months of follow-up). A smaller final minimal lumen diameter (MLD) and the presence of diabetes were the strongest independent predictors of clinical restenosis after successful stenting. Other predictors included smoking (a negative predictor), multivessel disease, and stent length.6 Other studies have reported the clinical predictors of restenosis to be diabetes mellitus, prior history of restenosis, gender, hyperlipidemia, hypertension, unstable angina, vasospastic angina, renal disease, and smoking.7 A history of diabetes mellitus, as well as insulin resistance states and hyperinsulinemia, have been shown to correlate with the subsequent risk of developing in-stent restenosis in native, coronary and saphenous vein graft lesions.1,6–8 However, two studies have failed to show diabetes as a predictor of instent restenosis.1 Despite the increased risk of instent restenosis, the use of stents in diabetic patients has the same improved outcome that has been documented in non-diabetic patients.6 The GUSTO IIb Trial showed that although diabetics have higher clinical event rates following balloon angioplasty for acute MI than nondiabetics, stenting serves as an ‘equalizer’ with respect to outcome in diabetics following percutaneous revascularization.6 A possible mechanism that explains the higher risk of in-stent restenosis in diabetic patients compared with non-diabetic patients is the increased propensity for intimal hyperplasia after stent implantation.6,8 The increased intimal hyperplasia may be caused by the increased levels of insulin-like growth factor 1 and insulin, which promote smooth muscle proliferation and matrix protein secretion, as well as resulting in endothelial cell dysfunction and impaired endothelial regeneration following injury.1 Besides optimal stent deployment, only abciximab has reduced in-stent
restenosis in diabetic patients. The Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC), Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa (EPILOG), and Evaluation on Platelet Inhibition in Stenting (EPISTENT) studies showed that abciximab reduced TVR and mortality in diabetic patients, irrespective of angioplasty or stenting.9 Also, improved periprocedural glycemic control may reduce the restenosis rate in these patients.10 Previous studies demonstrated that women undergoing percutaneous transluminal coronary angioplasty (PTCA) have a worse outcome compared with men. However, the new studies have questioned the role of gender as a predictor of outcome in the current stenting era. King et al showed that women continue to have worse inhospital and 6-month outcomes after coronary stenting.6 On the other hand, Bartorelli et al showed that women treated with coronary stenting had clinical and angiographic results similar to those observed in men.6 In these studies, the female patients were older and had higher incidences of comorbidities (hypertension, diabetes, unstable angina) than the male patients. Patients with chronic renal disease are also at risk for in-stent restenosis, even in the absence of diabetes mellitus and independent of lipid profile. The United States Renal Data System database identified 5085 dialysis patients who were hospitalized for coronary artery bypass graft (CABG) (1994–96), 4516 for PTCA (1994–96), and 828 for PTCA/stent (1995–96). The study concluded that dialysis patients in the USA have improved 1-year survival after coronary stenting compared to PTCA and CABG.11 A history of prior restenosis of the same lesion undergoing stent implantation or at another site increases the likelihood of in-stent restenosis, although the findings have not been consistent. Kastrati et al showed that in patients with multiple lesion interventions, the risk of a lesion developing restenosis is 2.5 times higher if a companion lesion has restenosed.12 The randomized REST trial reported a restenosis rate of 18%
133
579_Stenting_ch.09
14/8/2001 14:12
Page 134
IN-STENT RESTENOSIS
in lesions with previous restenosis postangioplasty. The more recurrences there are at the same site of stent implantation, the higher the risk of subsequent restenosis, particularly if the time interval is short between placement of the stent and restenosis (e.g. 3 months).13
Angiographic factors predicting restenosis Angiographic factors that predict in-stent restenosis include the size of reference vessel, severity of the stenosis, presence of calcium, eccentric lesion, saphenous vein graft location, ostial or proximal lesion location, left anterior descending lesion location, chronic total occlusion, long lesion, bifurcation lesion, and vessels receiving collaterals13 (Table 9.1). A diffuse pattern of stent restenosis that extends through
the entire stent has been identified as the independent predictor of in-stent restenosis.14 In a large German study of more than 2500 patients, the risk of in-stent restenosis was highest in patients with diabetes and complex lesions.15 Many reports have also found that long, complex lesions treated with multiple stents develop restenosis more frequently. An Italian study showed that the in-stent restenosis rate was lower in short lesions treated with a short stent and the rate did not increase in longer lesions covered with a short stent, implying that the length of the stent and not the lesion is the critical factor in restenosis.16 In the study by Hoffmann et al, the three most consistent predictors of in-stent restenosis were ostial lesion, plaque burden by IVUS, and final lumen diameter as determined by IVUS.17
Procedural factors predicting restenosis Clinical Diabetes (ID NID) Smoking Prior history of restenosis Renal dialysis Angiographic Final MLD Plaque burden Reference vessel size Location in SVG, ostium or LAD Total occlusion Bifurcation lesion Long lesion Post-procedural FFR or Doppler FR Procedural High-pressure balloon inflation Multiple stents or stent length Abciximab in diabetics ID, insulin dependent; NID, non-insulin dependent; LAD, left anterior descending artery; SVG, saphenous vein graft.
Table 9.1 Predictors of in-stent restenosis.
134
Procedural factors recognized to contribute to restenosis include balloon-to-artery ratio, presence of significant residual gradient, significant residual stenosis or final MLD, and the extent of dissection7 (Table 9.1). The extent of residual stenosis or the final MLD has been shown to be the most potent predictor of restenosis in both non-stented and stented vessels. A number of recent studies have shown that high-pressure stent deployment is advantageous. The STRESS III Trial demonstrated a 37% reduction in major adverse cardiac events at 1 year (death, MI, CABG, TLR) by using highpressure stent deployment and antiplatelet therapy. When AVE-MICRO stents were implanted with a pressure of more than 10 atm, a significant reduced restenosis rate occurred when compared with low-pressure implantation of less than 10 atm (17% versus 35% at 3–6 months of follow-up). In the Optimal Stent Implantation (OSTI-2) Study, Stone et al showed that maximal stent expansion using focal balloons, traditionally considered oversized and
579_Stenting_ch.09
14/8/2001 14:12
Page 135
PROCEDURAL FACTORS PREDICTING RESTENOSIS
guided by IVUS to be within 0.2 mm of the external elastic membrane, was safe and resulted in a low rate of clinical restenosis.18 Not all studies have consistently shown similar results. Several European studies showed unsatisfactory results with high-pressure stent deployment for calcified lesions and small vessels (3 mm). An animal study using oversized, self-expandable coronary stents suggested that oversized balloons and highpressure stent deployment can result in more perivasculitis, reduction in distal microcirculation, and more early neointimal hyperplasia.1 Consistent with this hypothesis are the findings in saphenous vein grafts that high-pressure stent deployment (16 atm) is associated with a smaller MLD at 6 months, probably due to increased neointimal proliferation within the stent.1
Pre prior 3-mm stent
Coronary stent design may also affect the rate of restenosis. For instance, one IVUS study found significantly less intra-stent neointimal thickening with the Multilink Stent compared with GFX stents.19 Others have described a possible allergic reaction to nickel and molybdenum, components of stainless steel stents that may trigger in-stent restenosis in some patients.20 Multiple stent implantations have been shown to be a significant risk factor for in-stent restenosis, with longer stented lesions having a higher rate of restenosis. Long stents are just as likely to develop restenosis as multiple stents. Management is difficult, since restenosis is often diffuse (Figure 9.2). Reported angiographic rates of restenosis from observational trials range from 19% to
Post RA 1.75/2.15 mm
Post 3.75-mm PTCA
Figure 9.2 An example of restenosis within a stent due to inadequate initial stent placement, as shown in the middle panel. Redilatation (right panel) shows a large final lumen diameter. Courtesy of Ted Feldman MD, The University of Chicago, Section of Cardiology.
135
579_Stenting_ch.09
14/8/2001 14:12
Page 136
IN-STENT RESTENOSIS
76%.1 This wide variability is probably due to the above-mentioned predictive factors. The risk factors are additive, so the restenosis rate can rise from 15% to 45% when four or more risk factors are present. Of all factors analyzed, the most potent is the post-procedural lumen diameter, leading to the current widely embraced strategy of ‘bigger is better’ in percutaneous procedures.7 However, in large studies with complete angiographic follow-up, the predictive power of the above-mentioned factors was remarkably poor.7 Even final MLD only correctly predicted the occurrence of restenosis in 30% of patients.12 Angiography is a poor method to evaluate final MLD, perhaps because there is a poor correlation between angiographic and IVUS vessel diameters. In contrast, the amount of arterial plaque determined by IVUS correlates with the occurrence of restenosis. Also, IVUS studies have shown that adaptive arterial remodeling before intervention results in increased in-stent neointimal hyperplasia and incidence of restenosis after stent implantation.21
New predictors of restenosis A number of studies have shown that flow reserve following stenting is predictive of restenosis and, when combined with MLD, can identify patients with a high risk for restenosis.22 Stancovic et al23 have demonstrated that a ratio of the corrected Thrombolysis In Myocardial Infarction (TIMI) frame count to MLD was a predictor of restenosis after balloon angioplasty. The authors demonstrated that this index independently predicted angiographic and clinical restenosis in native non-stented vessels and was better than flow reserve or angiography alone. Presumably, the ratio reflects the relationship between flow and resistance, being an indirect measurement of the overall pressure gradient. This study suggests that both the stenosis and distal resistance to flow are important in predicting restenosis; however, this has not yet been tested in patients receiving stents. Serological evidence for Chlamydia pneumo-
136
niae and other infectious pathogens frequently precedes coronary atherosclerotic lesions, suggesting a potential role of chronic infection in the development of coronary heart disease.24 A group from Japan showed that a prior infection with C. pneumoniae was associated with accelerated neointimal hyperplasia of stented lesions. They suggest that the C. pneumoniae antibody may be a possible new predictor for in-stent restenosis. Several recent studies have also suggested that genetic and serum markers can identify patients at high risk for restenosis. These include ACE phenotypes, polymorphisms of glycoprotein IIIa, endothelial nitric oxide synthetase, and PAI-1 genes.
Treatment The most effective treatment of in-stent restenosis is to prevent it by initial optimal stent deployment. Optimal deployment of the stent, sized to the external elastic membrane by IVUS, will result in the largest final lumen diameter with the least residual stenosis and ensure the lowest restenosis rate. However, restenosis can develop despite these efforts, and new treatment strategies are needed. Treatment of in-stent restenosis with atherectomy, laser or restenting has been disappointing. While a number of studies initially suggested that debulking the lesion with laser, rotablater or directional atherectomy may reduce restenosis, more recent studies have not shown benefit in comparison to balloon angioplasty.25 A recent randomized trial of rotablater prior to balloon angioplasty, the ARTIST Study, failed to show benefit.26 Laser has been shown to be safe and effective in the treatment of in-stent restenosis, but does not improve the restenosis rate compared with rotablator or other techniques.27 Stenting inside of a previously placed stent can result in a large lumen, but such a ‘stent sandwich’ has not been clearly shown to result in a decreased rate of restenosis.28 It seems best to reserve its use to those situations where an inad-
579_Stenting_ch.09
14/8/2001 14:12
Page 137
RADIOTHERAPY
equate result occurs with other devices. Regardless of the device used, the best way to reduce restenosis is to ensure the largest final lumen diameter. In focal in-stent restenosis, this can be accomplished by balloon angioplasty alone, but when diffuse restenosis occurs or multiple stenoses are present in long or multiple stents, debulking offers advantages by maximizing the final result and thus reducing restenosis (Figure 9.2). The greatest hope in reducing instent restenosis is the development of new stents and new pharmacological agents, including gene therapy and radiation therapy.
Radiotherapy The treatment of in-stent restenosis, especially when diffuse (10 mm in length), is challenging and has a high recurrence rate (30–70%), regardless of the technique used. - and -radiation to prevent restenosis have been studied for almost 40 years in animal models, but only recently in clinical trials. The most recent clinical trials of brachytherapy for in in-stent restenosis are the SCRIPPS, BETA WRIST, PREVENT, GAMMA trials, and the Stent versus bisectional Coronary Atherectomy Randomized Trial (START). The SCRIPPS trial was a double-blind, randomized trial comparing 192Ir with placebo sources. There was a significant reduction of the rate of TVR and angiographic restenosis in the 192 Ir group versus the placebo group at 6 months (44.8% versus 11.5% for TVR, and 54% versus 17% for angiographic restenosis). The early clinical benefits have been shown to be durable at 3-year follow-up (48.3% versus 15.4% for TVR, and 64% versus 33% for angiographic restenosis). No events occurred in the 192Ir group to suggest major untoward effects of vascular radiotherapy.29 The WRIST trial randomized 130 patients with in-stent restenosis to -radiation with 192Ir or placebo. The treatment group had a 16% incidence of angiographic restenosis and a 24% rate of TVR at 6 months, as compared to 67% and 72%, respectively, for the placebo group.30
The BETA WRIST study was designed to examine the efficacy and safety of the -emitter yttrium-90 for the prevention of recurring instent restenosis. Fifty consecutive patients with in-stent restenosis in native coronary arteries underwent balloon angioplasty, laser angioplasty, rotational atherectomy, and/or stent implantation. The -radiation system used a yttrium-90 wire source with a centering balloon, and the dose was 20 Gy to a distance of 1.0 mm from the surface of the inflated balloon. At 6 months, the binary angiographic restenosis rate was 22%, the TLR rate was 26%, and the TVR rate was 34%. All rates were significantly lower than those of the placebo group of GAMMA-WRIST. The recent GAMMA I study also demonstrated an angiographic and clinical reduction in restenosis in patients with in-stent restenosis of 35%.31 Most recently, these results were confirmed in the START trial, where 476 patients were randomized to placebo or 16–20 Gy using a 90Sr/90Y source (J. Popma, personal communication). The results were remarkably similar to those reported for the other trials, with a 34% reduction in TVR and a 36% reduction in restenosis (45.2% versus 28.8%, p 0.001). As a result, two devices for intravascular radiation have been approved by the FDA for the treatment of in-stent restenosis. In contrast, the clinical experience with a -emitting stent has been disappointing. The Milan Dose–Response Study showed the feasibility of 32 P radioactive -emitting stent use in patients with coronary artery disease (CAD), but at 6-month follow-up there was no reduction in restenosis, largely due to restenosis at the stent edges that was independent of the radiation dose. This observation has been called the ‘edge effect’ or the ‘candy wrapper’ effect.32 The mechanism by which radiation induces restenosis at the edges appears to be through stimulation of neointimal proliferation with low-dose radiation or through geographical miss (misplacement of the radioactive source with inadequate exposure of the damaged area). While significantly greater with the radioactive stent, the ‘edge effect’ has
137
579_Stenting_ch.09
14/8/2001 14:12
Page 138
IN-STENT RESTENOSIS
been recognized to occur with all radiation sources. Another recognized problem of radiation is a high rate of late stent thrombosis that can occur up to 6 months and occasionally longer after the procedure, presumably due to inhibition of reendothelization. The placement of a new stent greatly enhances the chances of this occurring. As a result, nearly all studies recommend the prolonged use of antiplatelet agents, such as aspirin and clopidogrel, for at least 6 months and avoidance of restenting.33
New stents and drugs To minimize acute stent thrombosis and development of restenosis, stents coated with biodegradable and non-biodegradable polymers have been proposed as a method to reduce stent thrombosis and for local drug delivery. While many polymers can cause a potent inflammatory reaction, more recent coatings appear to be more biocompatible. A German group demonstrated in animals the beneficial effect of a stent coated with polylactic acid releasing recombinant polyethylene glycol–hirudin and iloprost on the development of restenosis after coronary stent placement at 4 weeks, independent of the extent of vascular injury.34 Most recently, a Japanese group reported the successful development of a poly-L-lactic acid biodegradable stent in 15 patients.35 The 6-month restenosis rate was only
138
10.8%. Heparin-coated stents in animal studies have been shown to prevent late coronary instent restenosis, but clinical trials have been disappointing.36 The positive results of the MVP study, a study of vitamin C and E and probucol, have suggested that anti-inflammatory agents or antioxidants may also reduce restenosis.37 However, in a small pilot study, cilostazol was not shown to prevent in-stent restenosis.38 A large multicenter trial is currently underway.
Conclusion It is likely that the use of stents will continue to grow and that the problem of in-stent restenosis will continue to be a significant problem in the future. While optimal stent deployment and adjunctive pharmacological agents can minimize restenosis, additional therapy is clearly necessary. Because of the regulatory and logistical issues related to radiation therapy, it is likely that intravascular radiation will not be used as a front-line treatment, but rather as a means to treat those who develop in-stent restenosis. The development of new stents with coatings, local drug delivery or more effective pharmacological agents will be necessary. While we are clearly not able to satisfactorily prevent the problem today, the future looks bright for a solution to this major clinical problem.
579_Stenting_ch.09
14/8/2001 14:12
Page 139
REFERENCES
References
1. Kutryk MJB, Serruys PW. Coronary stenting. Current Perspectives 1999; 1:234–292. 2. Topol EJ, ed. Textbook of interventional cardiology, 3rd edn. Philadelphia, PA: Lippincott Raven Publishers, 1998. 3. Holmes DR, Hirshfeld J Jr, Faxon D et al. ACC expert consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol 1998; 32:1471–1482. 4. Goldberg SL, Colombo A, Nakamura S et al. Benefits of intracoronary ultrasound in the deployment of Palmaz–Schatz stent. J Am Coll Cardiol 1994; 24(4):996–1003. 5. Nakamura S, Colombo A, Gaglione S et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994; 89:2026–2034. 6. Cutlip DE, Chauhan M, Rizzitano CM, Duntz RE. Predictors of clinical restenosis after coronary stenting. Circulation 1998; 98(suppl): I-435 (abstract). 7. Faxon DP. Identifying the predictors of restenosis: do we need new glasses? Circulation 1997; 95:2244–2246. 8. Takagi T, Akasaka T, Kaji S et al. Increased intimal hyperplasia after coronary stent implantation in patients with hyperinsulinemia: a serial intravascular ultrasound study. Circulation 1998; 98(suppl):I–229 (abstract). 9. Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922–928. 10. Asakura Y, Suzuki M, Nonogi H et al. Restenosis after percutaneous transluminal coronary angioplasty in patients with noninsulin-dependent diabetes mellitus (NIDDM). J Cardiovasc Risk 1998; 5:331–334. 11. Herzog CA, Ma J, Collins AJ. Long term survival of dialysis patients in the United States after coronary artery bypass surgery, coronary angioplasty, and coronary stenting. Circulation 1999; 100(suppl):I–365 (abstract).
12. Kastrati A, Schömig A, Elezi S et al. Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. Circulation 1998; 97:2396–2401. 13. Klugherz BD, Meneveau NF, Kolansky DM et al. Predictors of clinical outcome following percutaneous intervention for in-stent restenosis. Am J Cardiol 2000; 85:1427–1431. 14. Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872–1878. 15. Elezi S, Kastrati A, Neumann F-J et al. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875–1880. 16. Albiero R, Marsico F, Vaghetti M et al. The role of lesion length and stent length in restenosis after stenting. Circulation 1998; 98(suppl):I–284 (abstract). 17. Hoffman R, Mintz GS, Mehran R et al. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz–Schatz stents. J Am Coll Cardiol 1998; 31:43–49. 18. Stone GW, Bailey S, Roberts DK et al. A prospective, multicenter trial of the safety, feasibility, and efficacy of ultrasound guided ‘maximal’ stenting to the media–adventitial border final late clinical and angiographic results from the OSTI-2 study. J Am Coll Cardiol 2000; 35(suppl A):46A (abstract). 19. Ishikawa S, Asakini Y, Kato T et al. Comparison of serial intravascular ultrasound findings of multilink and GFX stents. J Am Coll Cardiol 2000; 35(suppl A):64A (abstract). 20. Köster R, Vieluf D, Kiehn M et al. Association of in-stent restenosis with hypersensitivity reactions to nickel and molybdenum. J Am Coll Cardiol 2000; 35(suppl A):84A (abstract). 21. Peters RJG, Kok WEM, DiMario C et al. Prediction of restenosis after coronary balloon angioplasty. Results of PICTURE (Post-IntraCoronary Treatment Ultrasound Result Evalu-
139
579_Stenting_ch.09
14/8/2001 14:12
Page 140
IN-STENT RESTENOSIS
22.
23.
24.
25. 26.
27.
28. 29.
30.
140
ation), a prospective multicenter intracoronary ultrasound imaging study. Circulation 1997; 95:2254–2261. Kern MJ, Dupouy P, Drury JH et al. Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: a combined intravascular ultrasound Doppler flow and imaging study. J Am Coll Cardiol 1997; 29:1520–1527. Stankovic G, Manginas A, Voudris V et al. Prediction of restenosis after coronary angioplasty by use of a new index. TIMI frame count/minimal luminal diameter ratio. Circulation 2000; 101:962–968. Davidson M, Kuo C-C, Middaugh JP et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998; 98:628–633. Carrozza JP Jr. In-stent restenosis: should an old device treat a new problem? J Am Coll Cardiol 2000; 35:1577–1579. Von Dahl J, Dietz U, Silber S et al. Angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis. Clinical and angiographic results from a randomized multicenter trial (ARTIST Study). J Am Coll Cardiol 2000; 35:7A (abstract). Mehran R, Dangas G, Mintz GS et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotation atherectomy: comparative mechanisms and results. Circulation 2000; 101:2484–2489. Antoniucci D, Valenti R, Moschi G et al. Stenting for in-stent restenosis. Catheter Cardiovasc Interv 2000; 49:376–381. Teirstein P, Massullo V, Jani S et al. Three year clinical and angiographic follow-up after intracoronary radiation. Results of a randomized clinical trial. Circulation 2000; 101:360–365. Waksman R, Bhargava B, White L et al. Intra-
31.
32.
33.
34.
35.
36.
37.
38.
coronary -radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000; 101:1895–1898. Leon MB, Moses JU, Lansky AJ et al. Intracoronary gamma radiation for the prevention of recurrent in-stent restenosis: final results from the GAMMA-I Trial. Circulation 1999; 100(suppl):I–75 (abstract). Albiero R, Adamian M, Kobayashi N et al. Short and intermediate term results of 32P radioactive -emitting stent implantation in patients with coronary artery disease. The Milan Dose–Response Study. Circulation 2000; 101:18–26. Waksman R, Bhargava B, Mintz GS et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol 2000; 36:65–68. Alt E, Haehnel I, Beilharz C et al. Inhibition of neointima formation after experimental coronary artery stenting. A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost. Circulation 2000; 101:1453–1458. Tamai H, Igaki K, Kyo E et al. Initial and six month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102:399–404. Ahn YK, Jeong MH, Kim JW et al. Preventive effects of the heparin-coated stents on restenosis in the porcine model. Cath Cardiovasc Interv 1999; 48:324–330. Tardif J-C, Côté G, Lespérance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337:365–372. Park S, Lee CW, Kim H et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499–503.
579_Stenting_ch.10
14/8/2001 14:18
Page 141
10 Restenosis, a pragmatic approach David R Holmes
There have been dramatic changes in the field of interventional cardiology over the last decade of practice. These changes are the result of improvements in technology and the application of this technology to an increasingly diverse group of patients and lesions. Despite the dramatic changes in the field, the problem of restenosis remains,1 although in the current era, it is quite different in its pathophysiology and response to treatment.
Pathology of restenosis We have learned an increasing amount about the pathology of restenosis, which has important implications for treatment. There are four major components—acute recoil, chronic constrictive remodeling, neointimal hyperplasia, and matrix formation. The relative importance of each of these varies depending on the initial treatment used, as well as the initial angiographic result, and the patient population treated. The most important determinate of the underlying substrate of restenosis is whether a stent was initially placed. When a stent is not used, restenosis is the result of varying degrees of neointimal hyperplasia and constrictive remodeling, with the latter often predominating and accounting for 60–70% of the process. On the other hand, when a stent is placed, constrictive remodeling is eliminated and restenosis is usually the result of neointimal hyperplasia. Indeed, with stent implantation, the formation of neointimal hyperplasia is enhanced
compared with conventional angioplasty; the well-known reduction of restenosis with stenting is a manifestation of the larger acute gain at the time of initial treatment and prevention of the chronic constrictive remodeling. In addition to the four elements mentioned above, there have been other important mechanisms identified which may form part of the underlying problem.2–4 These include: inflammation, which could result in the chronic constrictive remodeling; allergy to elements of stainless steel; and specific stent design, which may impact on the amount of acute arterial wall damage at the time of implantation. Understanding these underlying mechanisms may result in the development of new approaches for the prevention of restenosis.
Post-angioplasty restenosis As previously documented, chronic constrictive remodeling plays an important and dominant role in restenosis following conventional dilatation. As the frequency of stent implantation continues to increase, the number of patients with post-angioplasty restenosis will decrease. Given that stents are placed in approximately 80–90% of all interventional cases, in patients treated with conventional angioplasty alone there was presumably a reason why a stent was not placed initially. Information on the specific reasons for this is important in terms of selecting subsequent treatment.
141
579_Stenting_ch.10
14/8/2001 14:18
Page 142
RESTENOSIS, A PRAGMATIC APPROACH
In some patients the stent was not placed because it could not be advanced to the target lesion, because of either poor guide catheter support, vessel tortuosity, or vessel calcification. Identification of these issues will help in planning the subsequent procedure. For example, if the stent could not be placed at the time of the initial procedure because of severe calcification, then treatment of restenosis should involve rotational atherectomy so that a stent can subsequently be placed. Alternatively, if the stent could not be placed because of vessel tortuosity, then changing guide catheters, use of an extra support wire or use of a shorter, more flexible stent should be considered. In some patients, the initial decision to avoid stent placement may have resulted from the presence of a small diffusely diseased vessel, a significant side-branch that could not be protected, or ostial location. Subsequent treatment strategies should be aimed at ameliorating or solving these problems. For example, if the vessel at the time of initial dilatation had appeared to be too small for stent implantation, then intravascular ultrasound (IVUS) might be performed to document the true vessel size, thereby facilitating the decision to place a stent for treatment of restenosis. There is information available on typical artery dimensions. Some of this has been obtained from analysis of normal angiograms; some has been obtained from IVUS studies. For example, the proximal and middle left anterior descending (LAD) should be at least 3.0–3.5 mm, and in males is often 3.5 mm. Angiographic estimation of a 2.5-mm dimension in this location is a reflection of diffuse disease and could potentially lead to placement of a stent which is too small. IVUS is very helpful in this regard. It may also be useful to sequentially dilate such a lesion with a slightly larger balloon or use a cutting balloon to gauge the size of the stent to be used. With these considerations in mind, it remains a goal to place a stent for treatment of postangioplasty restenosis. This goal is based upon observational series as well as randomized trials.
142
In the Restenosis Stent Study Group, Erbel et al5 studied 383 patients who had clinical and angiographic restenosis after conventional percutaneous transluminal coronary angioplasty (PTCA). The patients were randomized to standard balloon angioplasty or stent placement. Subsequently, the stented group did significantly better, with less recurrent restenosis (18% versus 32% p 0.03), less target vessel revascularization (10% versus 27% p 0.001), and improved event-free survival at 250 days (84% versus 72% p 0.04). Subacute closure (SAC) rates were increased at 3.9% in the stent group. This was probably related to the fact that the study design used Coumadin, not the currently used dual antiplatelet treatment. Use of this dual antiplatelet approach should eliminate this increased incidence of SAC.
In-stent restenosis The frequency of in-stent restenosis is in large part dependent upon three factors: (1) vessel size, with smaller vessels having higher rates; (2) stent length, with longer stents having higher restenosis rates; and (3) the presence of diabetes mellitus, which increases the likelihood of restenosis. Depending upon these three factors, algorithms have been developed with restenosis rates ranging from 6% to 45% (Table 10.1). An underreported cause of in-stent restenosis is failure to optimally deploy the stent initially (Figure 10.1). With current deployment balloons, which can be dilated to higher pressure, this is less common than it once was. It still, however, remains a problem. In some clinical series of in-stent restenosis, in 20–30% the initial stent placement was suboptimal. IVUS is important in this regard and can be used to guide not only the initial implant procedure but also the treatment of in-stent restenosis. If the initial stent was underdeployed, then a larger balloon or higher pressure should be used. In this setting, care should be taken to avoid damage to the adjacent arterial wall. Several patterns of in-stent restenosis have
579_Stenting_ch.10
14/8/2001 14:18
Page 143
POST-ANGIOPLASTY RESTENOSIS
Lesion length Post-procedure In-stent MLD Diabetics 2.5 mm 3.0 mm 3.5 mm 4.0 mm Non-diabetics 2.5 mm 3.0 mm 3.5 mm 4.0 mm
10 mm
15 mm
20 mm
25 mm
35% 23% 15% 9%
39% 26% 17% 10%
43% 30% 19% 12%
46% 33% 22% 14%
27% 17% 10% 6%
30% 19% 12% 7%
33% 22% 14% 8%
37% 25% 16% 10%
Adapted from Kuntz (not published).
Table 10.1 Predicted angiographic restenosis rates.
Figure 10.1 IVUS of a patient with prior stent implantation who presented with in-stent restenosis. IVUS at the time of presentation with in-stent restenosis documented underdeployed stents.
143
579_Stenting_ch.10
14/8/2001 14:18
Page 144
RESTENOSIS, A PRAGMATIC APPROACH
been identified. These patterns have been found to have prognostic implications. Mehran et al6 identified four patterns (Figure 10.2): (1) focal in-stent restenosis less than 10 mm, which had the best prognosis, with the need for subsequent target lesion revascularization (TLR) in 19.1% of cases; (2) restenosis lesions >10 mm but still confined within the stent, with a subsequent TLR rate of 34.5%; (3) diffuse proliferative instent restenosis extending beyond the stent, with a subsequent TLR rate of 50%; and (4) diffuse proliferative occlusive in-stent restenosis, with a subsequent TLR rate of 80.4%. Factors associated with the development of diffuse and aggressive intra-stent restenosis have been studied in a consecutive series of 456 coronary lesions with in-stent restenosis.7 The descriptive features of Mehran et al6 were used. Aggressive restenosis was defined as either an increase in lesion length or a decrease in minimal lumen diameter (MLD) at the time of in-stent restenosis compared with baseline. Diffuse restenosis was seen in 63%; of these, 18% had a total occlusion. Diffuse restenosis was associated with longer initial lesion length, longer stent length, smaller initial reference artery diameter, female gender, and the use of coil stents. Aggressive restenosis was clinically different, with a
In-stent restinosis I
II
III
IV
3.3 0.0 50.0 36.3 13.7
0.0 0.0 80.4 66.7 16.7
% Death MI TLR PTCA CABG
2.5 1.2 19.1 14.8 4.3
2.6 2.6 34.5 26.3 8.2
Mehran: Circ 100:1072-8, 1999
p 0.001 by ANOVA
Figure 10.2 Relationship between pattern of in-stent restenosis and outcome.
144
shorter time to symptom recurrence and more frequent myocardial infarctions. Several strategies for the treatment of in-stent restenosis have been tested.
Conventional angioplasty This approach is helpful particularly if the initial stent was underdeployed (Figure 10.1) or if the in-stent restenosis is focal either within the body of the stent or at its margins. The use of IVUS to guide this approach is extremely important. From a practical standpoint, for focal lesions it is tempting to use a very short balloon. While that may be effective in some patients, there may be substantial balloon movement during inflation. To avoid this problem, a longer balloon is more optimal. Cutting balloons are used with increasing frequency in this setting to prevent balloon migration. Although using this catheter has not been convincingly shown to decrease subsequent restenosis rates, it greatly decreases catheter motion during balloon inflation. A recent randomized trial of balloon dilatation versus stent implantation for treatment of in-stent restenosis has been reported. In total, 450 patients8 were enrolled, 224 to stent implantation and 226 to balloon angioplasty. The instent restenotic lesion was focal in 33%. Angiographic success rates were identified at 99.6%, and procedural success rates were greater than 96%. In-hospital outcome was excellent, with a mortality of 0.4% in each limb and any major adverse cardiac events (MACE) <4.5%. The primary endpoint was angiographic restenosis. Overall, there was no difference in subsequent restenosis, the rates being 38% in the stent group and 39% in the angioplasty group. Vessel size did play an important role, however; in small vessels 2.6 mm by angiography, the stent group had increased subsequent recurrent restenosis—59% versus 44% (p 0.05). This was reversed in the larger vessels, which had improved outcome in the stent group. In a single-center registry experience, Bossi et al9 evaluated the outcome of 234 patients who
579_Stenting_ch.10
14/8/2001 14:18
Page 145
ABLATIVE TECHNIQUES
had undergone successful balloon angioplasty for treatment of in-stent restenosis. In this series, there was a mixture of lesion types. The majority (38%) were focal, while 29% were diffuse, and 29% were proliferative. Only 4% of lesions were totally occluded. No patients were treated with an ablative technique such as atherectomy. An initial success rate was achieved in 99%. Followup was available for a median of 459 days. As can be seen from Table 10.2, the incidence of subsequent death or myocardial infarction was low. Only 20.6% of patients required target lesion revascularization. As was true in the Mehran et al6 series, there was a relationship between lesion type and subsequent TLR, but the slope of this relationship was considerably less steep. In the Mehran series,6 with focal instent restenosis the subsequent TLR rate was 19.1%, while with total occlusion it was 80.4%. In the Bossi et al9 series, the TLR rates for these lesion types were 12.5% and 20% respectively (p 0.0225). The reason for this difference is unclear. Other important predictors of subsequent TLR were MLD after repeat intervention with a hazard ratio of 0.38 (95% confidence intervals 0.16–0.93, p 0.034), and, most importantly, the time to in-stent restenosis <90 days with a hazard ratio of 4.67 (95% confidence intervals 2.18–10.02, p < 0.0001).
Follow-up (days) Event free (death, MI, TLR) Death MI TLR PTCA CABG
Ablative techniques These techniques make intuitive sense, because the problem of in-stent restenosis is neointimal hyperplasia. Both excimer laser and rotational atherectomy have been tested. Köster et al10 evaluated 6-month clinical and angiographic outcome after successful excimer laser angioplasty for treatment of in-stent restenosis. Ninety-six patients were studied, and 141 stents were treated. At baseline, the average lesion length was 16 9 mm, and the majority had lesions >10 mm. Initial procedural success was excellent, with no Q-wave infarction and no procedural mortality. During follow-up, there was one infarction and one sudden death. The restenosis rate using a definition of 50% diameter stenosis was 65%. These authors evaluated the effects of a variety of clinical and angiographic factors on subsequent recurrent instent restenosis (Table 10.3). As can be seen, only small and insignificant differences were seen. Of importance is the fact that although overall restenosis rates were high, in 24 patients the lesion was only of ‘moderate severity’, from 50% to 69%, and the event-free survival rate without repeat coronary intervention was 50%. Rotational atherectomy has also been studied both in registry experiences and now in randomized clinical trials.
459 176 6 4 53 40 13
286–693 176/234 (75.2%) 6/234 (2.6%) 4/234 (1.7%) 53/257 (20.6%) 40/53 (75.5%) 13/53 (24.5%)
CABG, coronary artery bypass graft; MI, myocardial infarction.
Table 10.2 Follow-up results after angioplasty for in-stent restenosis.
145
579_Stenting_ch.10
14/8/2001 14:18
Page 146
RESTENOSIS, A PRAGMATIC APPROACH
Patients treated Lesion length 10 mm 22 >10 mm 67 Residual stenosis after laser <30% 9
30% 80 Diameter of laser catheter 1.4 mm 2 1.7 mm 46 2.0 mm 41 Type of catheter Concentric 39 Eccentric 50 Catheter/vessel ratio 0.45–0.69 67 0.70–0.95 22 Stent location Vein graft 13 Native vessel 76 Vessel diameter <3.00 mm 63
3.00 mm 26 Final minimal lumen diameter after balloon angioplasty 2.50 mm 38 >2.50–3.00 mm 40 >3.00 mm 11 Stent number/vessel
2 stents 38 Single 51 History of previous or current total occlusion Yes 21 No 68 Diabetes mellitus 26 No diabetes mellitus 63 a
Patients with recurrent stenosis
p value
12 (55%) 46 (69%)
0.34
4 (44%) 54 (68%)
0.17
2 (100%) 27 (59%) 28 (68%)
0.45
26 (67%) 31 (62%)
0.82
43 (64%) 15 (68%)
0.92
8 (62%) 51 (67%)
0.92
39 (62%) 19 (73%)
0.45
29 (76%) 22 (55%) 6 (55%)
0.10a
23 (61%) 34 (67%)
0.83
13 (62%) 42 (63%) 18 (69%) 40 (63%)
0.99 0.79
2.50 mm versus >2.50–3.00 mm; 76% versus 55%, p 0.045.
Table 10.3 Relationship between baseline and treatment characteristics and recurrent restenosis.
A multicenter randomized trial11 has been performed with 298 patients and in-stent restenosis of the native coronary arteries. Patients were randomized to percutaneous transluminal coronary angioplasty or rotational atherectomy fol-
146
lowed by adjunctive low-pressure balloon dilatation. The primary endpoint was MLD, using quantitative coronary angiography at 6 months. The lesion lengths of the in-stent restenotic lesions were identical at 13.6 mm, and complete
579_Stenting_ch.10
14/8/2001 14:18
Page 147
VASCULAR BRACHYTHERAPY
occlusions were uncommon, at approximately 5%. Procedural success was similar, being 89% in the dilatation group and 88% in the rotational atherectomy group. Initial clinical success rates were also similar, being 86% and 84% respectively. Burr-to-artery ratio was 0.8, and 77% of cases were treated with a burr 2 mm. Quantitative coronary angiography at follow-up documented more restenosis with rotational atherectomy (64.8% versus 51.2%), more late loss (0.91 versus 0.67, p 0.0015) and less net gain (0.45 versus 0.67, p 0.0019), despite equivalent acute gain. Target lesion reintervention was required in 31% of PTCA patients and 39% of rotational atherectomy patients. The results of this randomized multicenter trial are in contrast to those of a single-center randomized trial of 200 patients with in-stent restenosis, randomized to either dilatation or rotational atherectomy.12 Preliminary data in this trial document no difference in 30-day major adverse cardiac events, but less target lesion reintervention for rotational atherectomy, although procedural performance in both limbs was different, with more new stents placed in the dilatation limb which could have had impacted the results. At the present time, rotational atherectomy has not been proven to reduce recurrent restenosis in the setting of in-stent restenosis.
Vascular brachytherapy The most effective treatment for in-stent restenosis is vascular brachytherapy, which has been studied in single-center and multicenter randomized clinical trials (Figure 10.3) and is now approved for use. Both gamma and beta systems have been tested; both have advantages and disadvantages. Data from two pivotal trials are available,13,14 one for a gamma system and one for a beta system. The baseline clinical characteristics were similar in each trial between the placebo and the specific brachytherapy device. (Table 10.4). There were however, some important differences between the trials; the lesion length was longer in the GAMMA I13 trial than in START.14 The in-hospital outcomes (Table 10.5) were also similar between the two limbs of each trial, as well as between the two trials. The GAMMA I trial randomized 252 patients to either iridium-192 or placebo. A 14-seed source ribbon was used in 43% of the patients to treat the longer lesions represented in this trial. The mean dose delivered to the vessel wall at 2 mm from the source was 13.5 2.2 Gy. The mean diameter of the treated reference vessel was 2.69 0.51 mm. The primary endpoint of this trial was 9-month MACE, which included
Figure 10.3 Reduction in recurrent restenosis rates in trials of vascular brachytherapy.
80 69
70
Restenosis
60
58
54
50
50
44 P% Rx %
40 30 20
17
19
22
25 14
10 0 SCRIPPS N 55
WRIST N 130
PREVENT N 105
GAMMA 1 N 252
START N 476
147
579_Stenting_ch.10
14/8/2001 14:18
Page 148
RESTENOSIS, A PRAGMATIC APPROACH
GAMMA I
Age (years) Male (%) Diabetes (%) Smoking (%) Prior MI (%) LVEF (%) Unstable angina Lesion length (mm) LAD (%) Prior intervention at target >1 (%)
START
Placebo
Iridium-192
Placebo
90
Sr/90Y
61 11 74.4 31.4 — 47.1 53.8
58 12 74.8 31.3 — 53.4 53.6
61.1 63.4 32.3 8.1 47.8 54.6
61.5 68.4 30.7 12.5 46.7 54.2
20.3 31.4 46.3
19.0 45.0 44.3
16.0
16.3
MI, myocardial infarction; LVEF, left ventricular ejection fraction; START, Stent versus Directional Coronary Atherectomy Randomized Trial.
Table 10.4 Baseline clinical characteristics of patients treated in pivotal vascular brachytherapy trials.
GAMMA I
START
%
Placebo
Iridium-192
Placebo
90
Sr/90Y
Death MI Q-wave Non-Q-wave Acute thrombosis MACEa
0 2.5 0.8 1.7 0 3.3
0.8 2.3 0.8 1.5 0 2.3
0 1.7 0 1.7 — 2.2
0 1.6 0 1.6 — 2.5
a
Death, MI, revascularization of the target lesion. MI, myocardial infarction; START, Stent versus Directional Coronary Atherectomy Randomized Trial.
Table 10.5 In-hospital outcome.
death, myocardial infarction (including late thrombosis), emergency bypass surgery, and the need for revascularization of the target lesion. Prespecified endpoints included angiographic restenosis. The incidence of restenosis was dra-
148
matically improved with vascular brachytherapy, at 32.4% versus 55.3% (p 0.01). This was mirrored by a striking reduction in target vessel revascularization (TVR) and TLR in patients treated with GAMMA vascular brachytherapy.
579_Stenting_ch.10
14/8/2001 14:18
Page 149
VASCULAR BRACHYTHERAPY
Overall, the MACE rate was significantly improved (p 0.02) in the vascular brachytherapy-treated patients (9-month MACE 28.2% versus placebo patients at 43.8%) (Table 10.6). The follow-up of this study did document an imbalance in the frequency of myocardial infarction as well as late thrombosis which was investigated further in both the START trial and in other vascular brachytherapy trials (see below). The START14 trial randomized 476 patients with in-stent restenosis to either 90Sr/90Y or placebo. The baseline demographics were similar in the two groups: ~65% were men, and diabetes was present in 31–32%. The lesions were relatively short: 16.0 mm placebo, 16.3 mm 90Sr/90Y. The in-hospital outcome was excellent (Table 10.5) and not different between the two groups. The primary endpoint of the trial was target vessel failure at 8 months, while secondary endpoints included angiographic restenosis. As can be seen at 8 months, there was a dramatic reduction in TVR, TLR, and overall MACE. Subacute thrombosis was infrequent in either limb (Table 10.6). Angiographic analysis documented a dramatic reduction in restenosis in the stented
segment by 66%. The importance of the edge/margin effect was well documented, with narrowing of the difference in restenosis between placebo and beta radiation; it was, however, still significantly less with beta (28.8%) than with placebo (45.2%) (decreased by 36%, p 0.001). These two trials point out the benefit of vascular brachytherapy for treatment of in-stent restenosis. They also point out (along with other data) the very significant downside of this approach, namely delayed late subacute closure occurring up to several months following the initial treatment. This phenomenon, which occurred in 7–11% of cases, has been of great concern because, when it occurs, it may result in death, myocardial infarction, or severe unstable angina. A substantial amount of data has been accumulated which would indicate that two factors are involved in the problem: (1) placement of a new stent in conjunction with vascular brachytherapy; and (2) not extending the prolonged dual antiplatelet therapy. In the absence of these two factors, the problem appears to be avoided. The exact duration for which antiplatelet therapy is required is as yet
GAMMA 1 % Death MI Q-wave Non-Q-wave SAT Late thrombosis TVR TLR MACE
Placebo
Iridium-192
0.8 4.1 2.5 1.7
3.1 9.9 4.6 5.3
0.8 46.3 42.1 43.8
5.3 31.3 24.4 28.2
START Placebo
90
Sr/90Y
0.4 3.0 0 3.0 0.4
1.2 1.6 0 1.6 0
24.1 22.4 25.9
16.0 13.1 18.0
SAT, subacute thrombosis; START, Stent versus Directional Coronary Atherectomy Randomized Trial.
Table 10.6 Intermediate-term outcome at 8–9 months.
149
579_Stenting_ch.10
14/8/2001 14:18
Page 150
RESTENOSIS, A PRAGMATIC APPROACH
unknown. Typically, if no new stent is placed, ASA (aspirin) and clopidogrel are used for 6 months, while if a new stent is placed, both agents are used for 12 months. Another problem that has been identified with vascular brachytherapy is that of the edge effect, whereby the stented segment treated with vascular brachytherapy is free of recurrent stenosis but a new lesion develops at the edges of the initial lesion. Sometimes termed the ‘candy wrapper effect’, this requires subsequent treatment in some patients and eliminates the effectiveness of the vascular brachytherapy. This effect may be the result of missing the lesion to be initially treated, either because of inadequate catheter source length, movement of the source or imprecise placement of the source, or may be the result of enhancement of neointimal hyperplasias from lower radiation levels delivered to the edge, when combined with arterial damage at the time of treatment. Approaches to prevention require the use of longer source trains, limiting barotrauma to the in-stent lesion itself, avoiding damage to the remainder of the artery adjacent to the initial lesion, and precise positioning of the source itself. Implementation of vascular brachytherapy is complex, involving close collaboration with cardiology, radiation oncology, and radiation physicists. At the present time, it is the only documented approach to improve the outcome of treating in-stent restenosis. There are other approaches being tested for
150
treatment of restenosis. Some of these involve delivery of alternative energy sources to impact on the arterial wall, such as photodynamic therapy, light activation or soft X-rays. Other approaches include systemic therapy; one of the most promising of these is Tranilast, which is the object of the largest restenosis trial performed, involving 11 500 patients.15 Finally, drug-coated stents are also being tested.16
Summary Restenosis remains a significant problem for interventional cardiology. The need for increased subsequent procedures, typically the result of restenosis, is what distinguishes outcomes in comparable patients with multivessel coronary artery disease treated with percutaneous coronary intervention (PCI) and those treated with coronary artery bypass graft. In these patients, death and myocardial rates are not different, but the need for additional procedures is increased in PCI patients. Clearly, the gap is narrowing with the almost universal use of stents, but still remains. Newer approaches for prevention of restenosis, such as systemic pharmacologic therapy and drug-coated stents, will undoubtedly help to narrow the gap even further. It is too much to expect that in diverse patient subsets restenosis rates will be zero. For the, hopefully, smaller groups of patients with restenosis, the new strategies outlined here will improve outcome.
579_Stenting_ch.10
14/8/2001 14:18
Page 151
REFERENCES
References
1. Schwartz RS, ed. Coronary Restenosis. Blackwell Scientific Publications, Boston, 1993. 2. Kornowski R, Hong MK, Tio FO et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224–230. 3. Farb A, Sangiorgi G, Carter AJ et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99(1):44–52. 4. Köster R, Vieluf D, Kiehn M et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356(9245):1895–1897. 5. Erbel R, Haude M, Hopp HW et al. Coronary artery stenting compared with balloon angioplasty for restenosis after critical balloon angioplasty. Restenosis Stent Study Group. N Engl J Med 1998; 339:1672–1678. 6. Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis. Classification and implication for long-term outcome. Circulation 1999; 100:1072–1078. 7. Goldberg SL, Loussararian A, DeGregorio J et al. Predictors of diffuse and aggressive intrastent restenosis. J Am Coll Cardiol 2001; 37: 1019–1025. 8. Alfonso F. Restenosis intra-stent: balloon angioplasty versus elective stenting—results of randomized trial. ACC 2001. 9. Bossi I, Klersy C, Black AJ et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35:1569–1576. 10. Köster R, Kähler J, Terres W et al. Six-month
11.
12.
13.
14.
15.
16.
clinical and angiographic outcome after successful excimer laser angioplasty for in-stent restenosis. J Am Coll Cardiol 2000; 36:69–74. Vom Dahl J, Dietz U, Haager PK et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the Angioplasty versus Rotational atherectomy for Treatment of diffuse In-stent restenosis (ARTIST) Randomized Multicenter Trial (submitted). Sharman SK, Kim AS, King T et al. Randomized trial of rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis (ROSTER) final results. Circulation 2000; 102:3530A. Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary GAMMA radiation therapy to inhibit the reoccurrence of restenosis after stenting. N Engl J Med 2001; 344:250-256. Popma JJ. Late clinical and angiographic outcomes after use of Sr-90/Y-90 beta radiation for the treatment of in-stent restenosis: results from the Sr-90 treatment of angiographic restenosis (START) Trial. J Am Coll Cardiol 2000; 36(1):311–312. Holmes D, Fitzgerald P, Goldberg S et al. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind placebo-controlled trial. Am Heart J 2000; 139:23–31. Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103(2):192–195.
151
579_Stenting_ch.10
14/8/2001 14:18
Page 152
579_Stenting_ch.11
14/8/2001 14:19
Page 153
11 Percutaneous intervention in acute coronary syndromes Michael J Curran, Cindy L Grines
Introduction In the last decade we have witnessed dramatic advances in percutaneous interventional techniques, devices, and adjunctive pharmacology to treat patients with acute coronary syndromes (ACS) and acute myocardial infarction (AMI). In this chapter, we will address how these advances may be applied to both patient and lesion subsets, making recommendations for therapy based foremost on the randomized, controlled data that are available. Although ACS encompass a spectrum ranging from unstable angina to acute infarction, in this chapter ACS will refer to presentation with unstable angina or non-Q-wave myocardial infarction (MI).
Acute coronary syndromes Acute coronary syndromes are defined by clinical symptoms and signs of prolonged or accelerating myocardial ischemia, and these patients represent a heterogeneous spectrum of patients with varying severity and burden of coronary artery disease.1 The pathophysiology of these presentations can range from progressive increasing severity of stable atherosclerotic plaque to intracoronary plaque rupture, mural hemorrhage, and resultant thrombus formation.
Prospective trials in unstable angina/non-Q-wave myocardial infarction The relative merits of an early invasive versus conservative management strategy to treat patients with ACS have been obscured by the abundance of retrospective data in which higherrisk patients selectively referred for an invasive approach seemed to have worse outcomes.2 The majority of these studies are outdated, with both medical and invasive treatment arms not having the benefit of routine use of aspirin, -blockers, heparin (fractionated or unfractionated), glycoprotein (GP) IIb/IIIa inhibitors or intracoronary stents. Nevertheless, in an analysis of over 30 000 patients randomized to ‘modern day’ medical therapy for unstable angina versus addition of a GP IIb/IIIa receptor antagonist, at 30 days MI or death occurred in 9.1% of treated patients, which is still not a low number of patients reaching this endpoint.3 The question is whether or not, with appropriate patient selection and adjunctive medical therapy, an early invasive approach will provide incremental benefit to optimal pharmacologic therapy for ACS. Four prospective, randomized trials have now been completed that specifically address the issue of whether a conservative or early invasive strategy is superior in managing patients with ACS (Table 11.1).4–7 The TIMI IIIB trial was conducted from 1989 to 1992, randomizing patients
153
154 7.8%
24%
5.1%
61%
98%
NA NA
14.1%a
NA
23 months
30 days
23 months
23 months
28.6%
5.7%
12.2%
7.8%
45%
64%
NA
NA
NA
29.9%
10.4%
44%
98%
30 days
NA
NA
NA
Early
8.6%
6 months
14%
22%
1 year 6 months
7.8%
9.4%
2.1%b
77%
98%
(1222)
invasive
6 months
6 months
5.7%a 26.9%
6 months
6 months
Interval
33%
48%
(458)
Conservative
FRISC II6
6 months 6 months
11.6%a 39%a
6 months
30 days
10.1%a
30 days
11%
NA
4.8%
3.1%
7.3%
4.7%
61%
6 months
97%
(1114)
60%
6 months
24%a
Early invasive
30 days
30 days
12.4%
1.7%b
37%
47%
(1235)
Conservative Internal
13.7%a
NA
6.9%a
5.8%a
9.5%
7.0%a
44%
36%
51%
(1106)
Conservative
TACTICS (TIMI 18)7
Table 11.1 A comparison of randomized trials of early invasive versus conservative management for unstable angina/non-Q-wave myocardial infarction.
p <0.05; b mortality only. NA, not reported.
42 days
Rehospitalization
a
42 days
1 year
Recurrent angina
42 days
Death/MI 42 days
42 days
Revascularization
Non-fatal MI
7.2% 10.8%
42 days
Angiography
(462)
(733)
Early
(740)
Conservative Interval invasive
Early
VANQWISH5
14/8/2001 14:19
invasive
Interval
Endpoint
TIMI IIIB4
579_Stenting_ch.11 Page 154
579_Stenting_ch.11
14/8/2001 14:19
Page 155
ACUTE CORONARY SYNDROMES
presenting with unstable angina or non-Q-wave MI first to thrombolytic therapy with or without tissue plasminogen activator (t-PA), and then to an early (18–48-h) invasive strategy versus a conservative strategy.4 At 6 weeks, the composite endpoint of death, MI or abnormal stress test was not significantly different between the early invasive versus the conservatively managed groups (16.2% versus 18.1%, p 0.4). However, there was significantly longer hospitalization, more recurrent angina, increased rehospitalization and greater overall cost in the conservatively managed patients (Table 11.1). Similarly, the VANQWISH trial enrolled patients with non-Q-wave MI from 1993 to 1996, and randomly assigned 920 patients to invasive versus conservative management. At hospital discharge, at 1 month, and at 1 year, there was a significant increase in the combined endpoint (death or MI) in the invasively managed group, leading the authors to conclude that a conservative, ischemia-guided approach is more safe and effective.5 These earlier randomized trials have frequently been referenced as evidence for equivalent outcomes between a conservative or early invasive approach in ACS; however, this conclusion warrants further analysis. Percutaneous intervention was performed after thrombolytic administration in 50% of the patients in TIMI IIIB, and in 12.5% of the patients in VANQWISH, a strategy that is known to be complicated by increased ischemic events. Although early mortality was high in the invasive arm of VANQWISH, this was due solely to an 11.6% surgical mortality from coronary artery bypass graft (CABG), and there were no early deaths in patients treated with percutaneous intervention. None of the trials used modern adjunctive pharmacology (GP IIb/IIIa inhibition) to any extent. Moreover, the early invasive strategy was not that ‘early’ in any of these studies, with angiography being performed at a median time of 36 h in TIMI IIIB, and revascularization in VANQWISH being delayed by a median of 8 days. In fact, in VANQWISH, only 44% of patients were
revascularized in the invasive arm, in spite of the fact that 95% of the patients in the invasive arm had significant coronary artery disease, and 48% had left main or three-vessel coronary disease. Finally, in both studies, patients in the conservative arm underwent frequent revascularization, making it difficult to interpret outcomes. Two randomized trials have now been completed which better reflect clinical outcomes with a conservative versus early invasive approach for ACS using contemporary adjunctive medical therapy and interventional techniques. The FRISC II trial randomized 2457 patients to an early invasive versus conservative management strategy after treatment with aspirin, beta blockers and the low molecular weight heparin (LMWH) dalteparin. The majority (70%) of patients in the invasive arm received stents, 30% received GP receptor inhibitors, and there was infrequent early crossover from conservative to invasive arms (9%). At 6 months there was a significant decrease in the composite endpoint of death or MI in the invasive group (9.4% versus 12.1%; p 0.031), with a significant decrease in MI (7.8% versus 10.1%; p 0.045) and a trend toward lower mortality (1.9% versus 2.9%; p 0.10).6 At 1-year follow-up, this difference in mortality became significant (2.2% versus 3.9%; p 0.016), and all other endpoints remained significantly better for patients in the early invasive versus the conservative arms. Recently, the TACTICS (TIMI 18) trial randomized 2220 patients with ACS syndromes to an early invasive versus conservative management strategy after all patients were treated with aspirin, heparin, and the GP receptor inhibitor tirofiban.7 On initial presentation, 54% of patients were troponin positive. The combined primary endpoint of death, MI or rehospitalization for unstable angina was significantly better in the patients managed with an early invasive versus conservative strategy, both at 30 days (7.4% versus 10.5%; p 0.009) and at 6 months (15.9% versus 19.4%; p 0.025) (Table 11.1).
155
579_Stenting_ch.11
14/8/2001 14:19
Page 156
PERCUTANEOUS INTERVENTION IN ACUTE CORONARY SYNDROMES
Referral for angiography From these trials, certain patient subsets were identified that derived benefit from an early invasive approach. In TIMI IIIB, death and MI were significantly less in patients aged 65 or older (7.9% versus 14.8%; p 0.02), and in FRISC II the greatest benefit with the early invasive strategy was found in men, age >65, with history of prior MI, rest chest pain, ST depression, and elevated serum troponin levels.4,6 Similarly, in TACTICS, patients with a positive serum troponin level had an absolute 10% reduction in the primary endpoint at 6 months with an early invasive approach (14.3% versus 24.2%; p < 0.001).7 A reduction in the primary endpoint with an early invasive strategy in TACTICS was seen regardless of age or sex, yet it was most highly significant in diabetic patients, those with ST segment changes on presentation, or those determined to be at intermediate or high risk by Thrombolysis in Myocardial Infarction (TIMI) unstable angina score.8 These patients with intermediate or high-risk features are the most likely to benefit from an early invasive approach, and, in addition, patients with recurrent ischemia after medical stabilization (clinically evident or silent), and patients at low risk who fail medical stabilization or have inducible ischemia, are most likely to benefit from an early invasive approach.9 In aggregate, we view these trials as demonstrating a clear superiority of an early invasive versus a conservative strategy in patients presenting with an ACS. Using contemporary interventional techniques and adjunctive medical therapy, we feel that the evidence supports a low threshold for early invasive management in all but the lowest-risk patients. Clearly, the vast majority of patients who present with unstable angina or non-Q-wave MI ultimately undergo angiography with a high rate of revascularization, and early angiography serves to better risk stratify patients, identifying not only those who need urgent revascularization with percutaneous transluminal coronary angioplasty (PTCA) or
156
CABG, but also those who have normal coronaries and non-cardiac pain. More importantly, the randomized trials clearly demonstrate a reduction in recurrent angina, need for antianginal medication, and rehospitalization, as well as a decrease in MI and trend toward decreased mortality (FRISC II).4–7 The risk stratification algorithm developed by Braunwald10 has been prospectively validated in two studies,11,12 and in patients with high- or intermediate-risk features on presentation, referral for angiography confers no additional risk, with similar cost-effectiveness13–15 as a conservative approach. We therefore feel that all patients at increased risk for coronary events should be considered for angiography. Those at very low risk by clinical and diagnostic variables may be managed by either approach (Table 11.2).
Adjunctive therapy and timing of revascularization in acute coronary syndromes Modern day medical therapy has greatly improved the outcomes for medical stabilization in ACS, particularly the use of LMWH and GP IIb/IIIa antagonists.3,15 In the past, early percutaneous intervention performed on patients with ACS was associated with high procedural success but increased periprocedural complications, largely due to periprocedural (enzymatically detected) infarction;16 however, these retrospective studies are inherently biased due to higherrisk patients being referred for early angiography. There is mounting evidence that complications from percutaneous intervention in patients with ACS can be neutralized with aggressive anti-thrombotic and antiplatelet therapy.6,7,17,18 In the PURSUIT trial, early percutaneous intervention (<72 h) in patients with ACS was associated with an early hazard, with an increase in the composite endpoint of death or MI at 30 days, but with a reduction in death or Q-wave MI. This early hazard was eliminated with eptifibatide use, with a 31% reduction in
579_Stenting_ch.11
14/8/2001 14:19
Page 157
ACUTE CORONARY SYNDROMES
Findings
High risk
Low risk
Clinical
Angina at rest <48 h Recurrent chest pain after admission Angina within 2 weeks of MI Rest angina Angina refractory to medical therapy Congestive heart failure or hemodynamic instability with angina Known severe CAD, prior MI, PTCA, CABG with rest/crescendo angina Advanced age Diabetes mellitus
New-onset angina within 2 weeks to 2 months Angina at a lower threshold, yet good functional capacity No CHF, hemodynamic instability Known CAD, with atypical presentation and no high-risk features
Electrocardiographic
ST depression Anterior ischemia or T-wave inversion Left bundle branch block
Normal or unchanged ECG Non-specific ST-T or T-wave abnormalities
Echocardiographic
Wall motion abnormality with angina Anterior wall motion abnormality Reduced LV function
Normal LV function and wall motion
Laboratory
Elevated troponin or CK-MB
No elevated serum markers
Non-invasive testing
Reversible perfusion defect Increased lung uptake on nuclear imaging Angina with exercise Wall motion abnormality with stress
Normal non-invasive testing Fixed perfusion abnormality in region of prior infarction
Medical therapy
ASA, consider thienopyridine -blockers, nitrates Intravenous heparin or LMWH sq Glycoprotein IIb/IIIa inhibitors
Aspirin -blockers, nitrates Consider IV heparin or sq LMWH heparin for rest symptoms (and perhaps early angiography)
Evaluation
Early angiography with revascularization as per ST elevation MI
Medical stabilization and non-invasive evaluation versus early angiography
CAD, coronary artery disease; LV, left ventricular.
Table 11.2 Risk stratification in unstable angina: high- versus low-risk clinical and diagnostic variables for increased risk of adverse cardiac events.
157
579_Stenting_ch.11
14/8/2001 14:19
Page 158
PERCUTANEOUS INTERVENTION IN ACUTE CORONARY SYNDROMES
death or non-fatal MI (11.6% versus 16.7%; p 0.01) in treated patients undergoing percutaneous intervention. The incremental benefit of an invasive versus conservative strategy following initiation of aspirin, heparin and GP IIb/IIIa inhibition was definitively shown in the TACTICS (TIMI 18) trial, and this benefit came at no increased risk of stroke and a significantly decreased length of hospitalization, but with a small but significant increase in risk of major bleeding in the invasive group (5.5% versus 3.3%; p 0.01).7 Contemporary therapy for patients presenting with ACS and intermediate or high-risk features should include early initiation of GP IIb/IIIa inhibition and referral for early angiography.
Acute myocardial infarction In the last quarter of a century we have recognized that acute reperfusion of an occluded coronary artery leads to reduction in infarct size, myocardial salvage and prolongation of life. Acute reperfusion therapy for MI has undergone rapid evolution, fueled by an effort to most rapidly and safely achieve TIMI 3 flow in the infarct-related artery. The optimal method of reperfusion for AMI has been a point of controversy for almost two decades, but the evidence continues to mount from well-designed randomized trials that catheter-based reperfusion is the treatment of choice for the vast majority of patients.
Comparison of primary (direct) angioplasty versus thrombolytic therapy In spite of its widespread availability, ease of administration, and known clinical benefits, thrombolytic therapy falls short of being the optimal reperfusion strategy for the vast majority of patients presenting with AMI. This was clearly evidenced when data from 10 prospective randomized trials totaling 2606 lytic-eligible
158
patients19–28 randomized to either primary angioplasty or thrombolytic therapy were summarized in a meta-analysis by Weaver et al.29 In these trials, all patients were given aspirin and antithrombotic therapy (heparin/hirulog), and 54% of patients randomized to lytics received accelerated t-PA. In this analysis, primary angioplasty resulted in a 34% risk reduction in death (4.4% versus 6.6%; p 0.02), a 58% risk reduction for death or reinfarction (7.2% versus 11.9%; p < 0.001), a 65% reduction in the risk of all stroke (0.7% versus 2.0%; p 0.007), and a greater than 10-fold decrease in the risk of intracranial hemorrhage (0.1% versus 1.1%; p < 0.001). It has been appropriately noted that the magnitude of both absolute and relative reduction in mortality in this analysis is greater with primary angioplasty versus lytic therapy (4.4% versus 6.6%; p 0.02) than that noted in a meta-analysis of lytic therapy versus placebo (9.6% versus 11.5%; p 0.0001).26,30,31 These results were manifest in spite of the fact that nearly one-half (1138) of the patients included in this analysis were from the GUSTO IIb trial. Despite similar outcomes in patients in the thrombolyic arms of GUSTO IIb and PAMI, a reduced benefit was seen in the PTCA arm of GUSTO IIb compared with the PTCA group in PAMI; this was likely due to fewer patient undergoing PTCA (81% vs. 90%) and lower rates of TIMI 3 flow (73% vs. 97%) in the PTCA arm of GUSTO Iib.29,30 Although each of these randomized trials was underpowered to demonstrate mortality differences, we feel that the pooled data in this meta-analysis provide incontrovertible evidence of the superiority of primary angioplasty in improving mortality, and in reducing reinfarction, stroke, and intracranial hemorrhage, in patients with AMI. Moreover, these early clinical benefits appear to be sustained at long-term follow-up, with reduced rates of death (6.2% versus 8.2%; OR 0.73; p 0.039) and reinfarction (4.8% versus 9.8%; p < 0.0001) at 6 months, with the absolute benefit being greatest in high-risk patients (diabetics and elderly) (Figure 11.1).31 In a 2-year
579_Stenting_ch.11
14/8/2001 14:19
Page 159
ACUTE MYOCARDIAL INFARCTION
follow-up of the PAMI I trial, patients undergoing primary angioplasty had less recurrent ischemia (36.4% versus 48%; p 0.026), lower re-intervention rates (27.2% versus 46.5%; p < 0.0001), reduced hospital readmission rates (58.5% versus 69%; p 0.035) and a lower combined incidence of death or reinfarction (14.9% versus 23%; p 0.034) compared to patients receiving t-PA, and in multivariate analysis, primary angioplasty was independently predictive of a reduction in death, reinfarction or target vessel revascularization (p 0.0001).32
Mechanisms of improved outcomes with primary angioplasty versus thrombolytics Primary PTCA probably results in improved clinical outcomes compared with thrombolytic therapy, not only because it results in greater rates of TIMI 3 flow in the IRA, but also because it results in more complete and sustained vessel patency. The pooled risk for early re-occlusion of the IRA is nearly twofold higher with thrombolytics compared with primary PTCA (7.2% versus 3.7%; p < 0.001),30 and angiographically documented early re-occlusion is associated with a nearly threefold increase in mortality (11% versus 4.5%; p 0.01).33 Late re-occlusion has
been documented in 25–40% of patients treated with thrombolytics, resulting in significant increases in late reinfarction and mortality,34–39 whereas primary PTCA results in late reocclusion rates of 9–13%.30,31,41 A large randomized trial demonstrated that the rate of re-occlusion at 6 months with primary stenting is even lower than that seen with primary angioplasty (Stent-PAMI, 5.1% versus 9.3%, p 0.04).40 Although, ostensibly, thrombolytics can be administered earlier (average 45–60 min) and result in vessel patency sooner than primary angioplasty can be performed, the inherent delay in performing primary PTCA has not resulted in an increase in mortality. Thus, primary PTCA is superior to thrombolysis with regard to acute and late patency, TIMI 3 flow rates, reduced recurrent ischemia, re-occlusion, reinfarction, stroke, and death (Figure 11.2).
Specific issues related to angioplasty for acute myocardial infarction High-risk patients The greatest benefit of primary PTCA is derived in the subset of patients who are defined as having ‘high-risk’ features on presentation—age >70, anterior infarction, heart rate >100, lower
30 Days
6 Months p 0.0001 16.40% p 0.0001
p0.005
p 0.055
p 0.001
9.70% 6.90% 4.20%
Death
p 0.019 p 0.0001 2.90% 1.93% 1.10% 0.77% 0.10% Reinfarction
9.90%
8.10% 6.10%
7.70%
Stroke
ICH
Lytics PTCA
4.40%
Death
Reinfarction Death/ReMI
Figure 11.1 Combined data from the Primary Coronary Angioplasty Trialists collaboration on 2635 patients from 10 randomized trials of primary PTCA versus lytic therapy for AMI (from ref. 31).
159
579_Stenting_ch.11
14/8/2001 14:19
Page 160
PERCUTANEOUS INTERVENTION IN ACUTE CORONARY SYNDROMES
30-day mortality (%)
10
Mortality vs. TIMI 3 Flow
1 2
8
5 3
Thrombolytics 6
4 6 4
8
2
7,9 PTCA 10
0 0
20
40
60
80
100
TIMI 3 Flow (%)
Figure 11.2 The relationship of 90-minute TIMI 3 flow in the IRA and mortality in studies of thrombolytics (䉬) and PTCA (䊏) in the treatment of AMI. (1 totally occluded vessels, 2 GUSTO I-SK arm, 3 GUSTO ItPASK, 4 GUSTO I-accel t-PA, 5 IMPACT-AMI: eptifibatide plus alteplase, 6 GUSTO IIb(PTCA arm), 7 PAMI 2-PTCA, 8 PAMI 1-PTCA, 9 CADILLAC (PTCA no abciximab or stent with abciximab.), 10 CADILLAC (PTCA with abciximab or stent without abciximab).
blood pressure or Killip class >1. Mortality is significantly decreased with primary PTCA in high-risk patients (3.2% versus 9.8%; p 0.005), and for both high- and low-risk patients, rates of reinfarction, stroke and recurrent ischemia are significantly reduced.42 In addition, the vast majority ( 70%) of patients with acute infarction are considered thrombolytic ineligible, due to either relative or absolute contraindications to thrombolytic therapy. These patients tend to be older, female, have a history of multivessel disease, prior MI, and depressed left ventricular (LV) function. Primary angioplasty can be performed in these patients with a procedural success rate approaching 90%,42–44 and although procedure-related mortality is higher in these patients, their r